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ABSTRACT  
Background: Essential hypertension is regarded as a complex disease, the 
phenotype of which results from interactions between numerous genes and 
environmental factors. Genome-wide association studies of blood pressure (BP) and 
hypertension have been developed to explore the potential genes involved in blood 
pressure and identified a number of trait-associated variants. Among those variants, 
single nucleotide polymorphisms (SNPs) rs1173771 (G/A) and rs1421811 (G/C) are 
located at the natriuretic peptide receptor C (NPR3) gene locus. Their major alleles 
are related with blood pressure elevation. Studies have implicated NPR-C in 
mediating some of the cardio-protective actions of natriuretic peptides and its direct 
involvement in the pathogenesis of hypertension. However, the precise role of these 
association between genetic variants at NPR3 and blood pressure control has not 
been elucidated. 
 
Objective: To functionally characterise the effect of BP-associated SNPs at the NPR3 
gene locus in the context of BP regulatory pathways. 
 
Methods: Primary human umbilical artery smooth muscle (HUASMCs) and vein 
endothelial (HUVECs) cells were genotyped for BP-associated NPR3 variants. 
Endogenous mRNA and protein expression levels were assessed by qRT-PCR, allelic 
expression imbalance assay and western blotting. Open chromatin regions were 
assayed using formaldehyde-assisted isolation of regulatory elements (FAIRE). 
Interaction between variants flanking region with nuclear protein was detected by 
electrophoretic mobility shift assay (EMSA). Cell proliferation and migration were 
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determined by cell counting and scratch assays. Angiotensin II (Ang II)-induced 
calcium flux was evaluated using the intracellular fluorescent probe.  
 
Results: The BP-elevating allele of the NPR3 variants in rs1173771 linkage 
disequilibrium (LD) block was associated with lower endogenous mRNA and protein 
levels in HUASMCs. This is consistent with the finding that BP-elevating allele is less 
located within open chromatin. The decreased NPR3 expression in HUASMCs 
carrying the BP-elevating allele is associated with increased cell proliferation and 
intracellular calcium flux in response to Ang II stimulation. No differences in migration 
rates were detected. No genotype-dependent characteristics were observed in 
HUVECs NPR3 expression and cell proliferation. 
 
Moreover, RT-PCR showed a linkage between of the BP-elevating allele of the NPR3 
variants in rs1421811 LD block and lower endogenous mRNA in HUASMCs. 
Intracellular calcium flux detection also revealed a trend of higher response to Ang II 
stimulation in BP-elevating allele homozygous HUASMCs. However, No genetic 
differences were detected in proliferation and migration rates of HUASMCs, and 
HUVECs NPR3 expression and cell proliferation studies did not present any 
significant genotype-dependent association.  
 
Conclusions: This study has identified a potential mechanism for BP-associated 
SNPs at NPR3 locus to influence BP predominantly via an effect on vascular smooth 
muscle cell behaviours. 
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1.1. Blood pressure control  
At the basic level, blood pressure can be approximated by Ohm’s Law modified for 
fluid dynamics, pressure = flow X resistance. Blood flow depends on the cardiac 
output (CO) and blood volume, whereas resistance is primarily determined by the 
contractile state of small arteries and arterioles throughout the body, also called total 
peripheral vascular resistance. These components of blood pressure are subject to a 
range of regulatory influences. 
 
1.1.1 Cardiac output 
Cardiac output is the volume of blood pumped per minute by left ventricle of the heart, 
and it is equal to the stroke volume (SV) times the heart rate (HR). SV is defined as 
the volume of blood ejected per contraction and is controlled by the energy with which 
the myocytes contract and the pressure required to force out the blood.1  Both HR and 
SV are important in adapting the cardiac output to its metabolic demands. Heart rate 
itself is highly variable and therefore acts as a driving force for cardiovascular 
regulation.2   
 
1.1.2  Kidney sodium excretion 
As sodium is the major cation in the extracellular fluid (e.g. increased dietary salt 
intake could increase the extracellular fluid volume), renal sodium excretion provides 
a crucial pathway for reducing body fluid volumes and returning systemic pressures 
to normal. Due to the capacity of the kidney to rapidly increase urinary sodium 
excretion in response to elevations in blood pressure, also called ‘pressure 
natriuresis’, the kidney has been regarded as one of central organs in circulatory 
homeostasis and blood pressure control.3  The peptide hormone angiotensin II, which 
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increases thirst, promotes salt retention by the kidney, causes vasoconstriction, and 
enhances the release of catecholamine from neurones and the adrenal gland.4 
 
1.1.3 Vascular tone /peripheral vascular resistance 
Along with changes in circulating volumes, peripheral vascular resistance is also an 
important determinant of blood pressure. Vascular resistance is the force that opposes 
the flow of blood through a vascular bed. It is equal to the difference in blood pressure 
across the vascular bed divided by the cardiac output.5–7 Most phenotypes of 
hypertension result from an increased vascular tone that leads to an elevated total 
peripheral resistance.8,9  Vascular resistance under both normotensive and 
hypertensive conditions is under control of multiple hormonal mediators. For instance, 
G protein–coupled receptors on vascular smooth muscle cells and their associated 
signalling pathways are required for maintenance and control of blood pressure.10,11 
Peripheral vascular resistance could also be modified, e.g. by arterial wall 
modifications due to ageing, medial hypertrophy due to obesity.12 
 
1.1.4  Autonomic nervous system 
Vascular resistance and cardiac output are both controlled by the autonomic nervous 
system. This in turn is divided into two subsystems: the parasympathetic nervous 
system (PNS) and the sympathetic nervous system (SNS).13 A major role of the SNS 
is the maintenance of BP (short-term) and the regulation of blood flow via the arterial 
baroreflex. The arterial baroreflex works by sensing changes in BP via baroreceptors 
which respond to vessel wall stretch. Longer term control of arterial pressure however 
has traditionally been attributed to the kidney.14,15 
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In summary, normal control of blood pressure requires complex integration of 
regulatory mechanisms across multiple physiological systems, including the kidney, 
skin, the vasculature, the central and sympathetic nervous systems, and various 
hormonal regulators (Figure 1.1).16 
 
 
 
Figure 1.1 Pathophysiological mechanisms involved in hypertension. 
AME = apparent mineralocorticoid excess; CNS = central nervous system;  
GRA = glucocorticoid-remediable aldosteronism.16 
 
 
1.2 Hypertension 
Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or 
a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive 
medication.17 It is one of the most common chronic diseases in the human population. 
It is predicted to be prevalent in 30% of the worldwide population by 2025, with 
approximately 1.56 billion suffering from hypertension.18 Cardiovascular diseases 
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including stroke, myocardial infarction (MI), congestive heart failure, arterial aneurysm 
and chronic renal failure are complications of hypertension and are major sources of 
morbidity and mortality 19. The relationship between blood pressure and risk of 
cerebrovascular disease events is continuous, consistent and independent of other 
risk factors. 20  
 
Advances in the diagnosis of hypertension and multiple different therapeutic 
strategies targeting the disease have played a major role in recent dramatic declines 
in coronary heart diseases and stroke mortality all over the world and the public has 
been more aware of this disorder and its risks. However, control rates remain 
unsatisfactory, and a substantial proportion of people with hypertension under 
treatment do not achieve the target levels of blood pressure control recommended by 
current guidelines. Public health data have confirmed inadequate control of BP under 
various anti-hypertensive medications among treated hypertension patients. Indeed, 
only 20% to 30% of treated individuals achieve current targets.21,22 Similar numbers 
were observed in a ten-year study (1998-2008) in hypertensive patients in America.23  
These findings highlight the need for a more effective way of hypertension prevention. 
 
1.3 Essential hypertension and genes 
In approximately 5% of all hypertension cases, the cause is secondary to conditions 
such as primary hyperaldosteronism (Conn’s syndrome), Cushing’s syndrome 
(excessive glucocorticoids), phaeochromocytoma or renal diseases; it may also be 
drug-induced. The majority of hypertension cases are labelled as essential 
hypertension, defined as high blood pressure without any known secondary cause, 
constituting the remainder 95% of cases.24,25 Essential hypertension is regarded as a 
complex disease, the phenotype of which results from interactions between numerous 
genes and environmental factors including high salt intake, smoking, alcohol 
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consumption, BMI (body mass index), age and stress. The genetic contribution to 
essential hypertension comes in the form of multiple alleles in polygenes that can alter 
the function and/or the expression level of the encoded protein, creating endo-
phenotypes that complicate into hypertension with other risk factors 26 (Figure 1.2). 
 
 
Figure 1.2 Hierarchy in genetics of cardiovascular disease. 
Several subclinical physiological phenotypes contribute to each cardiovascular risk 
factor. Phenotypes depend on unknown number of polygenes; polygenic effects 
depend on an unknown number of alleles. 26 
 
 
Epidemiological and familial aggregation studies have established that there is a 
significant heritability component (30%-50%) for both blood pressure and 
hypertension.27  The importance of genetic influence is perhaps best illustrated by the 
observation that the risk of developing hypertension for people with a family history of 
hypertension is increased by approximately four times compared with the general 
population28. The role attributable to genetic factors amounts to some 25% among 
hypertensive families and can reach 65% when monozygotic twins are compared. 
Unravelling the genetics of hypertension holds promise for providing an unbiased 
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approach for understanding its pathogenesis, risk profiling and identifying therapeutic 
targets.29 
1.3.1 Genetic variants/biomarkers  
Substantial genetic variations exist in human genome, such as insertions and 
deletions (indels), structural variation, and epigenetic modification.30,31 The majority 
(90%) of human genetic variants are single nucleotide polymorphism (SNP) that is a 
single-nucleotide substitutions of one base for another occurring every 100–300 
genome bases in a DNA sequence, and has a population frequency of at least 1%.32,33. 
However, not all single-nucleotide changes are SNPs. Some specific disease-causing 
point mutations are also caused by single allelic variants which often occur within a 
gene's coding or regulatory regions and affect the function of the protein encoded by 
the gene.34 With advances in high-throughput genome-wide chip-based strategies, 
their interrogation at large scale is now feasible, and tens of thousands of SNPs in 
their first versions can interrogate more than 5 million variants across the human 
genome.35 
 
Each SNP is usually constituted by two, rarely more, different possible nucleotide 
bases (alleles) at the same genetic position. The allele with a higher frequency (>50%) 
in a population is regarded as the major allele, otherwise, the other is the minor allele 
(<50%). It is widely accepted that gene variants with minor allele frequencies (MAF) 
from 5% to 50% are considered common, those with MAF between 1% and 5% are 
considered less common, and those with MAF less than 1% are considered rare. 
Different MAF classes of variant determine its optimal research strategies.36 
 
To date, two principal heritable types of BP-associated variants are recognised 
(Figure 1.3). The first type is monogenic hypertension involved with variants occurring 
near exclusively in rare familial syndromes. These are usually exonic mutations with 
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large effect sizes usually causing catastrophically high BP levels with severe and early 
onset cardiovascular morbidity and mortality in many cases. The other type is 
common essential hypertension which to date is mostly caused by a mixture of 
common variants with  modest effect sizes.37 
 
 
Figure 1.3 Relation of risk allele frequencies, penetrance / effect sizes (odds 
ratios) and feasibility of identifying risk variants by common genetic tests. 37 
 
 
 
1.3.2 SNPs to gene expression/function and phenotype  
Based on the genetic position of variants, SNPs are mainly classified into five groups: 
1) exonic SNPs: Nonsynonymous SNPs, SNPs may change the encoded amino acids 
(nonsynonymous); and synonymous SNPs: those nucleotide substitutions that do not 
change the amino acid.  
2) Intronic SNPs: SNPs within introns;   
3) 5' UTR SNPs: SNPs at the 5' end of the gene;   
4) 3' UTR SNPs: SNPs at the 3' end of the gene including the region of the mRNA 
between the stop codon and the poly-A tail;  
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5) intergenic SNPs: those nucleotides located in the intergenic regions between 
genes.38 
 
It is intuitive that nonsynonymous SNPs (amino acid substitutions) can change the 
gene expression or subsequently alter function of a protein. Intronic, 3-UTR, 5’-UTR 
and synonymous SNPs which can be catalogued as non-coding SNPs could also 
influence gene expression.39  Cis-regulatory sequences have been regarded as 
critical regions to regulate the transcription of nearby genes. They are typically 
composed of non-coding DNA containing binding sites for transcription factors (TFs) 
and/or other regulatory molecules. Tighter or looser binding of regulatory proteins will 
lead to up- or down-regulated transcription, change gene expression and hence may 
produce phenotype difference.40 
 
In addition, SNPs located in intron or exon can function as part of cis-acting RNA 
sequence elements presenting in pre-mRNAs. They can impact alternative splicing, 
subsequently resulting in a single gene coding for multiple proteins.41  
 
 
1.3.3  Strategies for identifying blood pressure genes/biomarkers 
1.3.3.1 Candidate-gene studies 
The candidate gene approach is a common strategy in the hunt for genes that are 
involved in essential hypertension with the use of classic epidemiological techniques. 
The aim of this approach is to determine whether hypertension is associated with 
‘candidate gene’ markers, most frequently consisting of single nucleotide 
polymorphisms (SNPs).42 The selection of candidate genes for such studies has 
generally been based on a mechanistic understanding of the roles of the encoded 
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proteins in blood pressure regulation. These candidates are mainly involved in the 
renin–angiotensin–aldosterone system (RSA system) or other determinants of 
sodium and blood-volume regulation, adrenergic pathways, vascular-associated 
genes; metabolism-associated genes, other miscellaneous’ roles.43 
 
Human candidate gene studies have examined more than 60 genes likely to be 
implicated in essential hypertension,42  but most of the studies were often dependent 
on prior knowledge of the gene product in question, and genes whose products are 
unknown or believed to be “unimportant” in the pathogenesis of hypertension were 
likely to be ignored. It is common phenomenon that candidate genes did not provide 
accurate and consistent evidence in hypertension associated analysis.44 
 
1.3.2.2 Genome-wide linkage studies 
Genome-wide linkage studies (GWLS) utilize genetic markers - notably microsatellite 
(also called simple sequence repeats) polymorphisms and SNPs that are linked with 
a disease phenotype and located anywhere within the genome. This approach is 
carried out without any prior knowledge of a likely contribution to the phenotype of 
interest. 
 
Since the mid-1990s, with the availability of increased numbers of markers, genome-
wide linkage studies have now identified well more than 60 hypertension-associated 
quantitative trait locus (QTLs) across the genome 45  QTL refers to a position in the 
chromosome that may influence the trait of interest.46 
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These results indicate that no single genomic region has a uniformly large effect on 
predisposition to hypertension.47  At present, all human autosomal chromosomes 
have been reported to contain regions linked to BP and hypertension.43 
 
1.3.3.3 Genome-wide association studies 
Genome-wide association studies (GWAS) is an approach that involves scanning 
markers across the genomes of many people to find genetic variations associated 
with a particular disease. It is based on the concept that common complex diseases 
are governed by several SNPs having subtle effects and are context-dependent. 
 
Association studies are carried out with a categorical (often binary case/control) or 
quantitative design. From the statistical perspective, quantitative traits are preferred 
because they improve power to detect a genetic effect, and often have a more 
interpretable outcome. Other disease traits do not have well-established quantitative 
measures. In these circumstances, individuals are usually classified as either affected 
or unaffected – a binary categorical variable. 48 The basic paradigm used in GWAS 
recently is to catalogue very common variants and genotype them based on arrays 
directly or indirectly through linkage disequilibrium (LD) in individuals.36   
 
There has been a recent increase in the number of publications of GWAS data for 
complex diseases in different populations and ethnic groups. The first large GWAS 
experiment for hypertension was carried out by The Wellcome Trust Case Control 
Consortium (WTCCC) in 2007 which studied 7 complex diseases including: bipolar 
disorder (BD), coronary artery disease (CAD), Crohn’s disease (CD), hypertension 
(HTN), rheumatoid arthritis (RA), type I diabetes (T1D), and type II diabetes (T2D) 
(WTCCC 2007). 
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In contrast to linkage studies, association studies have good sensitivity and 
successfully represent variants with a MAF frequency of ~5% or higher in the general 
population, but they are prone to false positive results. Even an association between 
a particular allele and high blood pressure is found but it does not imply ‘cause’, and 
determination of the causative variant among possibly hundreds of variants in LD with 
association is also challenging. It has been showed that interactions between the 
various alleles of different genes may be more important than allelic variation at a 
single locus in the determination of blood pressure,49  until now, GWAS study have 
reported more than 60 loci associated with blood pressure.45 
 
Association studies to date have largely focused on studying individual common 
variants, because they could be more readily assayed with initial genomic 
technologies. Nonetheless, the genetic variants identified thus far appear to explain 
less than half of the estimated heritability in most diseases and traits. The 'missing 
heritability' of complex diseases highlights the importance of exploring the potential 
rare variants. Association studies are now increasingly being applied to sets of rare 
variants as well.50 
 
 
1.3.3.4 Next generation sequencing  
 
Nucleic acid sequencing is a method for determining the exact order of nucleotides 
present in a given DNA or RNA molecule. The Human Genome Project was 
accomplished in 2003 with first-generation sequencing, known as Sanger sequencing. 
With the growing demand for a cheap and rapid approach for sequencing, next 
generation sequencing (NGS) has been developed. Its platforms perform massively 
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parallel high-throughput sequencing, allowing millions of fragments of DNA from a 
single sample are sequenced in unison.51 The base methodology includes template 
preparation, sequencing and imaging, and data analysis.52  In many cases, targeted 
sequencing for specific genes or genomic regions, e.g. whole exome, RNA 
messenger, is preferred to detect a suspected disease. For instance, exome 
sequencing could identify the causative mutations in pathogenic presentations where 
the exact genetic cause is not known.53 
 
1.3.4 Mendelian forms of hypertension /monogenic hypertension 
There are several rare Mendelian forms of hypertension with distinctive co-
phenotypes, such as the hypertension and hypokalemia seen in Liddle’s syndrome 
with causal proteins SCNN1B, SCNN1G encoded by 16p13-p21.54  Lifton et al have 
found mutations of more than 20 genes are responsible for those rare disorders.9  To 
date, dozens of genes have been identified, leading to a number of distinguishable 
Mendelian syndromes causing hypertension (Table 1.1). They mainly influence two 
main pathways: renal salt excretion/sodium homeostasis and steroid hormone 
metabolism.9,55 
 
 
Table 1.1 Characteristics of Mendelian Disorders of Hypertension and 
Hypotension. 
Locus Gene(s) 
Mode of 
inheritance 
Genomic and 
biological 
mechanism 
Phenotypic annotation OMIM 
Therapeutic 
notes/clinical 
management 
1p32.3 BSND 
Autosomal 
recessive 
Mutations in a beta-
subunit for CLCNKA 
and CLCNKB chloride 
channels 
Bartter syndrome, type 4 #602522 
Aldosterone 
inhibitors and 
angiotensin-
converting enzyme 
(ACE) inhibitors 
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1p36.13 CLCNKB 
Autosomal 
recessive 
Loss of function 
mutations in 
chloride channels, 
impaired chloride 
reaborsportion in 
the thick ascending 
loop of Henle 
Bartter syndrome, type 3                                                               
Low blood pressure                                        
hypokalaemic metabolic 
alkalosis                                           
elevated plasma renin and 
aldosterone 
#607364 
Aldosterone 
inhibitors and 
angiotensin-
converting enzyme 
(ACE) inhibitors 
1p36.13 SDHB 
Autosomal 
dominant 
Tumors or extra-
adrenal paraganglia 
associated 
pheochromocytoma 
Paragangliomas 4 #115310 
Alpha adrenergic 
blockers for 
pheochromocytoma 
1q23.3 SDHC 
Autosomal 
dominant 
Tumors or extra-
adrenal paraganglia 
associated 
pheochromocytoma. 
Paragangliomas 3 #605373 
Alpha adrenergic 
blockers for 
pheochromocytoma 
2q36.2 CUL3 
Autosomal 
dominant 
Deficiency in cullin–
ring E3 ligase 
complexes increase 
activity of 
cotransporter of 
NCCT and ROMK 
Pseudohypoaldosteronism, 
type IIE 
#614496 
Thiazide diuretics, 
low-sodium diet 
3q25.3 VHL 
Autosomal 
dominant 
Mutations in 
the VHL tumour 
suppressor gene 
Von Hippel-Lindau 
syndrome      
Associated with retinal, 
cerebellar, and spinal 
hemangioblastoma, renal 
cell carcinoma (RCC), 
pheochromocytoma, and 
pancreatic tumors. 
#193300 
Alpha adrenergic 
blockers, surgical 
resection 
4q31.23 NR3C2 
Autosomal 
dominant 
Gain of function in 
mineralocorticoid 
receptor; salt 
wasting with 
hyperkalemic 
acidosis resulting 
from renal 
unresponsiveness to 
mineralocorticoids 
Hypertension exacerbation 
in pregnancy 
Pseudohypoaldosteronism 
type I 
#605115    
#177735 
Spironolactone 
contraindicated and 
delivery of fetus 
5q31.2 KLHL3 
Autosomal 
dominant 
Loss of function 
mutations lead to  
inhibition of KLHL3 
and increase activity 
of cotransporter of 
NCCT and ROMK 
Pseudohypoaldosteronism, 
type IID  
Hyperkalaemia. 
Hyperchloremic metabolic 
acidosis 
#614495 
Thiazide diuretics, 
low-sodium diet 
6p21.33 CYP21A2 
Autosomal 
recessive 
Loss of function, 
impaired synthesis 
of aldosterone and 
following excessive 
salt loss 
Congenital adrenal 
hyperplasia 
#613815 
Mineralocorticoid , 
sodium chloride 
7p22.3-
7p22.1 
   
Familial 
Hyperaldosteronism type 2 
#605635 
Spironolactone, 
eplerenone 
8p11.23 STAR 
Autosomal 
recessive 
Loss of 
steroidogenesis 
Lipoid congenital adrenal 
hyperplasia 
#201710 
Glucocorticoid and 
mineralocorticoid 
replacement 
8q24.3 CYP11B1 
Autosomal 
dominant 
Impaired reductions 
in cortisol and 
corticosterone 
synthesis 
Adrenal hyperplasia, 
congenital, due to 11-beta-
hydroxylase deficiency; 
#610613 Glucocorticoids 
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8q24.3 CYP11B2 
Autosomal 
recessive 
Defect in the 
penultimate 
biochemical step of 
aldosterone 
biosynthesis 
Hypoaldosteronism, 
congenital, due to CMO I 
deficiency;                                       
decreased aldosterone and 
salt-wasting, increased 
plasma corticosterone and 
11-deoxycorticosterone 
#610600 Glucocorticoids 
10q11.2 RET 
Autosomal 
dominant 
Mutations in the 
RET oncogene 
Multiple Endocrine 
Neoplasia, Type IIA                                
Associated with multiple 
endocrine neoplasms, 
including medullary thyroid 
carcinoma, 
pheochromocytoma, and 
parathyroid adenomas. 
#171400 
Alpha adrenergic 
blockers, surgical 
resection 
10q24.3 CYP17A1 
Autosomal 
recessive 
CYP17A1 deficiency 
result in low levels 
of glucocorticoids 
with a consequent 
loss of the feedback 
inhibition of the 
hypothalamic-
pituitary axis and 
elevated ACTH 
secretion 
Adrenal hyperplasia, 
congenital, due to 17-beta-
hydroxylase deficiency 
#202110 Glucocorticoids 
11q12.2 SDHAF2 
Autosomal 
dominant 
Tumors or extra-
adrenal paraganglia 
associated 
pheochromocytoma. 
Paragangliomas 2 #601650 
Alpha adrenergic 
blockers, surgical 
resection 
11q23.1 SDHD 
Autosomal 
dominant 
Tumors or extra-
adrenal paraganglia 
associated 
pheochromocytoma. 
Paragangliomas 1 #16800 
Alpha adrenergic 
blockers, surgical 
resection 
11q24.3 KCNJ5 
Autosomal 
dominant 
Mutations in 
potassium inwardly-
rectifying channel 
Familial 
Hyperaldosteronism type 
3; 
elevated aldosteronism 
levels, and high levels of 
the hybrid steroids 18-
oxocortisol and 18-
hydroxycortisol 
#613677 Adrenalectomy 
11q24.3 KCNJ1 
Autosomal 
recessive 
Mutation in the 
potassium 
channel ROMK 
Bartter syndrome, 
antenatal, type 2 
#241200 
Sodium and 
potassium 
supplement; 
cyclooxygenase 
(COX) inhibitor : 
indomethacin; 
some specific 
inhibitor of COX2 
12p12.3 WNK1 
Autosomal 
dominant 
Gain of function 
mutation in WNK1 
results in salt 
retention via sodium 
and potassium 
transporters 
Pseudohypoaldosteronism 
type IIC Gordon's 
syndrome;                       
hypertension, 
hyperkalaemia 
#614492 
Thiazide diuretics, 
low-sodium diet 
15q21.1 SLC12A1 
Autosomal 
recessive 
Loss of function in 
sodium-potassium-
chloride 
cotransporter-2 in 
the thick ascending 
loop of Henle 
Bartter syndrome, 
antenatal, type 1  
hyposthenuria, moderate 
hypokalaemic metabolic 
alkalosis 
#601678 
Sodium and 
potassium 
supplements; 
Aldosterone 
inhibitors and 
angiotensin-
converting enzyme 
(ACE) inhibitors 
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12p13.31 SCNN1A 
Autosomal 
recessive 
Mutation in subunits 
of the renal 
epithelial sodium 
channel of the distal 
nephron  leads to 
renal salt wasting 
Pseudohypoaldosteronism, 
type I;        hyponatremia, 
hyperkalaemia, and 
increased plasma renin 
activity 
#264350 
Aggressive salt 
replacement and 
control of 
hyperkalemia 
16p12.2 
SCNN1B, 
SCNN1G 
Autosomal 
dominant 
Mutation in subunits 
of the renal 
epithelial sodium 
channel (ENaC)of 
the distal nephron 
cause hyperactivity 
of ENaC 
Liddle’s Syndrome;                                                    
frequently severe 
hypertension associated 
with hypokalaemic 
metabolic alkalosis 
#177200 
Low salt diet , 
amiloride and 
triamterene 
16q13 SLC12A3 
Autosomal 
recessive 
Loss of function 
mutation in thiazide-
sensitive Na-Cl 
cotransporter result 
in lower sodium 
reabsorption 
Gitelman syndrome ;                                             
low blood pressure with 
elevated plasma renin 
#263800 
Potassium and 
magnesium 
supplement, NaCl 
intake 
16q22.1 HSD11B2 
Autosomal 
recessive 
Loss of function 
mutations in 
HSD11B2 leads to 
inefficient 
conversion of 
cortisol to cortisone 
Apparent 
Mineralocorticoid Excess             
low-renin hypertension 
associated with low 
aldosterone, metabolic 
alkalosis, hypernatremia, 
and hypokalaemia 
#218030 
Spironolactone, 
dexamethasone 
17q21.2 WNK4 
Autosomal 
dominant 
Loss of function 
mutations in WNK4 
results in salt 
retention via sodium 
and potassium 
transporters 
Pseudohypoaldosteronism 
type IIB Gordon's 
syndrome;                                            
hypertension with low 
plasma renin, normal or 
elevated potassium 
#614491 
Thiazide diuretics, 
low-sodium diet 
tRNA tRNA(Ile) Mitochondrial 
Loss of 
mitochondrial 
function 
hypertension, 
hypercholesterolemia and 
hypermagnesemia 
#500005 - 
 
Notice: OMIM: Online Mendelian Inheritance in Man (http://www.omim.org/ ). 
 
 
These discoveries in monogenic hypertension and resulted in new understanding of 
blood pressure regulation. However, these rare Mendelian blood pressure 
phenotypes account for less than 1% of human hypertension and in the main these 
genes have not been found to be associated with common forms.56  
 
1.4 Essential hypertension and GWAS 
Linkage analyses are very effective in identifying Mendelian forms of hypertension 
that are determined by rare alleles with large effect size.57  However, the vast majority 
of the genetic contribution to blood pressure remains unexplained. This is probably 
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because of the complexity of the trait and the likelihood that blood pressure variation 
in the general population is determined by many genes that each have a modest effect 
and low penetrance.43  Thus, very large sample sizes are needed to identify the 
possible variants using some approaches. Over the past few years, genome-wide 
association studies (GWAS) have begun to identify the primary genetic loci of 
hypertension. As compared to linkage analysis, GWAS provides a more powerful 
method of identifying the associated variants that underlie susceptibility to common 
disease, including hypertension,58 and the science community has more interest in 
the complex haplotype-based association studies.24 
 
This approach has the advantage of being an unbiased and comprehensive search 
across the genome for susceptibility of alleles. For instance, by allowing the 
recruitment of unrelated individuals and increasing the mapping resolution, GWAS 
provides a potential to discover novel candidate genes not identified through other 
methodological approaches.36 From 2007, there have been several large-scale 
GWAS of blood pressure. The major genetic analysis in these studies focused on SBP 
and DBP as quantitative traits and there are tight correlation of two variables based 
on significant overlap between the genetic regions associated with SBP and DBP.59,60  
 
In principle, GWAS tests for differences in allele frequency between cases and 
controls in unassociated individuals.61  If a particular allele occurs more frequently in 
individuals with the disease (cases) than in those without the disease (controls), then 
the region or gene loci that the marker (typically single nucleotide polymorphism, SNP) 
lies within is said to be associated with the disease. The tested polymorphism might 
not the causative one but it will show an association if it is in linkage disequilibrium 
(LD) with an unknown causative, risk or protective variant. Thus these SNPs show 
unequivocal association with BP, the functional dissection of these signals is not 
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straightforward. For each SNP, an association test is performed yielding a p-value and 
a regression analysis which estimates its effect size (beta). Most current reports 
accept an association having a p-value smaller than 5×10-8 as genome-wide 
significant, which is reached by dividing the usual alpha of 0.05 by 1 million (the 
effective number of tests performed) using “Bonferroni Correction”.62  
 
1.4.1 Advances in blood-pressure GWAS  
Since 2009, a sequential series of large-scale meta-analyses of genome-wide scans 
for blood pressure in individuals have identified a number of loci for SBP, DBP, pulse 
pressure (PP) and mean arterial pressure (MAP). A GWAS published in May 2009 
reported that 4 loci for SBP and 6 for DBP and rs2681472 located in the plasma 
membrane calcium-transporting ATPase 1 gene (ATP2B1) is associated with 
elevation of hypertension.59  Another study from Global BPgen consortium identified 
association between systolic or diastolic blood pressure and common variants in 8 
regions near the CYP17A1, CYP1A2, FGF5, SH2B3, MTHFR, c10orf107, ZNF652 
and PLCD3 genes.63 Otherwise, the SNP rs13333226 in the promoter of the 
uromodulin (UMOD) gene was found associated with a reduction of hypertension and 
it is an expression SNP (eSNP) possibly decreasing urinary uromodulin excretion.64  
 
To date, large GWAS in Europeans have totally reported more than 60 new loci for 
SBP, DBP, in which alleles have effect size of up to 0.5-1.0mmHg, 60,65–6768 the 
summary of genetic variants robustly associated with blood pressure traits see the 
Table 1.2.  
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Table 1.2  Summary of genetic variants robustly associated with blood pressure 
traits. 
Chr 
SNP ID and dbSNP 
annotation 
Gene locus 
name 
Genes mapped to 
the locus 
Biological function of gene 
candidate 
Study 
type 
1 *rs5068 UTR 
MTHFR-
NPPA/ 
NPPB 
CLCN6, 
KIAA2013, 
MTHFR, NPPA 
N/a 
GlobalBP 
GWAS 
1 rs880315 INT CASZ1 CASZ1 
Zinc finger transcription factor 
necessary for cardiac and vascular 
morphogenesis. 
meta 
1 *rs17030613 INT 
ST7L-
CAPZA1 
CAPZA1, MOV10, 
RHOC, ST7L, 
WNT2B, PPM1J, 
LRRN2 
N/a 
ICBP 
GWAS 
1 rs2169137 INT MDM4 
MDM4, PIK3C2B, 
RP11-430C7.4 
N/a 
gene-
centric 
1 rs2004776 INT AGT AGT 
Angiotensinogen is a liver-
synthesised pro-peptide for 
angiotensin and angiotensin II, and 
a substrate for renin. 
gene-
centric 
2 *rs16849225 INR 
FIGN-
GRB14 
- 
Region contains putative lincRNA 
of unknown function. 
meta 
2 rs16823124 INT PDE1A PDE1A 
Ca2+/calmodulin-dependent cyclic 
nucleotide phosphodiesterase 
gene-
centric 
3 *rs1717027 INT ULK4 ULK4, TRAK1 N/a 
CHARGE 
GWAS 
3 rs13082711 INR SLC4A7 SLC4A7, NEK10 N/a 
CHARGE 
GWAS 
3 rs419076 INT MECOM MECOM 
A transcriptional regulator and 
oncoprotein involved in 
hematopoiesis, apoptosis, 
development, and cell 
differentiation/proliferation. 
ICBP 
GWAS 
3 rs319690 INT MAP4 
CSPG5, DHX30, 
MAP4, SMARCC1 
N/a meta 
3 rs347591 INT HRH1 HRH1, ATG7 N/a 
gene-
centric 
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4 *rs16998073 INR FGF5 - 
Locus associated with intergenic 
region. Closest gene encodes an 
oncogene and key regulator of 
human hair growth. 
GlobalBP 
GWAS 
4 rs13107325 NS SLC39A8 SLC39A8 
Member of solute carrier family 
demonstrating divalent cation 
transport properties. 
ICBP 
GWAS 
4 rs13139571 INT 
GUCY1A3-
GUCY1B3 
GUCY1A3 
Subunit of guanylaye cyclase 
which catalyzes conversion of GTP 
to cGMP. 
ICBP 
GWAS 
4 rs6825911 INR ENPEP - 
Locus associated with intergenic 
region. Closest gene encodes an 
ectopeptidase, expressed in 
nephrons with catabolic role in 
RAS. 
meta 
4 rs871606 INR CHIC2 FIP1L1 
A subunit of the cleavage and 
polyadenylation specificity factor 
complex that polyadenylates 3' end 
of mRNA precursors. 
meta 
5 *rs1173771 INR NPR3 - 
Locus associated with intergenic 
region. Closest gene encodes 
natriuretic peptide receptor 3. 
ICBP 
GWAS 
5 *rs11953630 INR EBF1 - 
Locus associated with intergenic 
region. Closest gene encodes a 
transcriptional activator COE1. 
ICBP 
GWAS 
6 rs805303 INT PRRC2A 
PRRC2A, BAG6, 
GPANK1, 
CSNK2B, 
LY6G5B, 
ABHD16A, 
LY6G6F, C6orf25, 
DDAH2, MSH5, 
SAPCD1, VWA7, 
HSPA1A 
N/a 
ICBP 
GWAS 
6 rs1799945 NS HFE 
HFE, HIST1H2AC, 
HISTH1T, 
N/a 
ICBP 
GWAS 
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HIST1H2BC, 
HISTH4C 
6 rs6924906 INR - FAM46A 
Locus associated with intergenic 
region. Closest gene encodes a 
retina-expressed gene product of 
unknown function. 
meta 
6 rs13209747 INR RSPO3 RSPO3 
A soluble protein implicated in Wnt/ 
beta-catenin signalling. 
meta 
6 rs17080102 INT PLEKHG1 PLEKHG1 
Promotes protein-bound GDP to 
GTP exchange and activation of 
Rho, modulating cytoskeleton 
remodelling 
meta 
6 rs2854275 INT HLA-DQB1 
HLA-DQB1, HLA-
DRB1, HLA-
DRB3, HLA-DOB 
N/a 
gene-
centric 
7 rs3918226 INT NOS3 NOS3 
Enzyme catalysing L-arginine 
conversion to NO, a vasomotor 
tone and blood flow regulator. 
gene-
centric 
7 *rs17477177 INT PIK3CG - 
Locus associated with intergenic 
region. Closest gene encodes 
kinase protein mediating signalling 
regulating cell survival, 
proliferation, and motility. 
meta 
7 rs17428471 INR 
EVX1-
HOXA 
- 
Locus associated with intergenic 
region. Closest gene encodes a 
transcriptional repressor 
functioning during embryogenesis 
meta 
7 rs2949837 INR IGFBP3 - 
Locus associated with intergenic 
region. Closest gene encodes an 
insulin-like growth factor binding 
protein found in human endothelia. 
meta 
7 rs2282978 INT CDK6 
CDK6, ERVWE1, 
GATAD1, PREX1 
N/a 
gene-
centric 
7 rs10224002 INT PRKAG2 
PRKAG2, 
NUB1,WDR86 
N/a 
gene-
centric 
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8 *rs2898290  BLK-GATA4 
C8orf14, BLK, 
C8orf8, C8orf12, 
C8orf13, C8orf16, 
C8orf49, CTSB, 
FDF1, GATA4, 
MTMR9, NEIL2, 
TDH, XKR6 
N/a meta 
8 rs2071518 UTR NOV NOV 
A small secreted cysteine-rich 
regulatory protein which associates 
with ECM and plays a role in CV, 
skeletal, fibrosis and cancer 
development. 
meta 
8 rs12541063 INT MIR30D MIR30D 
Small, non-coding RNA derived 
from miR30 precursor. miR30 
members are highly expressed in 
the heart. 
meta 
8 rs2446849 INR CDH17 - 
Locus associated with intergenic 
region. Closest gene encodes a 
protein which is a cadherin-like, 
calcium-dependent, membrane-
associated glycoprotein. 
meta 
10 *rs4373814 INR CACNB2 CACNB2 
Encodes the obligatory subunit for 
function of voltage-gated Ca+2 
channel also associated with 
Bruguda syndrome. 
CHARGE 
GWAS 
10 *rs1530440 INT C10orf107 C10orf107 Unknown 
GlobalBP 
GWAS 
10 rs932764 INT PLCE1 PLCE1 
Catalyses hydrolysis of 
polyphosphoinositides to initiate 
second messenger signalling 
cascades influencing cell 
differentiation. 
ICBP 
GWAS 
10 *rs1801253 INR ADRB1 ADRB1 
Encodes adrenergic receptor 
subtype beta 1 that mediates the 
physiological effects of 
neurohormone epinephrine 
meta 
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10 rs7088591 INR IPMK - 
Locus associated with intergenic 
region. Closest gene encodes 
inositol phosphate multikinase 
involved in intracellular secondary 
messenger pathways. 
meta 
10 *rs3824755 INT 
CYP17A1-
NT5C2 
AS3MT, C10orf32, 
CNNM2, NT5C2, 
CYP17A, 
C10orf26, INA 
N/a 
CHARGE 
GWAS 
10 rs4746172 INT VCL ADK, AP3M1, VCL N/a 
gene-
centric 
11 rs381815 INT PLEKHA7 PLEKHA7 
This protein is part of the 
adherents’ junction complex 
regulating cell-cell interactions. 
CHARGE 
GWAS 
11 rs7129220 INT ADM 
SBF2, ADM, 
AMPD3, SWAP70 
N/a 
ICBP 
GWAS 
11 rs633185 INT 
FLJ32810-
TMEM133 
ARHGAP42 
Encodes smooth-muscle specific 
RhoGAP regulating RHOA and 
tissue’s contractility. 
ICBP 
GWAS 
11 rs661348 INT LSP1 LSP1, TNNT3 N/a 
gene-
centric 
11 rs11222084 INR ADAMTS8 ADAMTS8 
The enzyme metalloproteinase 
encoded by this gene contains two 
C-terminal TS motifs, and disrupts 
angiogenesis in vivo. 
meta 
11 *rs1401454 INT SOX6 SOX6 
Transcription factor binding to a 
specific DNA sequence. Involved in 
cardiac and skeletal muscle 
development. 
meta 
11 rs11041530 INR PPFIBP2 
PPFIBP2, 
CYB5R2 
N/a meta 
11 rs217727 INR H19 
H19, LSP1, 
MRPL23, TNNT3 
N/a 
gene-
centric 
11 rs757081 NS NUCB2 
NUCB2, ABCC8, 
KCNJ11, 
PIK3C2A, 
PLEKHA7, RPS13 
N/a 
gene-
centric 
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11 rs3741378 NS RELA 
RELA, SIPA1, 
KAT5, 
N/a 
gene 
centric 
12 *rs17249754 INT ATP2B1 ATP2B1, POC1B N/a 
CHARGE 
GWAS 
12 *rs3184504 NS 
SH2B3-
ATXN2 
ATXN2, C12orf47, 
SH2B3, TRAFD1, 
PTPN1, C12orf51, 
ACAD10, NAA25, 
BRAP,ERP29,ALD
H2 
N/a 
CHARGE 
GWAS 
12 *rs2384550 INR TBX3-TBX5 - 
Transcriptional repressor 
implicated in blood vessel 
development and cardiomyocyte 
cell fate determination. 
CHARGE 
GWAS 
12 rs11066289  
RPL6-
ADLH1 
HECTD4 
Encodes E3 ubiquitin-protein 
ligase which transfers conjugated 
ubiquitin from enzyme to substrate. 
meta 
12 rs7297416 INT HOXC4 
HOXC4, HOXC5, 
HOXC6, HOXC8, 
HOXC9 
N/a 
gene-
centric 
13 rs2315885 INR MIR5007 miR1297 
Locus associated with intergenic 
region encoding small non-coding 
RNAs that regulate post-
transcriptional gene expression. 
This miR has been associated with 
oncogenesis. 
meta 
15 rs1378942 INT 
CYP1A1-
CSK-ULK3 
CPLX3, CSK, 
CYP1A2, 
LMAN1L, COX5A, 
ULK3, C15orf17, 
MPI, SCAMP5, 
RPP25, PPCDC 
N/a 
GlobalBP 
GWAS 
15 rs2521501 INT FES-FURIN FES, FURIN N/a 
ICBP 
GWAS 
15 rs1036477 INT FBN1 
FBN1, CEP152, 
DUT, SLC12A1 
N/a 
gene-
centric 
49 
 
Note: INT – intronic, INR – intergenic, NS – non synonymous, UTR – untranslated 
region. (*) denotes the first published SNP in instances where more than one rs 
number has been reported to be associated with a given gene locus. 
 
1.5 Blood-pressure associated SNPs at NPR3 gene locus 
1.5.1 rs1173771 linkage disequilibrium block  
Recently, the International Consortium for Blood Pressure Genome-Wide Association 
Studies (ICBP-GWAS) identified 29 variants associated with SBP, DBP or both from 
more than 200,000 individuals of European descent. Among those variants, is the 
index SNP rs1173771 (G/A) located at the natriuretic peptide receptor C (NPR3) 
locus. The major allele, G allele, is found to be associated with elevation of blood 
pressure. Its per-allele effect size is 0.504 mmHg for SBP and 0.261 mmHg for DBP 
(Figure 1.4).65
16 rs13333226 - UMOD UMOD 
Most abundant glycoprotein in 
normal urine. It localises to 
nephrons' distal tubules. Known to 
influence kidney stone formation. 
extreme 
case 
control 
study 
16 rs33063 INT NFAT5 NFAT5, WWP2 N/a 
gene-
centric 
17 rs12946454 INT PLCD3 
HEXIM1, HEXIM2, 
PLCD3, ACBD4, 
DCAKD, NMT1 
N/a 
GlobalBP 
GWAS 
17 *rs16948048 INT ZNF652 
LOC102724596, 
ABI3, B4GALNT2, 
PHOSPHO1, 
ZNF652 
N/a 
GlobalBP 
GWAS 
17 rs17608766 INT GOSR2 
GOSR2, RPRML, 
CDC27 
N/a 
ICBP 
GWAS 
20 rs1327235 INR JAG1 - 
This locus is associated with 
intergenic region. The nearest 
gene encodes ligand for receptor 
notch 1. 
ICBP 
GWAS 
20 *rs6015450 INT 
GNAS-
EDN3 
ZNF831, 
C20orf174 
N/a 
ICBP 
GWAS 
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Figure 1.4 Genome-wide –log10 P-value plots and effects for significant loci.  
NPR3-C5orf23 locus is marked with red rectangle.65  
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SNP rs1173771 is an intergenic variant, 20 kb downstream flanking the gene coding 
for NPR3. It is in high linkage disequilibrium (LD) (r2>0.75) with 14 SNPs in CEU 
population and 25 SNPs in CHB and JPT population in a 100kb sequence 
encompassing the NPR3 gene according to the 1000 Genomes Project. In those 
SNPs, three are located at NPR3 gene involving a 3 untranslated region (3’ UTR) 
SNP and two intronic SNPs. The remaining are intergenic SNPs located downstream 
of NPR3.  
 
Kato et al also identified a SNP rs1173766 (C/T) in 3’ flanking region of NPR3 
(P=1.9×10-8 for SBP; P=1.2×10−7 for DBP) in a blood pressure GWAS in 19 414 
subjects of East Asians,69  a finding replicated by de novo genotyping in 10 461 
Japanese subjects. This SNP is highly associated with rs1173771 (r2=1.0 in 
CHB+JPT), and this supports the finding that SNP rs1173771 is a blood-pressure-
associated SNP. 
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Figure 1.5 Regional plots of SNP rs1173771 in CEU (A) and CHB+JPT (B) at the 
NPR3 locus.  
SNPs (including rs173766) between the horizontal dashed lines are in high linkage 
disequilibrium (LD) (R-squared is 0.7) with SNP rs1173771 from the 1000 Genomes 
Project. 
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1.5.2 rs1421811 linkage disequilibrium block  
In addition, an association of the intronic SNP rs1421811 with hypertension 
susceptibility was observed using a bespoke gene-centric array at the study-specific 
significance threshold of p < 8.56 × 10−7, and effect size for its minor allele (G) is 
−0.67mmHg in SBP.70  SNP rs1421811 is an intronic variant located at NPR3 intron 
1. It is in high LD (r2>0.7) with 20 SNPs in CEU population and 25 SNPs in CHB and 
JPT population in a 100kb sequence encompassing the NPR3 gene according to the 
1000 Genomes Project (Figure 1.6). SNP rs1421811 is in low LD with rs1173771 
(r2=0.13 in CEU; r2=0.05 in CHB+JPT). 
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Figure 1.6 Regional plots of SNP rs1421811 in CEU (A) and CHB+JPT (B) at the 
NPR3 locus.  
SNPs between the horizontal dashed lines are in high linkage disequilibrium (R-
squared is 0.7) with SNP rs1421811 from the 1000 Genomes Project. 
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In total, SNPs in these two LD blocks are mainly non-coding variants including the 
intronic and intergenic SNPs.  As indicated in section 1.3.2, there is one possibility 
that these SNPs might be located in the regulatory elements interacting with 
transcriptional factors, or impacting alternative splicing, then influence gene 
expression, subsequent protein function and BP-related phenotypes.  
 
 
1.6 NPR-C signalling system and regulation 
1.6.1 NPR-C  
The NPR3 gene is located on human chromosome 5p14-p13. It has 8 exons, 7 
transcripts, and finally translated 3 subtypes of natriuretic peptide receptor C (NPR-
C). Subtype 1 (541aa) and 2 (540aa) are found to be functionally present in a 
variability of tissue and cells including vasculature.71 NPR-C is composed of disulfide-
linked homodimers of a single transmembrane 64–66 KDa protein. It contains a large 
extracellular domain of about 440 amino acids which is homologous to NPR-A and 
NPR-B, a single membrane-spanning domain and of a short cytoplasmic tail of 37 
amino acids.72  Its cytoplasmic domain contains a Ga inhibitory protein-activating 
sequence.73 NPR-A and NPR-B can activate guanylyl cyclase, but NPR-C does not 
demonstrate guanylyl cyclase activity.74  NPR-C is the most abundantly expressed 
NPR, comprising up to 95% of the total amount of NPR, and has similar affinity for all 
natriuretic peptides (NPs).75 NPR-C is distributed widely in several cells and issues 
including vascular smooth muscle cells and mesangial cells,76,77  the major endocrine 
glands, lungs, kidneys and the vascular wall including endothelium.78  
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Figure 1.7 Structure of NPR3 gene and its protein NPR-C. 
NPR-C was coded by NPR3 gene and its extracellular domain / ligand binding domain 
could bind with all natriuretic peptides (NPs) 75. 
 
1.6.2 NPR-C associated signalling pathways  
At the time of its discovery, NPR-C was primarily considered to be a systemic 
clearance receptor, removing natriuretic peptides (NP) from the circulation.75,79  
Binding of NP to NPR-C leads to internalization and removal of the peptides from 
blood.73 However, accumulating evidence has modified the initial view and suggested 
a separate/different physiological role of NPR-C. It has since been demonstrated to 
be coupled to the adenylyl cyclase/cAMP signal transduction system through 
inhibitory guannine nucleotide regulatory protein (Gi) and elicits physiological 
function.80–82  The cytoplasmic domain of NPR-C contains several Gi activator 
sequences which could bind and activate Gi regulatory protein.83   The α subunit of 
this Gi protein inhibits adenylyl cyclase, resulting in lower intracellular formation of 
cAMP. 84  This inhibitory effect is supported by the application of C-ANF4-23, a synthetic 
agonist of NPR-C, which inhibits adenylate cyclase activity in anterior pituitary, aorta, 
brain striatum and adrenal cortex in a concentration-dependent manner without 
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affecting cGMP levels.81   In other words, NPR-C is a negative regulator of adenylate 
cyclase/cAMP system, whereas both NPR-A and NPR-B are coupled to guanylate 
cyclase/cGMP system.72 
 
Moreover, when the Gi protein is activated, its β/γ subunit activates phospholipase C 
(PLC) and stimulates phosphatidyl inositol (PI) turnover in bovine and A10 vascular 
smooth muscle cells.85  Stimulation of NPR-C has been found to inhibit vascular 
smooth muscle cell proliferation through mitogen-activated protein kinase (MAPK) 
and PI3-kinase pathways.86  NPR-C has also been implicated in the modulation of 
other signalling pathways. Murthy et al. has shown NPR-C activation by C-ANF4-23 
can result in the activation of constitutive nitric oxide synthase (NOS) via Giα1 and Giα2 
in gastrointestinal smooth muscle.87  Furthermore, NPR-C binding to CNP or C-ANF4-
23 has been shown to inhibit L-type Ca2+ current (ICa,L) without modulating other 
voltage-gated Ca2+ currents in mouse atrial, ventricular, and sinoatrial node 
myocytes.88  
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Figure 1.8 Summary of NPR-C-coupled signalling systems. 
Natriuretic peptide (NP) receptors and associated signal transduction mechanisms 
activated by different natriuretic peptides. NPR-C, which is coupled to adenylyl 
cyclase through Gi protein. C-ANF4–23, ANP, BNP, and CNP interact with this receptor 
and inhibit adenylyl cyclase activity and suppress cAMP concentrations.72  
 
1.6.3 Regulation of NPR-C expression  
NPR-C expression has been showed to be influenced under various conditions and 
by a variety of hormonal factors. Chabrier et al. found a down-regulation of NPR-C by 
the treatment of angiotensin II (Ang II) in rat vascular smooth muscle cells (VSMCs).89 
Similarly, Yasimoto et al. showed Ang II treatment induced a decrease of NPRC 
mRNA levels in cultured rat aortic smooth muscle cells, whereas NPRA and NPRB 
were not alternated by this treatment.90  Other pro-hypertensive peptides, such as 
endothelin (ET-1) and arginine–vasopressin (AVP) have also been demonstrated to 
modulate NPR-C receptor expression. It is showed pre-treatment of endothelin (ET-
1) attenuated NPR-C protein expression by about 60% in A-10 SMCs,91  and was also 
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decreased by about 50% by AVP treatment in A-10 SMCs.72 Moreover, 
norepinephrine or isoproterenol could also down-regulate NPR-C density mediated 
by the activation of the beta 2-adrenergic receptor, as the effect was blocked only by 
a antagonized by a beta 2-selective adrenergic antagonist, but not by an alpha 1-, 
alpha 2-, or beta 1-adrenergic antagonists in rat VSMCs.92  Treatment of vascular 
endothelial cells with NaCl resulted in a marked reduction in the number of NPR-C, 
which may be related to the clearance function of NPR-C.93   It is also revealed that 
fibroblast growth factors (FGF-1 and FGF-2) and platelet-derived growth factor-BB 
(PDGF-BB) that activate tyrosine kinase receptors can reduce expression of NPR-C 
in PASMCs.94  In addition, nitric oxide (NO) was demonstrated to decrease the 
expression of natriuretic peptide receptor C (NPR-C) and adenylyl cyclase signalling 
in A10 SMC through cGMP-independent but MAPK-dependent pathway.95  However, 
transforming growth factor-1 (TGF-1) has been reported to augment the expression 
of NPR-C at the transcriptional level in a murine thymic stromal cell line (MRL 104.8a) 
96 and glucocorticoids could also increase NPR-C density on human cultured 
mesangial cells.97 
 
Table1.2 Hormonal factors for regulating NPR-C. 
 
Down-regulate Up-regulate 
Ang II, ET-1,AVP, NO, NaCI, isoproterenol 
FGF-1,FGF-2,DDGF-BB 
TGF-1 
Glucocorticoids 
 
 
NPR-C is also regulated by various pathophysiological states. It is demonstrated 
fasting inhibits NPR-C expression in rat adipose tissue.98  Several groups have 
shown that acute and chronic hypoxia cause the down-regulation of NPR3 gene 
expression and binding in rat lung without affecting other NPRs.99–101  Nagase et al. 
demonstrated that NPR3 gene expression was selectively attenuated in the kidney 
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by chronic salt loading in Dahl salt-sensitive and salt-resistant rats.102  More recently, 
it is indicated that the gene expression of NPR-C in aortic tissue of spontaneously 
hypertensive rats (SHR) was higher than that in normal rats(WKY).103 
 
1.6.4 NPR-C and diseases 
1.6.4.1 Hypertension 
When physiologically activated (as described in Figure 1.8), NPR-C seems to exert 
protective vascular effects, suggesting a direct anti-hypertensive role. Indeed, a great 
deal of evidence has supported this. A lower NPR-A / NPR-C ratio is observed in 
obese hypertensive patients. This might result in a down-regulation of biological 
activity and/or an up-regulation of clearance of natriuretic peptide in adipose tissue, 
and plays an important role in obesity-associated hypertension.104   An increased ANP 
receptor density has also been reported in cultured VSMC from spontaneously 
hypertensive rats (SHR) and other models of experimental hypertension suggesting 
that increased plasma levels of ANP in hypertension, may result in the down-
regulation of NP receptors.105 Nagase, Ando et al revealed that there is an 
exaggerated reduction of NPR-C number in the kidney in response to salt loading in 
Dahl salt-sensitive rats, suggesting a role of NPR-C in pathogenesis associated to 
renal sodium excretion in salt hypertension in this animal model.102  
 
Moreover, it is demonstrated C-ANF4-23 (a specific synthetic NPR-C receptor agonist) 
increased nitric oxide synthase (NOS) activity in cardiac ventricle and atria, renal 
medulla and cortex and aorta artery, and ANP would interact with NPR-C coupled via 
Gi to activation Ca2+ -dependent NOS.106  CNP/NPR-C signalling has also been 
revealed as an important pathway which underlies endothelium-derived 
hyperpolarizing factor (EDHF)-dependent regulation of vascular tone in the rat 
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mesenteric resistance arteries and in the coronary vasculature.107  Li, et al. reported 
that the gene expression of NPR-C in aortic tissue of spontaneously hypertensive rats 
(SHR) was higher than that in normal rats(WKY).103 In general, human hypertension 
is recognised as a state of NPR-C deficiency. 
 
Recently, a downstream SNP located at the natriuretic peptide receptor C (NPR3) 
locus has been identified as associated with hypertension by International Consortium 
for Blood Pressure Genome-Wide Association Studies (ICBP-GWAS).108 A separate 
combined study of admixture mapping and association analysis found an upstream 
SNP near NPR3 being associated with SBP and DBP.109 Furthermore, an intronic SNP 
in NPR3 gene is reported with a gene-centric array.110  This additional evidence also 
implies a potential role of NPR3/NPR-C in regulation of hypertension. 
 
1.6.4.2 Cardiovascular atherosclerosis and myocardial infarction 
NPR-C has also been implicated in the regulation of proliferative processes through 
various experimental in vitro studies. In particular, an anti-proliferative action has been 
described in smooth muscle, endothelial and astroglial cells.111,112   NPR-C was 
strongly expressed in the neointimal SMCs, and seems to be important in controlling 
neointimal growth after percutaneous trans-luminal revascularization (PCI).113 This is 
further supported by immunohistochemistry and immunofluorescence staining 
showed NPR-C near the luminal surface of the atherosclerotic plaque and in 
VSMCs.114  
 
Hobbs et al. have showed binding of CNP to NPR-C could contribute to maintain 
coronary perfusion of myocardium and that activation of this molecular mechanism 
could protect against the ischemia/reperfusion (I/R) injury by reducing the infarct size 
in the rat model.115 Thus, CNP/NPR-C signalling pathway may be viewed as important 
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in cardiovascular homeostasis. In addition, the mRNA levels of NPR-C were 
augmented in both the infarcted and non-infarcted regions of the left ventricular wall 
(LV), while it was decreased in the kidneys and lungs 28 days after MI.116 It has also 
been demonstrated that low levels of the natriuretic peptides preferentially activate 
NPR-C and increase cardiomyocyte proliferation through inhibition of adenylate 
cyclase.117  
1.6.4.3 Obesity  
NPR-C has been identified to be highly expressed in adipocytes and adipose tissue, 
and is stimulated by a high fat diet, and conversely suppressed by fasting.98,118,119  In 
addition, NPR-C gene expression in adipose tissue is higher in obese hypertensive 
than in obese normotensive subjects.104  It has been reported that insulin, an 
antilipolytic hormone, significantly increased NPR3 mRNA levels through the 
phosphatidylinositol 3-kinase (PI3-kinase) pathway.118  NP receptors in adipose tissue 
are also under estrogenic control. Higher NPR-C gene expression is found in 
mesenteric adipose tissue and in the kidneys in the overweight estrogen-deficient 
follitropin receptor knockout mice, which could be associated with obesity and 
hypertension.120  
1.6.4.4 Growth abnormality  
Matsukawa, Grzesik et al found mice with NPR3 gene disrupted (Npr3 -/-) had a high 
rate of mortality( more than 50%) compared with other genotypes during growth 
before reproducing, and exhibited striking skeletal deformities with abnormal long 
bone growth and chondrocytes.121 mRNA for NPR3 is readily detected in osteoblasts 
and 1,25 dihydroxyvitamin D3, a key regulator of mineral metabolism, significantly 
increased NPR3 mRNA in osteoblastic cells,122  indicating a role for NPR-C in 
regulation of growth. Another study confirmed that mice that carry a mutation in NPR3  
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gene exhibited a skeletal overgrowth phenotype, resulting in an elongated body and 
kyphosis.123  
 
A recent GWAS study indicated a SNP located on 5p14, 100 kb upstream of NPR3 
gene is associated with body height. Apart from NPR3 locus, another SNP only away 
6kb of natriuretic peptide precursor type C (NPPC) gene, which encodes CNP, is also 
found to be associated with overgrowth and skeletal abnormalities.124  CNP is also 
revealed as a molecule that regulates endochondral ossification of the cartilaginous 
growth plate, resulting in longitudinal bone growth.125  Thus, it might suggest CNP/ 
NPR-C signalling system represents an important pathway involved in determining of 
bone growth and height variation in humans. 
 
 
Figure 1.9 Schematic description of the intracellular mechanisms activated by 
NPR-C stimulation. 
 the direct effects (continuous lines) possibly exerted on main target tissues and the 
consequent potential contribution to pathological phenotypes.126 
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1.7 CNP/NPR-C signalling transduction system and hypertension  
C-type natriuretic peptide (CNP) belongs to a family of natriuretic peptides and plays 
an important role in the cardiovascular homeostasis.127,128  CNP is present in a high 
concentration in peripheral tissues, particularly vascular endothelial cells.128–131  The 
relatively high expression of CNP in the vascular endothelial cells and the presence 
of its receptors NPR-C on the underlying smooth muscle cells, suggests that this 
peptide has the capacity to affect vascular tone. Indeed, local infusion of CNP 
increases the forearm blood flow, an effect that is independent from nitric oxide 
(NO).131   Recent studies have revealed that the CNP/NPR-C signal transduction 
system is an important pathway in the regulation of peripheral blood flow and CNP 
acts as an endothelium-derived hyperpolarizing factor (EDHF) inducing relaxation 
mediated by the NPR-C pathway.115,132  
 
Moreover, a facet of the vasoprotective profile of CNP is mediated via NPR-C-
dependent ERK 1/2 phosphorylation, resulting in augmented endothelial cell 
proliferation and inhibition of vascular smooth muscle growth. This pathway may offer 
an innovative approach to reversing endothelial damage and vascular smooth 
muscle hyperplasia.133  NPR-C binding to CNP or C-ANF4-23 has been shown to inhibit 
L-type Ca2+ current (ICa,L) without modulating other voltage-gated Ca2+ currents in 
mouse atrial, ventricular,88 which subsequently affect vascular contraction and blood 
pressure control. Indeed, the NPR-C agonist, C-ANF compound 118, caused 
relaxation of isolated mesenteric resistance arteries, which is inhabitable by NPR-C 
antagonism. It also promoted a reduction of blood pressure in wild-type mice 
(ED50<1mg/kg), which could be blunted in NPR-C KO mice.134  
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Figure 1.10 Activation of natriuretic peptide receptor (NPR)-C by endothelial 
CNP underlies a key mechanism regulating vascular tone and local blood flow. 
NPR-C binding with CNP/c-ANF lead to augmented endothelial cell proliferation and 
inhibition of vascular smooth muscle growth via ERK 1/2 phosphorylation, and 
decreased calcium influx. 88 ,133   
 
 
To the basic level, hypertension implies an increase in either blood volume or total 
peripheral resistance (TPR) regulatory influence, thus, any impact or pathway 
influencing both or either determinant could be associated with pathophysiology of 
hypertension. 
 
As a candidate for endothelial derived hyperpolarising factor (EDHF), CNP potentially 
influences the peripheral blood flow and resistance of arteries and arterioles via NPR-
C. It is reported CNP infusion reduced MAP in spontaneously hypertensive rats.135  
Skau, Goetze et al found a decrease of plasma pro-CNP concentration in idiopathic 
intracranial hypertension (IIH), reflecting a role of endothelial deregulation of vascular 
tone in this disease.136  In addition, CNP also significantly attenuated the increases in 
right ventricular (RV) systolic pressure and the ratio of RV weight to body weight in 
monocrotaline-induced pulmonary hypertension.137   In a study of age-related 
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myocardial fibrosis in Fisher rats, there was an inverse relationship between 
decreasing circulating CNP and increasing LV fibrosis that precedes subsequent 
reductions in diastolic and systolic function. It was found there was a significant and 
progressive decrease in plasma CNP from 2 to 11 to 20 months of rats, a modest but 
significant increase in MAP at 20 months with increasing LV fibrosis, and they also 
demonstrated that involved anti-proliferative action of CNP/NPR-C on cardiac 
fibroblasts (CFs).138  
 
In summary, as indicated by studies described above, NPR-C/CNP signalling pathway 
plays an important role in the development of hypertension.   
 
 
1.8 Original hypothesis  
Given the central role of the natriuretic peptide system in cardiovascular homeostasis 
and association of genetic variants at NPR3 with blood pressure level, we 
hypothesised that functional effects of these or nearby variants affect BP via 
regulating NPR3 gene expression and its related pathways on cell phenotypes.  
 
1.9 Aims and objectives 
The overall aim of this thesis is to investigate the potential functional role of blood-
pressure associated variants in NPR3 gene in the development of hypertension. 
 
Objectives: 
1. To investigate effects of BP-associated variations in the NPR3 gene on NPR3 
RNA and NPR-C protein expression in HUASMCs and HUVECs by quantitative RT-
PCR, allelic expression imbalance assay and western blot analysis. 
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2. To study possible interaction of transcription factors with BP-associated 
variants at the NPR3 locus in vitro and in vivo by electrophoretic mobility shift assay, 
chromatin immunoprecipitation, and formaldehyde-assisted isolation of regulatory 
elements analysis, 
 
3. To investigate effects of BP-associated variants at the NPR3 locus in 
CNP/NPR-C signalling pathway and on calcium flux, migration and proliferation of 
HUASMCs and HUVECs. 
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2. Materials & Methods 
 
 
 
 
 
 
 
 
 
69 
 
2.1 Human cell samples  
2.1.1 Isolation of human umbilical cords arterial smooth muscle cells 
(HUASMCs) 
VSMC cultures were isolated from human umbilical arteries ( Figure 2.1) according to 
the previous technique139 and approved by the appropriate ethics committee 
(08/H0704/140, AM05 Minor Amendment). Briefly, the umbilical cords were collected 
from The Royal London hospital and preserved in physiological saline solution (PSS) 
(0.85% w/v NaCl) before isolation. The arteries were isolated surgically from the cords 
and the tissue minced into small segments. The pieces were plated onto a 0.2 % w/v 
gelatin- (Sigma, G1890)-coated T25 flasks and incubated in a humidified incubator of 
5 % CO2 at 370C for 2 hours standing by, allowing arterial segments attach to the 
flasks. Then they were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
(Sigma) supplemented with 20% fetal bovine serum (FBS) (Gibco), 2 mM L-glutamine 
(Sigma), 100 U/mL penicillin (Sigma) and 100 mg/mL streptomycin (Sigma). The 
flasks were allowed to stay in the incubator for 7 days until replacement of DMEM 
medium. After that, cells were detached with 0.25% trypsin-EDTA (Sigma) and sub-
cultured to a fresh 0.04% gelatine-coated T25 flask when there was adequate 
proliferation of cells (70%-80% confluence).  
 
2.1.2 Isolation of human umbilical cords endothelial cells (HUVECs) 
Endothelial cells cultures were prepared from human umbilical veins (Figure 2.1) and 
generously donated by Biochemical Pharmacology at the William Harvey Research 
Institute. The cells were harvested by methods as previously described.139  In brief, 
the umbilical vein was washed with cold phosphate buffered saline (PBS) (137mM 
NaCl, 2.7mM KCl, 10mM Na2HPO4, and 2mM KH2PO4), then injected with 0.1% 
collagenase (Gibco) and incubated for 30 min. The vessels was purged with PBS 
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and this PBS containing HUVECs was collected and centrifuged. Cell pellet was 
suspended in Medium 199 (Sigma) supplemented with 15% fetal bovine serum 
(Gibco), penicillin-streptomycin (Sigma) and endothelial cell growth factors (2.5μg/ml 
thymidine, 10 U/ml heparin, 4.5μg/ml endothelial cell growth supplement, 2.5μg/ml 
human β-endothelial cell growth factor )(Sigma) and cultured in gelatin-coated flasks 
until growing up to confluence.  The cells were then detached by 0.25% trypsin- 
EDTA, resuspended into new flasks by certain dilution with fresh medium.  
 
 
Figure 2.1 Human umbilical cords arteries and vein. 
 
2.1.3 Cell culturing  
Once HUASMCs and HUVECs were isolated and harvested, they were both 
maintained in specific media (see below). For HUASMCs, the culture medium used 
was DMEM that was supplemented with 15% FBS, 2mM L-glutamine, 100 U/mL 
penicillin, 100 mg/mL streptomycin and SMCs growth factors (0.5ng/ml recombinant 
human epidermal growth factor, 2ng/ml recombinant human basic fibroblast growth 
factor, 5μg/ml recombinant human insulin) (ProSpec). Otherwise, Medium 199 
supplemented with 15% FBS, penicillin-streptomycin and endothelial cell growth 
factors (see section 2.1.2) were used for HUVECs. When the cells were grown up to 
about 80% confluence, they were detached by 0.25% trypsin-EDTA (Sigma) and 
sub-cultured into new 0.04% gelatine-coated flasks with fresh medium. Passages 2-
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6 of HUASMCs and passages 2-5 of HUVECs were utilised for subsequent functional 
experiments. 
 
In total, an amount of 282 umbilical cords were collected by the team during three 
years from 2012-2014. 247 cell samples were successfully obtained with 35 samples 
failed due to no cells growing or contaminations.   
 
2.1.4 Cell counting using a haemocytometer 
Cell counting was performed in several subsequent experiments including cell 
proliferation, migration and calcium flux assays by utilising haemocytometer. In brief, 
HUASMCs and HUVECs cell suspension were gently pipetted up and down to ensure 
the cells are evenly distributed. 10ul of cell suspension was then mixed with equal 
volume of 0.4% Trypan Blue (Sigma), and subjected at the edge of the coverslip on a 
pre-cleaned glass haemocytometer. 
The live, unstained cells (live cells do not take up Trypan Blue) were counted in one 
set of 16 squares under a microscope (as shown in Figure 2.2).The cell concentration 
per ml was calculation by following equation: 
Cell concentration = average number of cells in one large square × dilution factor ×104 
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Figure 2.2 Haemocytometer gridlines. 
Haemocytometer diagram indicating one of the sets of 16 squares that should be used 
for counting. 
 
2.1.5 Preservation and recovery of cells  
Both HUASMCs and HUVECs were preserved in liquid nitrogen for long term storage. 
Cells were cultured to confluency, detached by 0.25% trypsin-EDTA and resuspended 
in freezing medium (80% FBS, 10% dimethyl sulfoxide and 10% DMEM or M199) in 
cryovials at a concertation of 1X 107 cells/ml. To prevent cell death during freezing, 
cells was preserved in a freezing container (Nalgene® Mr. Frosty) filled with 100% 
isopropyl alcohol for gradually cooling to -80 °C by -1°C/minute, then was transferred 
to liquid nitrogen for long term storage.  
 
During the recovery, cells were taken out from liquid nitrogen and transported on dry 
ice, quickly thawed in a 37°C water bath. Cell pellets was harvested by centrifuging 
at 1,000g for 5 min at room temperature and suspended into pre-warmed growth 
medium in new 0.04% gelatine-coated flasks. After incubation at in a humid incubator 
of 5 % CO2 at 370C overnight, medium was removed and replaced with fresh growth 
medium.  
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2.2 Bioinformatics analysis  
To explore characteristics of BP-associated SNPs and potential transcriptional factor 
binding sites (TFBS) or micro RNA interactions, a series of programs and tools were 
used. The SNAP (SNP Annotation and Proxy Search; 
http://www.broadinstitute.org/mpg/snap/) based on data from the International 
HapMap Project was used for exploring BP associated SNPs in high LD in different 
populations. The UCSC Genomic Bioinformatics database (http://genome-
euro.ucsc.edu/; GRCh37/hg19 produced by Genome Reference Consortium), Gene 
Regulation (http://www.gene-regulation.com/pub/programs.html), were used to 
investigate potential transcriptional factor binding sites (TFBS) or histone-modification 
associated with BP-associated variants at NPR3 locus.  
Databases or programs such as TargetScan (http://www.targetscan.org/vert_61/) 
Micro RNA (http://www.microrna.org/microrna/home.do) and micRWalk v3.0 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) were used for searching 
possible micRNA associated with BP associated SNPs at NPR3 locus. As shown in 
Table 2.1, the potential transcription factors or histone modifications as well as miRNA 
were predicated to be associating to BP-associated SNPs in rs1173771 LD block at 
NPR3 locus. 
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Table 2.1 Bioinformatics update about BP-associated SNPs in rs1173771 LD 
block. 
 ENCODE  Other tools 
SNP Cell lines TFBS/HM TFBS 
rs1173771 
HUMM H3K27AC;H3K27M3  
HUMM tube H3K4M1  
HuVEC H3K9M3  
rs1173743 
HUMM H3K9M3;EZH2 PAI-2  
HUMM tube H3K9M3;H3K27M3 P53.05 
HuVEC H3K9M3  
rs1173747 
HUMM  GATA-1 
HUMM tube H3K27AC;H3K27M3 GR,GR-alpha, GR-beta 
HuVEC H3K9M3 Y-box binding factor; TCF3 
rs1173756 
HUMM H3K9M3; H3K4M1  
HUMM tube H3K27AC;H3K27M3;EZH2  
HuVEC H3K9M3  
TFBS: transcription factor binding sites; HM: histone modification; HUMM: skeletal 
muscle myoblasts; HUMM tube: skeletal muscle myotubes differentiated from the 
HSMM cell line. 
 
 
2.3 Genotyping (KASPar SNP Genotyping system) 
The Kbiosciences Competitive Allelic-specific PCR SNP genotyping system (KASPar) 
is a fluorescent genotyping system that is cost-effective and widely used. This 
technique involves two 5’-fluro-labelled oligos, one labelled with FAM, the other with 
VIC/HEX, and sequences of oligos are designed to interact with the sequences of the 
tails of allele specific primers. Once dsDNA denature, allele specific primers bind to 
ssDNA with target SNP and amplify the target region with the common reverse primer, 
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generating a complimentary copy of target allele tail. New allele-specific tail 
sequences increase with more cycles, and bind the complementary fluoro-labelled 
part of FRET cassette, releasing the fluorescence label from its quencher to generate 
a fluorescent signal.    
 
This method was used investigating genotypes of blood-pressure associated SNPs 
(rs1173771 LD block and rs1421811 LD block) at NPR3 gene locus in HUASMCs and 
HUVECs.  
 
Figure 2.3 Systemic principles of KASPar genotyping system. 
KASPar genotyping is a fluorescent genotyping system involving two 5’-fluro-
oligos/primers labelled with FAM, or VIC/HEX targeting each allele. After amplification 
by PCR, clusters representing different genotypes are separated by end-point 
fluorescent reading.   (Modified from: http://www.lgcgenomics.com/genotyping/kasp-
genotyping-chemistry/how-does-kasp-work/)  
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2.3.1 DNA extraction 
HUASMCs and HUVECs were harvested from flasks and suspended in 500μl lysis 
buffer (10 mM Tris pH 8.0, 10 mM EDTA, 100 mM NaCI, 0.5 % SDS), and then 250μl 
of 5 M NaCI. The samples were mixed until the cells were totally dissolved.  The 
mixture was centrifuged at room temperature for 5 min at 13,000g and the supernatant 
was removed to a fresh microcentrifuge tube. Following this, 500μl isopropanol was 
added, then mixed gently for 2 min. After the samples were centrifuged again and the 
supernatant discarded, the DNA pellet left in the tubes was washed with 500μl 70% 
ethanol, then the mixture was centrifuged at 13,000g at room temperature and the 
majority of supernatant was carefully removed. The DNA was allowed for air dry for 
approx. 30 min and was eluted with 40μl nuclease-free water with gentle mixing. In 
the end, the concentration of DNA was quantified by NanoDrop (Thermo Scientific) 
and adjusted to 5 ng/µl for further use. The ratio of absorbance at 260 nm (A260) and 
280 nm (A280) is used to assess the purity of DNA, and a ratio of ~1.8 is generally 
accepted as “pure” for DNA. Lower than 1.8 indicates protein contamination in the 
samples. Ratio of A260/A230 is used as a secondary measure of nucleic acid purity 
with an expected 260/230 values in the range of 2.0-2.2. Values lower than 1.5 
indicates the presence of contaminants which absorb at 230 nm.  
 
2.3.2 KASPar genotyping  
Prior to commencing the technique, all the allelic-specific PCR primers (Table 2.2+2.3) 
were designed using the Primer Picker software. DNA samples of HUASMCs 
(10ng/2µl) were arrayed in micro PCR 384-well plates and at least 3 wells without 
DNA acted as no template controls (NTC). The plate was then oven dried. The assay 
mix and the master mix were prepared according to the KASPar genotyping manual. 
The master mix (2 μl / well) was then added in the plate and briefly spun down to 
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eliminate the bubbles. Once arraying was done, the plate was covered with optical 
transparent seal. Then the amplifications of samples were performed in a PTC-225 
DNA Engine Tetrad thermal cycler (MJ Research, USA) under the following conditions:  
 
 
Step 1:  94 OC for 15 min           hot start activation 
 Step 2: 94 OC for 10 seconds 
Step 3:  57 OC for 5 seconds               19 cycles 
Step 4: 72 OC for 10 min 
 Step 5:  94 OC for 10 seconds 
Step 6: 57 OC for 20 seconds              14 cycles 
Step 7: 72 OC for 40 seconds 
 
After the PCR cycles were completed, the plate was placed into the ABI 7900HT 
instrument which reads the fluorescence signal generated during the amplification 
process.  The fluorescent data was presented as a scatter plot by the SDS 2.3 
software, where each sample was indicated as a point on the graph. The plot should 
contain four separate clusters (Figure 2.4), three of which are the possible genotypes 
(2 homozygotes and 1 heterozygotes) and the fourth are the NTC or undetermined 
samples.  The amplification process could be continued by adding 3 cycles each time 
until a proper plot was got. 
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Figure 2.4  KASPar genotyping data plotted showing the four separate clusters. 
 
 
Table 2.2 Primers sequence information for KASPar genotyping for variants in 
rs1173771 LD block. 
SNP Primers Sequence 
rs1173771 
Allele_T_FAM 
5’-GAAGGTGACCAAGTTCATGCT 
GGCTGCTGGTGCTTTGTGAATAAA-3’ 
Allele_C_VIC 
5’-GAAGGTCGGAGTCAACGGATTGC 
TGCTGGTGCTTTGTGAATAAG-3’ 
Common Reverse  5’-AGCCAACCATATGATGATCTCATACCAA-3’ 
rs1173743 
Allele_T_VIC 
5’-GAAGGTCGGAGTCAACGGATTGCT 
TAGAGCTGAGAAAAGCAAGAA-3’ 
Allele_G_FAM 
5’-GAAGGTGACCAAGTTCATGCT 
TTAGAGCTGAGAAAAGCAAGAC-3’ 
Common Reverse 5’-CAGTTGCAGCTGTGGGGCCTTT-3’ 
rs1173747 
Allele_A_FAM 
5’-GAAGGTGACCAAGTTCATGCT 
CCTCAGTTTCTGGTTAAAATGATTGTTT-3’ 
Allele_C_VIC 
5’-GAAGGTCGGAGTCAACGGATT 
CCTCAGTTTCTGGTTAAAATGATTGTTG-3’ 
Common Reverse 5’-GACTGGGGCTTAGGGAGCTGAT-3’ 
rs1173756 
Allele_T_FAM 
5’-GAAGGTGACCAAGTTCATGCT 
GATCTATGCAATGGCCTTCATCTCA-3’ 
Allele_C_VIC 
5’-GAAGGTCGGAGTCAACGGATT 
ATCTATGCAATGGCCTTCATCTCG-3’ 
Common Reverse 5’-GCATCACTTTCCTTTTAGTTATGGCTGAT-3’ 
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Table 2.3 Primers sequence information for KASPar genotyping for variants in 
rs1421811 LD block. 
SNP Primers Sequence  
rs1421811 
Allele_C_FAM 
5’-GAAGGTCGGAGTCAACGGATTAAGT 
CAGAGACTTCCCAAGGCG-3’ 
Allele_G_VIC 
5’-GAAGGTGACCAAGTTCATGCTAAGT 
CAGAGACTTCCCAGGCC-3’ 
Common Reverse  5’-CAAACCGCGGATCTCGCCCATA-3’ 
rs3828591 
Allele_G_VIC 
5’GAAGGTGACCAAGTTCATGCTGAGC 
TAAGTGGCGACGCCTG-3’ 
Allele_C_FAM 
5’-GAAGGTCGGAGTCAACGGATTGA 
GCTAAGTGGCGACGCCTC-3’ 
Common Reverse 5’-GAAGCGTCCGCGGACGCCT-3’ 
 
rs3762988 
Allele_C_FAM 
5’-GAAGGTCGGAGTCAACGGAT 
TAACCAGGAGCAAAAGAGACATCT-3’ 
Allele_T_VIC 
5’-GAAGGTGACCAAGTTCATGCT 
AACCAGGAGCAAAAGAGACATCT-3’ 
Common Reverse 5’-GTGTGGATTACCCTGTTTGTGGAATTAAA-3’ 
rs7729447 
Allele_G_FAM 
5’-GAAGGTCGGAGTCAACGGATTGC 
ACCACTTATACCCCCTCCG-3’ 
Allele_A_VIC 
5’-GAAGGTGACCAAGTTCATGCTGCA 
CCACTTATACCCCCTCCA-3’ 
Common Reverse 5’-GAAGATGTAGGAGTATCCAAAAGAGGATA-3’ 
 
 
 
2.4 Quantitative Real-Time Reverse Transcription PCR (q RT-PCR) 
Quantitative reverse transcriptase polymerase chain reaction (q RT-PCR) was 
conducted to quantify NPR3 mRNA level in HUASMCs and HUVECs to test if the BP-
associated SNPs influence NPR3 gene expression. Real time qRT-PCR is a 
technique could detect the reaction progress in real time, by labelling the new 
synthesized cDNA during the reaction. The detected quantity of cDNA could be 
normalized relative to housekeeping genes (e.g. 18S rRNA, GADPH, β-actin), which 
is required for maintenance of basal cellular functions and are expected to maintain 
constant expression levels in all cells and conditions. Technologically, all qPCR 
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involves the use of fluorescence to detect the threshold cycle (Ct) during PCR when 
the level of fluorescence gives signal over the background and is in the linear portion 
of the amplified curve (Figure 2.5). Two common methods in quantitative PCR are: (1) 
non-specific fluorescent dyes such as SYBR-Green, which intercalate with any 
double-stranded cDNA. The overall fluorescence increase proportionally to the DNA 
concentrations and reflects the amount of cDNA templates in PCR reaction. (2) 
sequence-specific DNA probes consisting of oligos that are labelled with a fluorescent 
reporter such as TaqMan probes. TaqMan probes have a fluorophore (reporter) 
attached to 5’-end of the oligonucleotide probe and a quencher at 3’-end. 
Fluorescence detected in the real-time PCR process is directly proportional to the 
released fluorophore and the amount of DNA templates present in the PCR. 
SYBR Green quantitative PCR technique was used in this subject. 
 
 
Figure 2.5 Representative amplification curve of RT-PCR. 
Ct (Threshold cycle): the cycle number at which the fluorescence signal crosses 
threshold; ∆Rn: Fluorescence signal with baseline subtracted; Baseline: background 
noise level before a significant amplification occurs (3‐15 cycles) 
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2.4.1 RNA extraction 
The total RNA was extracted from HUASMCs and HUVECs using the commercially 
available SV total RNA isolation system (Promega). Briefly, cells from flasks were 
harvested in sterile 1.5ml Eppendorf tubes by centrifuged at 13,000g for 5 min, were 
then washed with ice-cold sterile phosphate buffered saline (PBS) and centrifuged at 
13,000g for another 5 min to collect the cell pellet. The extraction was then conducted 
according to the instructions of the kit. After extraction, purified RNA was determined 
using NanoDrop Spectrophotometer ND-1000 instrument and stored at -80oC until 
further use. The ratio of A260/A280 nm and A260/A230 are used to assess the purity 
of RNA, and ratios of ~2.0 for A260/A280, 2.0-2.2 for A260/A230 are generally 
accepted as “pure” for RNA.  
 
2.4.2 Conversion of RNA to complementary DNA  
To perform qRT-PCR on the total RNA, it firstly has to be converted to complementary 
DNA (cDNA).  This involves the use of RNA as a template in a reaction catalysed by 
the enzyme reverse transcriptase, which operates on a single strand of RNA, 
generating its complementary DNA. The conversion was performed using ImProm-
IITM Reverse Transcription System (Promega) as follows:     
 
2 µl of total RNA were transferred into a 1.5 ml Eppendorf tube and incubated in water 
bath at 700C for 5 min. The samples were centrifuged briefly and then placed on ice. 
The following reagents were then added to the tube containing the 2 µl of total RNA:   
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 MgCl2, (25mM) - 4 µl with a final concentration of 5mM 
 Reverse transcription 10x Buffer - 2 µl. 
 dNTP mixture, 10mM - 2 µl with a final concentration of 1mM 
 Recombinant RNasin® Ribonculease Inhibitor - 0.5 µl. 
 AMV reverse transcriptase - 15 units. 
 Random primers - 0.5 µl. 
 ddH2O - Up to 20 µl. 
 
 
The reactions were incubated for 10 min at room temperature, and then at 42°C for a 
further 60 min. The samples were heated at 95°C for 5 min, and quickly chilled at 4°C 
for another 5 min. 80 µl of ddH2O was added to the cDNA reaction and the samples 
were stored at -20°C until next step.  
 
2.4.3 SYBR-Green quantitative PCR 
SYBR Green quantitative PCR technique was used to conduct qRT-PCR with 18S 
rRNA as the internal reference gene for normalization of NPR3 gene expression. 
SYBR-Green qPCR was carried out using commercially available kit (SYBR® Select 
Master Mix kit) from Life Technologies as follows:  
2µl (10ng) of each cDNA sample was arrayed in a PCR 384-well plate and the 
appropriate volume of reaction mix was prepared according to Table 2.5. 8 µl of 
reaction mix was then transferred into each well of the plate. Each reaction was 
conducted in duplicate. After arraying samples, the plate was sealed with an optical 
transparent cover and centrifuged briefly to spin down the contents and eliminate any 
air bubbles. The reaction plate was then placed in the real-time quantitative PCR 
instrument (ABI 7900HT machine) and the thermal cycling condition was set as Figure 
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2.4. The fluorescence signal generated during the amplification process was read by 
the machine ABI 7900HT and analysed by software SDS 2.3 to get the amplification 
curve. The threshold cycle (Ct) value which represents the quantification of gene 
expression of each sample was calculated by the program and obtained after analysis. 
Table 2.4 The reagents used in SYBR Green method. 
Reagents  Volume 
SYBR Green ROX (2X) 5.0µl 
Forward Primer (10µM) 0.1µl 
Reverse Primer (10µM) 0.1µl 
Nuclear free water  3.8µl 
Template 2.0µl(10ng) 
Total volume  10.0µl 
 
 
 
 
Figure 2.6 Thermal cycling conditions for qRT-PCR. 
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2.4.3.1 Primers design and variants expression detection  
Before starting the assay, all primers of 18S rRNA, NPR3 were designed using 
Primer_BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primerblast/index.cgi?LINK_LOC=BlastHome). 
It was noticed that there are three transcript variants of human NPR3 mRNA indicated 
by NCBI nucleotide database (http://www.ncbi.nlm.nih.gov/nuccore/). Their NCBI 
Reference Sequences are NM_001204375.1 for transcript variant 1, NM_000908.3 
for transcript 2 and NM_001204376.1 for transcript variant 3. They were subjected to 
alignment by BLAST as shown in Figure 2.6. Common sequence among these three 
variants was utilised for primer design of total mRNA, and primers targeting each 
variant mRNA were designed using their specific sequences of each variant 
respectively. 
 
Figure 2.7 Alignment of three variants of NPR3 mRNA sequences to show the 
common sequences and specific sequences for each variant. 
 
For each target, three pairs of primers with product size around 150bp were designed 
and tested for specificity and sensitivity by end-point PCR. The primers pairs that had 
a good specificity and amplification efficiency were utilised in this assay.  
Correlation analysis was also conducted for the variants mRNA expression and total 
mRNA expression in HUASMCs (Figure 2.8). It is manifested a strong positive 
correlation, reflecting a very dependent pattern among variants and total mRNA in 
samples. Therefore, the total mRNA expression detection was utilised in subsequent 
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genetic analysis. Primers targeting 18S and total NPR3 mRNA are listed in the Table 
2.5. 
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Figure 2.8 Correlation plots between variants mRNA expression and total mRNA 
expression of NPR3 (N=112). 
 
 
Table 2.5 Primers of 18s and NPR3 cDNA for q RT-PCR. 
Gene  Forward primer Reverse primer 
18S 5' CCCAGTAAGTGCGGGTCATAA 3'    5' CCGAGGGCCTCACTAAACC 3' 
NPR3 5' GCCGCATTTCAAAACGACCT 3' 5' TGCCAACGGAGACCGATATG 3' 
 
 
2.5. Allelic expression imbalance (AEI)  
Regulatory polymorphisms (rSNPs) and some structural RNA SNPs (srSNPs) in the 
transcribed region can affect mRNA processing and turnover. Both rSNPs and srSNPs 
can cause allelic mRNA expression imbalance (AEI) in heterozygous individuals. AEI 
here was carried out to investigate the potential of BP associated SNP rs1173756 (3-
UTR SNP in NPR3) in mRNA processing, which involving some transcriptional factors, 
MicRNA or other elements. This method is subjected to samples which are 
heterozygous at SNP rs1173756. Both genomic DNA and cDNA of each sample were 
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amplified by PCR in the region flanking rs1173756, and subjected to fluorescent 
dideoxy sequencing, the allelic ratio of cDNA after analysis was then compared with 
genomic DNA.   
 
2.5.1 Preparation of DNA samples  
8 HUASMCs and 7 HUVECs samples were obtained from different individuals and 
have been confirmed as heterozygous (C/T) genotype for rs1173756 using KASPar 
SNP genotyping method (section 2.3.2). Genomic DNA was extracted as described 
in section 2.3.1. Total RNA of these samples was extracted and reversely transcribed 
into cDNA as described in qRT-PCR methodology (see section 2.4). Primers for 
targeting rs1173756 DNA fragments in genomic DNA and cDNA were designed using 
Primer_BLAST (Table 2.6) 
 
Table 2.4  Information of primers for rs1173756 DNA fragments. 
rs1173756 genomic DNA cDNA 
Forward primer 5’-TTGGAATGCCCTCACTTCTC-3’ 5’-TGCTTTGGAATGCCCTCACT-3’ 
Reverse primer 5’-GTGACGCCACTGGAACCTAC-3’ 5’-ACGCCACTGGAACCTACTTT-3’ 
Product size  220bp 221bp 
 
 
2.5.2 Polymerase chain reaction (PCR) 
PCR for genomic DNA and cDNA of rs1173756 fragments was performed using 
commercially available kit (Novagen): A number of 0.2ml nuclear free Eppendorf tubes 
were prepared and added into with the reagents shown in Table 2.7. All the samples 
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were placed into PTC-225 DNA Engine Tetrad thermal cycler (MJ Research, USA) 
and amplified using the following condition. 
 
 
Step 1: 94 OC for 5 min           hot start activation 
Step 2: 94 OC for 15 seconds 
Step 3: 55 OC for 15 seconds          35 cycles 
Step 4: 72 OC for 30 seconds 
Step 5: 72 OC for 2 min 
Step 6: 4 OC  
 
 
Table 2.5  Constitute reagents volume in PCR system. 
Reagents Volume (µl) 
10X PCR buffer 2.5 
MgCI2 (25mM) 1.5 (final concertation: 1.5mM) 
dNTP(2mM)  2.5 (final concertation: 0.2mM) 
Primer-mix (10µM) 1.0 
Taq polymerase 0.13 
DNA(10ng/µl) 2.0 
Nuclear free water 15.67 
In total  25 
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2.5.3 Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique used to separate nucleic acids according 
to their size under the influence of an electric current. The shorter fragments will 
migrate at a faster rate than the longer fragments. An agarose gel was prepared as 
follows: 
1.2 g of agarose powder (Sigma, UK) was dissolved in 60 ml of 1x Tris-borate-EDTA 
(TBE; Bioline Ltd, UK) buffer for a 2% w/v agarose gel. The solution was left to cool 
down and 6 µl of Gel Red (x10, 000: Biotium, USA) was added.  The solution was 
poured into a medium-sized casting tray containing a sample comb and allowed to 
solidify for 40 min at room temperature. The gel was then placed horizontally into an 
electrophoresis chamber containing sufficient amount of 1x TBE buffer to cover the 
gel.  25 µl of the amplified fragments were mixed with 2.7 µl of 10X bromophenol blue 
dye (Sigma, UK) and then pipetted into the wells.  A 100bp molecular ladder (ABgene, 
UK) was run alongside all samples.  After 40 min at 100 volts, the DNA fragments 
were visualized by using a UV transilluminator (UVP, Canada) as shown in Figure 2.7. 
 
 
Figure 2.6 The DNA fragments under a UV transilluminator. 
 
. 
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2.5.4 DNA purification from gel and quantification 
Kit from Promega were used for DNA purification from gel and the main procedure 
according to manufacture is as follows: After electrophoresis, DNA band was carefully 
cut from gel and the gel slices was placed in pre-labelled 1.5ml micro centrifuge tubes. 
The purification was done according to the instruction. Once DNA was purified, it was 
quantified using NanoDrop and stored at 4°C or –20°C until further use. 
 
2.5.5 Sanger sequencing  
Chain termination method (Sanger dideoxy method) is one of the most widely used 
technique for sequencing DNA.  All sequencing studies were done by Barts and The 
London Genome Centre using Big Dye 3.1 chemistry with visualization on the ABI 
3730 capillary sequencer. The following figure (Figure 2.8) shows an example of the 
sequencing result analysed by Bio Edit. 
 
Figure 2.7 A representative sequencing result. 
Sanger sequencing technique is mainly based on fluorescently labelled 
dideoxyribonucleotide terminators (ddNTPs). When ddNTP is added to the growing 
chain during DNA synthesis, the chain is terminated ending with the ddNTP with 
different colours. As shown in the figure, the color can tell which of the four DNA bases, 
A, C, T, or G are present at that position. The whole DNA sequence is inferred by 
reading the colours of all the different shortened products.  
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2.6 Western Blot Analysis 
Western blot analysis is a technique that identifies specific proteins from a protein 
mixture extracted from cells. It was performed here to explore whether BP-associated 
SNPs affect NPR-C protein expression in HUASMCs and HUVECs.  
 
2.6.1 Preparation of lysate from cell culture 
HUASMCs or HUVECs cultured in a T75 flask was washed twice with ice-cold PBS 
and placed on ice. 1ml of ice-cold PBS with protease inhibitor (PI) (Table 2.8) was 
added into the flask, the cells were then scraped from flasks using a cold plastic cell 
scraper. After that, the cell suspension was gently transferred into a pre-cooled 
microcentrifuge tube and centrifuged at 13,000g at 4 oC. The supernatant was 
discarded after centrifugation and cell pellet was harvested. 200μl of ice-cold radio-
immuno precipitation assay (RIPA) lysis buffer (150 mM NaCl, 0.1% Triton-X 100, 0.5% 
sodium deoxycholate,0.1% sodium dodecyl sulphate, 50mM Tris-HCl pH 8.0, 1X 
protease inhibitor) was added into each pellet and disrupted by pipette mixing, 
followed by sonication for 1-2 min. The lysate was placed on ice for an hour with 
pipetted mixing every 10 min. After being centrifuged at 13,000 x g for 20 min in a 4°C 
pre-cooled centrifuge, the supernatant was carefully collected into a fresh chilled tube 
without disrupting pelleted debris at the bottom. The protein was finally stored at -
80°C until further use. 
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Table 2.6 Components in protease inhibitor cocktail. 
Components  Company 
Working 
concentrations 
Phenylmethylsulfonyl flouride 
(PMSF) 
SLS, P7626 1mM 
Leupeptin hemisulfate SLS, L2884 1µg/ml 
Aprotinin from bovine lung SLS, A1153 1µg/ml 
Pepstatin A SLS, P4265 1µg/ml 
       
2.6.2 Quantification of protein using bicinchoninic acid assay (BCA) kit 
The quantification of protein was carried out with commercially available BCA kit from 
Pierce as follows: A series of bovine serum albumin (BSA) standards (0, 0.25, 0.5, 
0.75, 1.0, 1.5, and 2.0 μg/ml) were prepared before quantification. The BCA working 
solution was also prepared by a ratio of reagent A: B= 50:1 and mixed well by inverting. 
The protein samples to be quantified were diluted by 10 (1:9) and 5 (2:8) with lysis 
buffer used in section 2.5.1. Once the preparation work done, 10 μl of diluted samples 
and standards were added into a 96-well microplate (Thermo Scientific™ Pierce™ 
96-Well Plates) in duplicate. 200μl of working solution was then pipetted into each 
well, with following incubation at 37°C for 30 min. 
The plate was then allowed to cool down to room temperature and placed into a plate 
reader (MRX-TC Revelation, Dynex Technologies, UK) and the absorbance of each 
reaction at the wavelength of 570 nm was read. The value of each sample was 
corrected with the average absorbance of 0 μg/ml, then the standard curve was based 
on the light absorbance of standards as following Figure 2.9. Each sample was 
adjusted to the desired concentration with RIPA buffer. 20 μl aliquots of each sample 
were stored in -80°C until further use. 
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Figure 2.8 Standard curve for protein concentration quantification in 
bicinchoninic acid assay (BCA) assay.  
Eight concentrations (0-2.0μg/ml) of bovine serum albumin (BSA) were assayed. The 
response values (absorbances) were plotted and a best-fit line drawn through the 
points. If unknown samples were tested at the same time, their concentrations could 
be determined by reference to the standard curve.  
 
 
2.6.3 Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis 
Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique utilised to separate proteins based on their molecular weight upon 
application of an electric field across the gel. The binding of SDS to polypeptide chain 
imparts in most proteins charge per unit mass, thus resulting in a fractionation by 
approximate size during electrophoresis via different mobility. Briefly, 10% separating 
SDS-PAGE gel and 5% stacking SDS-PAGE gel were prepared as Table 2.9 and 
stored at 4°C before use. Equal amount protein of each samples were defrosted at 
37°C, and added with 5X protein loading buffer (312.5 mM Tris pH 6.8, 10% w/v SDS, 
y = 1.926x     R² = 0.997
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2
St
an
d
ar
d
 B
SA
 C
o
n
ce
n
tr
at
io
n
 (
u
g/
m
L)
Corrected Average Absorbance
Standard Curve
93 
 
50% v/v glycerol, 0.5% w/v bromophenol blue, 5% v/v β-mercaptoethanol), they were 
then boiled at 95°C for 5 min, followed by centrifugation at 13,000 x g for 5 min. 30 μl 
of protein samples (20 ng protein in each), along with 6μl of molecular weight markers 
(7-175 kDa, NEB, p7709s) were carefully loaded onto the wells of the SDS-PAGE gel 
filling with running buffer (SDS: 0.1% w/v, Tris base: 25mM,Glycine: 192mM), the gel 
was then run at 90 V for 30min in the stacking gel, then 160 V for another 
approximately 90min until appropriate separation of achieved.  
 
Table 2.7 Constitute reagents volume in separating gel and stacking gel. 
Separating (10%) Volume(ml) Stacking (5%) Volume(ml) 
30% Polyacrylamide  3.33 30% Polyacrylamide  0.68 
1.5M Tris (pH8.8)  2.5 1.0M Tris (pH6.8) 0.5 
10% Ammonium 
persulfate  
0.1 
10% Ammonium 
persulfate  
0.04 
10% SDS  0.1 10% SDS  0.04 
TEMED  0.004 TEMED  0.004 
H2O  3.97 H2O  2.72 
Total volume (mL) 10 Total volume  4 
 
2.6.4 Electro transfer 
Before transfer, a piece of 7.5cm×9.0cm polyvinylidene fluoride (PVDF) membrane 
(Hybond ECL, GE Healthcare) was pre-activated in methanol for 2 min, and washed 
with cold Tris-buffered saline with Tween (TBST) buffer (Tris HCI: 50mM,Tris base: 
50mM, NaCI: 150 mM, Tween-20: 0.1%v/v).  The filter papers and sponge were also 
pre-chilled in cold TBST before making stack. The gel was carefully removed from 
running unit, the transfer “Sandwich” was then prepared as following Figure 2.10, and 
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put into transfer unit filling with transfer buffer (Tris base: 25mM, glycine: 192mM, 
methanol: 20% v/v), and was run at 60 V for 2.5 hours at 4°C. 
 
 
Figure 2.9 Assembly of a transfer ‘sandwich’ in western Blot 
In the presence of transfer buffer, ‘Sandwich’ is assembled by placing two pieces of 
filter papers (yellow) soaked in transfer buffer followed by the gel (red) with separated 
proteins, the PVDF membrane (green), then two more pieces (yellow). Current arrow 
shows the direction of protein transfer from gel to membrane. 
 
2.6.5 Antibody staining and detection 
After transfer, the membrane was incubated for 1 hour at room temperature with 5% 
blocking solution (5% non-fat milk in TBST), then incubated with 1:1000 dilution of 
anti-NPR-C antibody (Table 2.10) in 5% blocking solution overnight at 4°C. The 
membrane was washed with TBST three times with gentle agitation, 10 min each at 
room temperature. This is followed by incubation with 1:3000 horseradish peroxidase 
(HRP)-conjugated anti-mouse IgG (Table 2.10) at room temperature for 1 hour. The 
membrane was washed again with TBST and rinsed in Tris-buffered saline (TBS). 
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While waiting for the last wash, appropriate volume of enhanced chemiluminescence 
(ECL) 1 and 2 reagents (Table 2.11) were prepared with ratio of 1:1 before mixing. 
The membrane was taken out from washing buffer and placed into a new container. 
The ECL mix was poured to cover the membrane and incubated for 5 min in dark 
room. The membrane after incubation with ECL was covered in transparent plastic 
wrap and put into a cassette. A piece of autoradiography film (Thermo scientific) was 
exposed to the membrane for 1 to 5 min until a desired signal was achieved. The film 
then developed (SRX-101A, KONICA MINOTA) 
Table 2.8 Information on the antibodies used in Western Blot analysis. 
Antibody Description Company Product No 
Anti-NPR-C antibody mouse monoclonal Abcam ab123957 
Anti-β-actin antibody mouse monoclonal Abcam ab 8226 
Anti-mouse IgG ,HRP-linked 
antibody 
 
Cell 
Signalling 
#7076S 
 
Table 2.9 Components in ECL solutions. 
Reagents in 
ECL-1 
Working 
concentration 
Reagents in 
ECL-2 
Working 
concentration 
Tris-HCl, pH 8.5 100mM Tris-HCl, pH 8.5 100mM 
Coumaric acid 0.405mM 
Hydrogen 
Peroxide 
0.018% 
Luminol 2.5mM   
 
2.6.6 Blocking peptide competition  
Two copies of PVDF membranes with identical HUASMC samples were collected 
after electro transfer. After 1h blocking, membrane 1 was put in “control” tube with 
1:1000 dilution anti-NPR-C antibody buffer, while membrane 2 was put into “blocked” 
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tube with 1:1000 dilution NPR-C antibody buffer with additional 1:333 dilution NPR-C 
peptide (ab42266, Abcam). Both were incubated with gentle agitation at 4 oC 
overnight, and staining detection was performed subsequently with ECL and film. 
Signals that were present on the “control” film but no in the “blocked” film were 
regarded as specific NPR-C fragments (Figure 2.11).  
 
 
 
Figure 2.10 Blocking competition with NPR-C blocking peptide in HUASMCs. 
Western blot analysis of extracts from HUASMCs (samples 1, 2, and 3) using anti-
NPR-C antibody (control) or the same antibody pre-incubated with NPR-C blocking 
peptide (blocked). Signals that were present on the “control” film but no in the “blocked” 
film were regarded as specific NPR-C fragments.  
 
 
2.7 Electrophoretic mobility shift assay (EMSA) 
The interaction of transcriptional or co-transcriptional factors with DNA is crucial for 
gene expression. The electrophoretic mobility shift assay (EMSA) is a technique that 
studies in vitro protein/DNA interaction. This technique is based on the observation 
that protein-DNA complexes migrate more slowly than the corresponding free nucleic 
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acids when subjected to non-denaturing polyacrylamide gel electrophoresis. During 
electrophoresis, the protein-DNA complexes are quickly resolved from free DNA, 
providing a "snapshot" of the equilibrium between bound and free DNA in the original 
sample. After electrophoresis, the distribution of species containing nucleic acid is 
determined, usually by autoradiography of 32P-labelled nucleic acids or covalent 
labelling of nucleic acids with a flurophore such as biotin. EMSA was conducted here 
to find the possible proteins in regulating NPR3 associated with BP associated 
variants (rs1173771, rs1173743, rs1173747, rs1173756) using biotin-labelled probes.  
2.7.1 Preparation of probes 
The allele specific probes were labelled with biotin by IDT and sequences of biotin-
labelled and non-labelled probes are shown in Table 2.12. To anneal the oligos to 
double-stranded probes, each oligo pair of labelled or unlabelled allele specific oligos 
of each SNP were mixed to certain concentrations (labelled oligos: 0.01μM; 
unlabelled oligos: 0.1 - 1μM) with annealing buffer (10mM Tris, pH8.0, 50mM NaCI, 
1mM EDTA) and heated at 95°C for 2 min, then allowed for cooling down to room 
temperature for 30min. 
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Table 2.10 Information of oligos in EMSA. 
SNP Oligos Sequence (forward oligos )* Sequence (reverse oligos) 
rs1173771 
EMSA_C alelle_F/R CTCATACCAACTTATTCACAA TTGTGAATAAGTTGGTATGAG 
EMSA_T allele_F/R CTCATACCAATTTATTCACAA TTGTGAATAAATTGGTATGAG 
rs1173743 
EMSA_T alelle_F/R CCTTTCCAGCTTCTTGCTTTT AAAAGCAAGAAGCTGGAAAGG 
EMSA_G allele_F/R CCTTTCCAGCGTCTTGCTTTT AAAAGCAAGACGCTGGAAAGG 
rs1173747 
EMSA_A alelle_F/R GGAGCTGATCAAACAATCATT AATGATTGTTTGATCAGCTCC 
EMSA_C allele_F/R GGAGCTGATCCAACAATCATT AATGATTGTTGGATCAGCTCC 
rs1173756 
EMSA_C alelle_F/R CAGTCAACAACGAGATGAAGG CCTTCATCTCGTTGTTGACTG 
EMSA_T allele_F/R CAGTCAACAATGAGATGAAGG CCTTCATCTCATTGTTGACTG 
Forward oligos * of each allele in each SNP were also prepared labelled ones with 
biotin in 5’ tail. SNP of interest indicated in red and underlined 
2.7.2 Cytosolic and nuclear protein extraction 
Buffer A and B involved in the extraction were prepared as Table 2.13. HUASMCs or 
HUVECs in a T75 flask was washed with ice-cold PBS twice. 1ml of buffer A was 
added directly to each flask, and incubated for 10 min at room temperature.  Cells 
were scraped from flasks into a 1.5 ml microfuge tube, with pipette mixing to disrupt 
cell clumps. Then the cell lysate was centrifuged at 4°C at about 15,000g for 3min. 
The supernatant was collected as cytoplasmic extract.  The pellet containing unlysed 
nuclei was resuspended in 125μl buffer B, also mixing by pipetting up and down, and 
placed on ice for 10min. The supernatant (nuclear extract) was collected 
centrifugation at 4°C at 15,000g for 5 min and quantified with BCA (section 2.5.2) 
using buffer B standards, then stored at -80°C until further use.  
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Table 2.11 Constitute in buffer A and buffer B. 
Reagents in buffer A Working solution Reagents in buffer B Working solution 
HEPES, PH 7.9 10mM HEPES, PH 7.9 10mM 
KCI 10mM NaCI 0.4M 
EDTA 0.1mM EDTA 1mM 
PI X1 PI X1 
IGEPAL 0.004% Glycerol 10% 
 
 
2.7.3 Pre-running 
6% non-denaturing polyacrylamide gel was made as Table 2.14. The gel was placed 
in the electrophoresis unit filled with 0.5X TBE (40 mM Tris-Cl pH 8.3, 45 mM boric 
acid, 1 mM EDTA). Loading buffer was pipetted into each well and the gel was pre-
electrophoresed for about 90 min at 100V until bromophenol blue run off.  
 
Table 2.12 Components in 6% non-denaturing polyacrylamide gel. 
Gel components 12ml 6% gel 
Acrylamide 30%  2.43ml 
1x TBE 0.6ml 
10% APS 120μl 
TEMED 12μl 
H2O 8.89ml 
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2.7.4 Electrophoretic binding reaction 
The reaction mix was prepared as Table 2.15 and incubated at room temperature for 
20 min. When specific antibody super shift is performed, the mixture with protein and 
oligos was incubated for 20 min first, then with antibody for further 20 min. 2µl of 10x 
DNA loading buffer (10mM Tris pH7.5, 1mM EDTA, 50%v/v glycerol, 1% bromophenol 
blue) was added into each sample (20µl in total), with pipetting the mix up and down 
several times. The samples were loaded into the wells of gel and run at 100 V at 4°C 
until the bromophenol blue dye went down 3 cm to the bottom. 
 
 
Table 2.13 Preparation of reaction mix. 
1x Reaction Mix Working solution Per reaction (18ul) 
1M Tris pH 7.5 10mM 0.18µl 
5M NaCl 50mM 0.18µl 
0.5M EDTA 1mM 0.036µl 
Glycerol 5% 0.9ul 
Protease Inhibitors 1x 0.72µl 
Labelled oligo (0.01µM stock) 10-14moles 1µl  
Poly (dI.dC)0.5mg/1ml 0.125mcg 0.225µl 
Nuclear extract 2ng/µl 
Up to 5µl (in each 
sample) 
(when doing competing assay) 
Competitor oligo(0.1µM stock) 
5x10-13 moles (50x) 1µl 
H2O   up to 18µl 
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2.7.5 Electrophoretic transferring and crosslinking. 
Nylon membrane (Amersham) was soaked in 0.5X TBE for 15 min before transfer. 
After electrophoresis, the gel was carefully removed into a cassette and was made a 
“sandwich” with nylon membrane and blotting papers in a lean electrophoretic transfer 
unit as Figure 2.6 then, transferred at 380mA (~100 V) for 30 min. When the transfer 
was complete, the oligonucleotides were crosslinked to the membrane using a 245nm 
UV-light cross linker at 120 mJ/cm2 for 45-60 seconds. 
 
2.7.6 Detection with Pierce kit 
Signal detection was conducted according to the instruction of Chemiluminescent 
Nucleic Acid Detection Module (89880, Pierce). After 5-min incubation of substrate 
working solution, the membrane was removed from the buffer and allowed to remove 
excess liquid. The moist membrane was then quickly wrapped in plastic wrap and 
placed into a film cassette, with eliminating bubbles and wrinkles. An autoradiography 
film (Thermo scientific) was immediately exposed to the membrane for 1 to 5 min until 
a desired signal was achieved. The film was then developed (SRX-101A, KONICA 
MINOTA). 
 
2.7.7 Efficiency test of biotin-labelled probes by dot blot assay 
A serial dilution (10-6, 10-7, and 10-8 M) of biotin-labelled probes were prepared with 
annealing buffer. 1μl of each test sample was dotted on the nylon membrane pre-
soaked in 0.5X TBE and allowed to air dry for 3-5 min. The membrane was then UV-
cross-linked immediately followed by the detection step as described in section 2.7.6. 
As is shown in Figure 2.12, the efficiency of biotin-labelled is high and there were very 
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bright dots for 1μl of 10-8M (10-14mole) of each probe, thus 10-8M (10-14mole) was 
chosen for the reaction amount of biotin-labelled probes in EMSA.  
 
 
Figure 2.11 The diagram of biotin-labelled probes after dot blot assay. 
 
 
2.7.8 Annealing efficiency test 
The biotin-labelled and unlabelled probes (as control) were prepared as section 2.7.1, 
and then were quantificated by NanoDrop (10ng/μl). 20μl of annealed oligos (double-
stranded DNA) and unannealed oligos (single-stranded DNA) were added into 0.5 ml 
Eppendorf tubes, mixed with 5μl 5X DNA loading buffer.  They were run at 120 V in a 
2% agarose gel for 50 min, the DNA fragments were then visualized by using a UV 
transilluminator. As shown in Figure 2.13, the annealed oligos on gel run much slowly 
than unannealed oligos and this validated they were double-stranded DNA fragments 
with a successful annealing.  
  
 
Figure 2.12 The annealed oligos under a UV transilluminator.  
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2.8 Cross-linked chromatin immune-precipitation (X-ChIP) 
Cross-linked ChIP is suitable for mapping the DNA targets of transcription factors or 
other chromatin-associated proteins. This study uses cross-linked chromatin as 
starting material, with reversible cross-linking achieved by formaldehyde. Cross-
linked ChIP was performed to investigate the potential transcription factors or other 
chromatin-associated proteins associated with BP-associated SNPs. ChIP assay 
was carried out with four basic steps.  
 
2.8.1 Cross-linking and sonication.  
When performing the ChIP, a final concentration of 1% of formaldehyde was added 
into a T75 cell flask and incubated for 10 min at room temperature. Then 1ml of glycine 
was added to quench excess formaldehyde. The cells were subsequently washed 
with ice cold PBS and scraped into tubes.  The cells were resuspended in ChIP lysis 
buffer (1% SDS, 10mM EDTA, 50mM Tris-HCI) and incubated on ice for 10 min and 
then sonicated to shear DNA to length between 200bp and 500bp (40 seconds 
sonication for HUASMC). The sonicated samples were centrifuged, and the 
supernatants, containing the sonicated DNA fragments, were kept. 
 
2.8.2 Immunoselection with specific antibody 
Sonicated lysates were diluted with ChIP dilution buffer (1% Triton X-100, 1mM EDTA, 
15mM Tris-Cl pH 7.5, 150mM NaCI)(1:100) and added into pre-blocked G-agarose 
beads and the solution mixed by rotating the tube at 4 oC for 60 min. The agarose 
beads were pelleted by centrifuge at 13,000g at 4 oC and the supernatant containing 
chromatin was collected. Specific anti-RNA polymerase II (5μg) was added into the 
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supernatant fraction and incubated overnight at 4oC with rotation. 10ng protein 
agarose G was added and the solution incubated for 3-hour then centrifuged. The 
supernatant was removed and the agarose/antibody/protein/DNA complex was kept.  
 
2.8.3 Reversing of the cross-linking  
The protein G agarose antibody / chromatin complex was washed with cold washing 
buffers, and the complex separated from the antibody by adding an elution buffer 
(1%SDS, 0.1M NaHCO3). The agarose was spun down and the supernatant fraction 
containing DNA-protein complex collected. 5M NaCI solution (final concentration: 
200mM) was added and the sample was incubated at 65 oC overnight to reverse 
histone-DNA crosslinking. Then a solution containing 0.5 M EDTA, 1M Tris-HCI and 
1ul 10mg/ml proteinase K was added and the sample incubated for 1 hour at 45 oC. 
 
2.8.4 Purification of DNA and detection of DNA sequence  
DNA purification was performed using a DNA purification kit (Wizard R SV genomic 
DNA purification system, Promega). The concentration of the purified DNA was 
determined using a NanoDrop. An aliquot of 20ng DNA per sample was used as a 
template in a standard end-point PCR. 
 
2.8.5 Optimization of sonication time 
After cross- linking and lysis as described in 2.8.1, each 200 μl of the lysates was 
sonicated with a series of times (25s, 30s, 35s, 40s, and 45s) separately and were 
centrifuged at 13,000g at 4 oC. The supernatant was collected and then processed as 
section 2.8.3 and section 2.8.4. 200 ng of sonicated DNA samples were run on a 2% 
agarose gel. The result was as Figure 2.14.  A range of DNA fragments from 100bp 
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to about 800bp could be observed and 40s was the optimal sonication time to get 
fragments from 200bp to 500bp. 
 
 
 
 
Figure 2.13 The DNA fragments range under different sonication times. 
 
 
2.9 Formaldehyde-assisted isolation of regulatory elements (FAIRE) 
 
Destabilization of nucleosomes from chromatin is a hallmark of functional regulatory 
elements of the eukaryotic genome. Historically identified by nuclease hypersensitivity, 
these regulatory elements are typically bound by transcription factors or other 
regulatory proteins (enhancers, silencer, insulator et al). FAIRE (Formaldehyde-
Assisted Isolation of Regulatory Elements) is an approach to identify these genomic 
regions and has proven successful in a multitude of eukaryotic cell and tissue types. 
Cells or dissociated tissues are cross-linked briefly with formaldehyde, lysed, and 
sonicated. Sheared chromatin is subjected to phenol-chloroform extraction and the 
isolated open DNA is purified and conducted to quantitative PCR or sequencing to 
detect the open chromatin state or hypersensitive sits in DNA fragments of interest.  
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Figure 2.14 Principles of formaldehyde-assisted isolation of regulatory 
elements (FAIRE).  
Cells was crosslinked with formaldehyde and sheared by sonication. DNA lysis was 
subjected to phenol/chloroform extraction to harvest the open chromatin (FAIRE DNA), 
which is hypersensitive sites interacting with regulatory factors during transcription. 
Reference chromatin (Input DNA) was also obtained from cells without formaldehyde-
crosslinking. Modified from http://www.encode.com and published literature.140 
 
2.9.1 Cross-linking and sonication 
Cells in a T75 flask was cultured with growth medium until reaching up 90% 
confluence and a final concentration of 1% of formaldehyde was added into and 
incubated for 5 min while rocking at room temperature. A final concentration of 125mM 
of glycine was added to quench the formaldehyde. The cells were then washed with 
ice cold PBS and scraped into fresh 1.5ml tubes. The cells were resuspended in lysis 
buffer (10mM Tris-HCl pH8.0, 2% v/v Triton X-100, 1% w/v SDS, 100mM NaCI, 1mM 
EDTA) and incubated on ice for 10 min and then sonicated to shear DNA to length 
between 200bp and 500bp (40 seconds sonication for HUASMC). The sonicated 
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samples were centrifuged, the supernatants, which contained the sonicated DNA 
fragments, were kept in -80 oC until next step. 
 
2.9.2 Preparation of DNA 
400µl cell lysate was added into fresh 1.5ml tubes and centrifuged at 15,000g for 5 
min at 4 oC to pellet cell debris. Supernatants containing chromatin was transferred 
into 1.5ml tubes and 1 volume of phenol/chloroform/isoamyl alcohol was added into 
each tube. The samples were then mixed by vortex and centrifuged at 15,000g at 4 
oC for 5 min. The aqueous (top) layer was removed into fresh 1.5ml tubes. 150µl 
10mM Tris-HCl pH7.4 was added into the tubes containing the interphase and organic 
layers, centrifuged and the top layer was transferred into previous aqueous material 
tubes. Extraction of open DNA fragments by phenol/chloroform/isoamyl alcohol as 
described above was repeated. 200µl chloroform/isoamyl alcohol was added into 
tubes and centrifuged at 12,000g for 5min to remove then trace of phenol. The 
aqueous layer was collected, with the addition of 2 volumes of 95% ethanol, 1/10 
volume of 3M Sodium Acetate (pH 5.2) and 1µl 20mg/mL glycogen (Thermo Scientific) 
was added into the materials. This was incubated at -80 oC for 2 hours. Samples were 
taken out and centrifuged at 12,000g for 15min to obtain a DNA pellet. The 
supernatant was carefully removed and DNA pellets were washed with 500µl ice cold 
70% ethanol. The DNA pellets were then dried by leaving tubes open for 60min and 
then eluted in 50µl 10mM Tris-HCl pH7.4.  Samples with 1µl proteinase K were 
incubated at 55 oC for 1h, with following heating at 65 oC overnight to reverse DNA-
DNA crosslinks. 
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2.9.3 Purification of DNA   
Samples were purified using the Wizard® SV Gel and PCR Clean-Up System 
(Promega, A9281) according to introduction. DNA was eluted twice with 15µl 10mM 
Tris-HCl pH7.4, then quantified by NanoDrop and stored at -80 oC until use in 
downstream processes. 
 
2.9.4 Detection of FAIRE enrichment by sequencing  
PCR for FAIRE DNA and input DNA flanking SNPs of interest were performed, and 
DNA purification from gel and following Sanger sequencing were carried out to detect 
allelic enrichment (technique details see section 2.5.2-2.5.5.) 
 
 
2.10 Cell proliferation assay 
 
Proliferation of VSMCs and ECs play an important role in the development of 
hypertension. NPR-C has been shown that, as a Gi protein coupled receptor, it could 
regulate cell proliferation via NPR-C related signalling pathway 133. Therefore, cell 
proliferation assay was carried out to explore whether BP-associated SNPs at NPR3 
gene locus influence the proliferation of HUASMCs and HUVECs using CCK-8 kit 
(Sigma, UK).  
 
This method is based on a chemical, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium, monosodium salt), which 
produces a water-soluble formazan dye upon bio- reduction in the presence of an 
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electron carrier. The amount of the formazan dye generated by dehydrogenases in 
cells is directly proportional to the number of living cells. 
 
 
Figure 2.15 Principle of the cell viability detection with Cell Counting Kit-8.  
The soluble tetrazolium salt in this assay, WST-8, is reduced by dehydrogenase 
activities in viable cells to give an orange-color formazan dye, which can be detected 
under the wavelength of 450nm. (http://www.dojindo.com/store/p/456-Cell-Counting-
Kit-8.html) 
 
 
In brief, cells were cultured in growth medium (see section 2.1.1). When the cells grew 
up to 80% confluence, they were detached with 0.25% trypsin-EDTA and sub-cultured 
into a new 0.04% gelatine-coated clear 96-well plate at a density (4,000 cells/ well for 
HUASMCs and 3,000cells/well for HUVECs) in triplicate, with fresh growth medium.   
 
After incubation in a humid incubator with 5% CO2 at 370C overnight, cell medium for 
HUASMCs was replaced with 100µl/well low-serum medium (DMEM with 0.5% FBS, 
2mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin) and cells was 
then starved for 24 hours. Subsequently, cells was cultured in 100µl/well growth 
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medium (formations see section 2.1.1) or with CNP /C-ANF4-23 at the concentration of 
100nM. ). For HUVECs, cells was starved for 4h with 0.2% BSA in M199 then cultured 
in 100µl/well growth medium (see section 2.1.2.), with or without CNP/ C-ANF4-23 at 
the concentration of 1nM. Cells were then incubated for 24 hours. 10µl/well of CCK-8 
solution was added into each well of the plate, and was incubated for 2 hour at 370C, 
then the absorbance at baseline and 24 hours in each group was measured at 450nm 
using a microplate reader (Dynex MRX TC Revelation Microplate Reader). 
 
2.10.1 Optimization of CNP concentration in HUASMCs  
As described above, HUASMCs were plated into 96-well microplate overnight and 
starved, then treated with a serial concentrations of CNP. After incubation of 24h, 
proliferation in control and CNP groups were assayed by CCK-8. As indicated in 
Figure 2.17, higher doses of CNP (100nM and 1µM) significantly inhibited HUASMCs 
proliferation compared with control group. 100nM CNP was chosen here for the 
subsequent HUASMC proliferation assay (Figure 2.17).  
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Figure 2.16 Optimization of CNP concentration in HUASMC proliferation.  
HUASMCs were treated by a range of CNP (100pM to 1µM) for 24h, and proliferation 
was detected by cell counting assay. It was observed higher doses of CNP (100nM 
and 1µM) diminished the HUASMCs proliferation. N=5, * P < 0.05 by paired t test 
when CNP group compared with control. 
 
 
2.11 In vitro scratch assay  
To investigate whether these BP-associated SNPs affect the VSMCs ability of 
migration, the in vitro scratch assay was performed. The scratch assay is a convenient 
and cost-effective method to study cell migration which is based on the observation 
upon creation of a new artificial gap, so called ‘scratch’, on a confluent cell monolayer. 
The cells on the edge of the newly created gap will move toward the opening to close 
the ‘scratch’ until new cell-cell contacts are established again. This assay was 
conducted according to a previously published method with a small modification.141  
 
Briefly, VSMCs were plated in a 24-well plate at a density of 1X105 cells/well to reach 
a confluent cell monolayer overnight before the assay. Parallel lines were drawn using 
a marker pen on the back of each well and then a straight-line wound was made 
vertical to them by scratching the cell monolayer with a p200 sterile tip. The debris 
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was washed away with pre-warmed PBS twice and growth medium once, followed by 
adding a serial of working mediums as shown in the Table 2.16 below. 
 
Table 2.14  Working media for in vitro scratch assay. 
Working media Compositions  
Complete medium  DMEM with 15% FBS 
CNP-complete medium 100nM CNP in complete medium 
C-ANF4-23 complete medium 100nM C-ANF4-23 in complete medium 
Low serum medium DMEM with 0.5% FBS 
CNP-low serum medium 100nM CNP in low serum medium 
C-ANF4-23  low serum medium 100nM C-ANF4-23 in low serum medium 
 
 
Images of the wound in each well were taken from some proper plots close to the 
parallel lines. Cells were then incubated in a humidified incubator with 5 % CO2 at 
370C and gap of the cell monolayer of each well was captured again after 6 hours and 
12 hours respectively. Image J software was used to measure the distances between 
two edges of the wound. 
 
 
2.12 Fluorescent imaging plate reader (FLIPR) calcium flux assay  
 
Calcium flux was to detect changes in intracellular calcium using some sensitive, 
reliable fluorescent calcium indicators or dyes. Cells are incubated with loading dye 
in assay buffer and indicators passes through the cell membrane and esterase in the 
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cytoplasm cleave the acetoxymethyl ester (AM) portion of the molecular during the 
incubation (Figure 2.19). Once the target is activated, intracellular fluorescence 
change due to increased calcium concentration can be detected by fluorescent 
imaging plate reader (FLIPR) or FlexStation microplate readers.  
 
 
 
Figure 2.17 Calcium flux assay principle  
Calcium sensitive dye ester is loaded into the cell and is cleaved by cell esterases to 
active dye. Ca2+ entering the cells bind to intra-cellular dye and results in increased 
fluorescent emission. (http://www.moleculardevices.com ). 
 
 
HUASMCs or HUVECs were plated into a gelatine-coated 96-well plate (clear bottom, 
black wall) at a density of 5,000 cells/well in triplicate with growth medium to get a 
confluence of around 80%, and incubated at 370C, 5 % CO2 overnight. Cell medium 
in plate was replaced with 50µl fresh growth medium before loading. Loading buffer 
for each plate was prepared with fluorescent dye calcium 6, assay buffer with 20mM 
HEPES (Gibco,15630-106) in 1X Hanks’ balanced salt solution (HBSS) 
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(Gibco,14065-056), and a final concentration of 2.5mM Probenicid ( Thermo Scientific, 
P36400) according to the introduction of the FLIPR Calcium 6 assay Kit (Molecular 
Devices). Equal volume (50 µl) of loading buffer was added into each well, then the 
cell plate was incubated for two hours at 370C, 5 % CO2. Compounds plate 1 (96-well 
microplate, V-shaped bottom) with Losartan (Sigma, UK), Isoprothenol (ISO) (Sigma, 
UK), CNP and C-ANF4-23, and compound plate 2 with Carbachol (Sigma, UK), 
angiotensin (Ang II) (Sigma, UK) were prepared freshly before reading (Table 2.17).  
All compounds were dissolved in ddH2O filtered with 0.22µm filter units (Millipore, 
SLGP033RS) at a stock concertation of 1mM and 100mM (only for carbachol).   
 
Table 2.15 The working concentrations of compounds used in FLIPR assay. 
Compounds in plate 1 Working concentrations  
Losartan 1µM 
ISO 50mM, 1µM 
CNP 1pM to 1µM 
C-ANF4-23 1pM to 1µM 
 
Compounds in plate 2 Working concentrations  
Carbachol 10mM 
Ang II  1pM to 10µM 
 
 
 
FLIPR machine programme was set up to 370C. 11µl of compounds in plate 1 were 
automatically dispensed into wells and incubated for 10min. 12µl of Ang II or 
Carbachol was then dispensed inside to stimulate the calcium flux. Once stimulation 
by agonists, Calcium flux signal was detected for 3min by every 1 second with the first 
15 seconds as baseline reading (F0). The peak response signal during the reading is 
regarded as Fmax, then the relative signal was calculated by the formula of (Fmax-
F0)/F0 (Figure 2.20). More than two independent experiments were run for each 
sample.  
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Figure 2.18 Representative trace of intracellular calcium changes in response 
to Ang II in HUASMCs. 
Calcium flux signal under stimulation of Ang II was detected for 3 min. Baseline 
reading in the first 15 seconds is F0, and the peak response signal during the reading 
is regarded as Fmax, then the relative signal was calculated by the formula of (Fmax-
F0)/F0.  
 
 
2.12.1 Optimization of loading dyes and Ang II concentrations in HUASMCs  
As described above, cells plates were incubated with three different loading dyes of 
Calcium 6 (Molecular Device), Fluo-4 (Invitrogen) and Calcium direct (Invitrogen) 
respectively and subjected to FLIPR reading with stimulation by 100µM pyrimidine 
nucleoside triphosphate (UTP) (Sigma), 10mM Carbachol as positive controls, PBS 
as negative control and a serial of Ang II from 1pM to 10µM. It is shown as Figure 
2.20-A, Calcium 6 has a more sensitive response in positive controls groups 
compared with other two loading dyes.  It was observed Ang II EC50 and EC80/90 in 
HUASMCs using calcium 6 are around 10nM, 100nM respectively (Figure 2.20-B). 
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Except 10nM (EC50) Ang II, 100nM Ang II was also chosen to utilised to detect the 
possible counteracting effect of compounds CNP/C-ANF4-23 on Ang II-induced 
intracellular calcium changes in subsequent experiments.  
 
 
Figure 2.19 Optimization of three different loading dyes (A) and Ang II 
concentration with calcium 6 (B) in HUASMCs. 
A, HUASMCs were incubated with three different loading dyes of Calcium 6, Fluo-4 
and Calcium direct respectively under stimulation by UTP and carbachol with PBS as 
negative control. B, A serial of Ang II from 1pM to 10µM were utilised to induce 
HUASMCs calcium flux and the concentration curve showed the EC50 of Ang II in 
HUASMCs was 10-7.8 M.  
 
2.12.2 Optimization of CNP/C-ANF4-23 concentrations in calcium flux in 
HUASMCs 
As described in section 2.12, HUASMCs were incubated with calcium 6 loading buffer 
for 2 hours at 370C, 5 % CO2, then pre-incubated with a range of CNP/C-ANF4-23 (1pM 
to 1μM), and Losartan (1μM) as antagonist control for 10 min. Ang II with a working 
concentration of 1nM was then dispensed into wells to stimulate the calcium flux. 
Fluorescent signal which presents the intercellular calcium changes was detected for 
3 min and calculated by the formula of (Fmax-F0)/F0. Three independent experiments 
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were run for each sample. As shown in Figure 2.21, a dose-dependent inhibition was 
observed in Ang II-induced calcium flux when pre-treated with CNP/ C-ANF4-23, and 
1μM CNP/ C-ANF4-23 could significantly counteract the intracellular calcium changes 
in response to 10nM Ang II.  
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Figure 2.20 Optimization of concentrations of CNP (1pM to 1μM) (A) and C-ANF4-
23 (1pM to 1μM) (B) with Losartan (1μM) as antagonist control in Ang II (10nM) - 
induced intracellular calcium changes in HUASMCs.  
Values are presented as mean ±SEM, *p<0.05 when control vs CNP/ C-ANF4-23, N≥ 
7 running in triplicate. 
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2.12.3 Preliminary test for agonists of calcium flux in HUVECs  
 
As described in section 2.12, HUVECs were incubated with Calcium 6 for 2 hours and 
subjected to FLIPR reading under stimulation by a range of agonists as listed in the 
Table 2.18 below and PBS as negative control.  As compared with calcium signal of 
HUASMCs under 100nM Ang II, the response to Ang II as well as the other agonists 
in HUVECs were very low (Figure 2.23). This small signal window is probably not very 
proper to detect the potential genetic difference among genotypes in HUVECs. Thus, 
calcium flux for HUVECs was not conducted in this subject.  
 
 
Table 2.16  Agonists used in HUVECs calcium flux. 
Agonists Working concentrations  
UTP 1mM 
bzUTP 1mM 
Carbachol 10mM 
Ang II 100nM 
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Figure 2.21 Optimization for agonist of calcium flux in HUVECs.  
HUVECs were subjected to FLIPR reading under stimulation by UTP, bzUTP, Ang II, 
carbachol and PBS as negative control. However, the calcium signals in HUVECs 
were all very low compared with HUASMCs under Ang II.   
 
 
2.13 Data and statistical analysis. 
Statistical analyses were performed using Graph Pad Prism version 5 (Graph Pad 
Software, California, USA). Results are expressed as mean ± SEM. Comparisons 
between two groups were made with paired, unpaired student t test (two tailed) or 
Wilcoxon signed-rank test. Differences among three or more than three groups were 
analysed with one-way ANOVA in conjunction with a post-test of Bonferroni's Multiple 
Comparison Test. Results were considered significant at a value of p < 0.05. 
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3. Result of Functional study of BP-
associated variants at the NPR3 
gene locus in HUASMCs 
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3.1 Genotyping results of BP- associated SNPs at the NPR3 locus in HUASMCs. 
Genomic DNA from HUASMCs was extracted and genotyped using the KASPar 
genotyping technique described in section 2.3. Genotyping results for the BP-
associated SNPs were obtained by at least 2 replicates. A presentative plot for allelic 
discrimination is shown in Figure 3.1. All the BP-associated SNPs genotyping results 
in HUASMCs are in accordance with Hardy-Weinberg equilibrium (Table 3.1).  
 
 
 
Figure 3.1 An allelic discrimination plot for SNP rs1173771 in HUASMCs 
analysed by SDS 2.3. 
Four clusters were separated after genotyping. Blue cluster stands for the genotype 
of CC, green for CT, red for TT and black represents NTC and samples undetermined.   
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Table 3.1 BP-associated SNPs genotyping result in HUASMCs.  
 
Variants in block 1 
rs1173743/ 
rs1173747(r2=1) rs1173756 rs1173771 
Major allele homozygotes  85 85 89 
Heterozygotes 107 112 107 
Minor allele homozygotes  34 35 34 
HWE calculation 
 
 P-value by Chi-Square Test  0.9725 0.8484 0.8467 
 
 
Variants in block 2 
rs7729447 rs3762988 
rs1421811/ 
rs3828591(r2=1) 
Major allele homozygotes  130 101 104 
Heterozygotes 70 89 86 
Minor allele homozygotes  9 20 19 
HWE calculation  
 P-value by Chi-Square Test  0.9128 0.9511 0.8953 
    
HWE= Hardy-Weinberg equilibrium 
 
Moreover, the linkage disequilibrium values between these SNPs in our HUASMCs 
collection are very similar to those in the HapMap data set obtained using the SNAP 
programme (Table 3.2).  
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Table 3.2 Linkage disequilibrium (LD) values between NPR3 SNPs. 
Lead SNP SNP in LD 
Hap map 
value 
(CEU) 
Value in current collection of 
HUASMCs 
rs1173771 
rs1173743/ 
rs1173747(r2=1) 
0.78 0.83 
rs1173771 rs1173756 0.78 0.81 
rs1173771 rs1421811 0.13 0.15 
rs1421811 rs3828591 1.0 1.0 
rs1421811 rs3762988 0.83 0.85 
rs1421811 rs7729447 0.56 0.63 
 
As predicted by HapMap and data in our collection, the LD between the two lead 
SNPs rs1173771 and rs1421811 is 0.13-0.15 (Table 3.2). Therefore, it appears that 
these two SNPs are in two separate LD blocks and thus functional studies were 
conducted independently for these two blocks. 
 
 
3.2 Functional study of variants in the rs1173771 linkage disequilibrium block 
in HUASMCs 
3.2.1 Effect of BP-associated SNPs on NPR3 mRNA level in HUASMCs  
Quantitative Reverse transcription PCR (qRT-PCR) was performed on mRNA 
extracted from HUASMCs (see section 2.5.1) to assess if the BP-associated SNPs 
rs1173771, rs1173743, rs1173747 and rs1173756 are associated with NPR3 
expression level. To test the NPR3 expression levels in HUASMCs, SYBR-Green 
qPCR technique was used here (as described in section 2.4). After analysis by SDS 
2.3, a Ct value which presents the quantitation of gene expression of samples was 
obtained, the delta Ct (ΔCt) of samples was then obtained by standardising to the 
internal reference gene 18S, and delta delta Ct (ΔΔCt) in each group by standardized 
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with the mean of ΔCt of BP-elevating allele homozygous group (reference group). 
Relative NPR3 expression levels were transformed using 2-ΔΔCt and plotted by each 
genotype of HUASMCs. The statistics was finally analysed by One-way ANOVA with 
a post-test of Bonferroni's Multiple Comparison Test.  
 
In addition of real-time PCR, another method, allelic expression imbalance (AEI), was 
also performed to investigate whether BP-associated SNPs could influence NPR3 
mRNA level. Briefly, this assay was conducted in HUASMCs that were heterozygous 
for the 3-UTR SNP rs1173756 (C/T), and the ratio of the two alleles in genomic DNA 
and mRNA was obtained and compared by Wilcoxon signed rank test.  
 
3.2.1.1 Association of BP-elevating allele with decreased NPR3 mRNA level  
 
In HUASMCs samples, there was lower relative NPR3 mRNA level in samples with 
the BP-elevating allele (major allele) the intronic SNPs rs1173747 and rs1173743, 
and no significant difference heterozygotes and homozygotes of this allele (AA versus 
AC) (Figure 3.3 B). It was also demonstrated that a similarly decreased level is 
present in BP-elevating allele carriers of 3-UTR SNP rs1173756 (Figure 3.3 C). This 
difference was also noted with the down-stream SNP rs1173771, but did not reach 
statistical significance with the current sample size. (Figure 3.3 D). These data show 
that the BP-associated SNPs in rs1173771 linkage disequilibrium block is associated 
with NPR3 gene mRNA expression level.  
 
 
126 
 
 
Figure 3.2 Quantitative analysis of mRNA levels of NPR3 among BP- associated 
SNPs in linkage disequilibrium block of rs1173771 in HUASMCs.  
A, Positions of BP-associated variants of rs1173771 linkage disequilibrium block at 
the NPR3 gene locus. B, C, D, genotype-dependent effect on NPR3 gene mRNA level 
by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assay for 
intronic variants rs1173743 and rs1173747 (r
2
=1.0) (B), 3’UTR variant rs1173756 (C), 
and 3’ flanking region variant rs1173771 (D), respectively. Values are presented as 
mean ± SEM, *P<0.05, **P<0.01 by Kruskal-Wallis test. 
  
3.2.1.2 Allelic expression imbalance of NPR3  
 
A further experiment, allelic expression imbalance (AEI) assay, was carried out to 
investigate the relative expression levels of the two alleles of the BP-associated SNPs.  
The 3’-UTR SNP rs1173756 was used as a maker in this assay because it is in the 
NPR3 transcript whereas the other SNPs are intronic or downstream and therefore 
cannot been directly analysed in this assay. Genomic DNA and cDNA (mRNA) of 
HUASMCs from 8 heterozygotes were subjected to end-point PCR and subsequent 
Sanger sequencing. As shown in Figure 3.4, the peak height of the BP-elevating allele 
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(major allele, C) versus that of the alterative allele (minor allele, T) was significantly 
lower in the chromatogram from cDNA than that from the chromatogram from genomic 
DNA in HUASMCs, suggesting lower NPR3 expression of the BP-elevating allele, 
which is in agreement with qRT-PCR data described above. 
 
 
Figure 3.3  Allelic expression imbalance of 3-UTR SNP rs1173756 in the NPR3 
gene in HUASMCs.   
A, Representative section of sequencing chromatogram showing the peaks of the two 
alleles (T and C) of rs1173756 in genomic DNA and corresponding cDNA samples 
from HUASMCs. B, The peak height of each allele was determined by the Peak Picker 
programme. Column chart shows means and SEM of relative peak heights of the two 
alleles in the chromatograms from genomic DNA and cDNA, respectively, in 
HUASMCs from 8 individuals, **P=0.0078 by Wilcoxon signed-rank test.  
 
 
3.2.2 Effects of variants in the rs1173771 LD block on NPR-C protein level 
 
To investigate whether the BP-associated SNPs influence NPR-C protein expression, 
Western blot analysis was completed with HUASMCs samples from individuals of 
different genotypes for rs1173747 (also for rs1173743, rs1173756 and rs1173771 due 
to LD). The assay revealed lower NPR-C protein levels in BP-elevating allele 
homozygotes than in BP-lowering allele homozygotes (Figure 3.4). These results are 
in line with the analyses of mRNA levels (section 3.2.1).                     
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Figure 3.4 Blood pressure-associated variant in rs1173771 LD block 
significantly affect natriuretic peptide receptor C (NPR3) protein level in human 
umbilical arterial smooth muscle cells (HUASMCs).  
 A,B, Western blotting shows NPR-C protein level is lower in HUASMCs homozygotes 
of the BP-elevating genotype compared with BP-lowering allele homozygotes, 
*P<0.05 by unpaired t-test (N≥5 for each genotype). 
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3.2.3 Interaction of BP-associated SNPs in rs1173771 LD block with nuclear 
proteins 
  
To investigate whether BP-associated SNPs interact with nuclear proteins, 
electrophoretic mobility shift assays (EMSA) were carried out. Biotin-labelled oligos 
representing regions around BP-associated SNPs were incubated with nuclear 
extracts from HUASMCs. In studies relating to the intronic SNP rs1173743, an allelic-
specific DNA-protein complex was observed in this in vitro assay, showing a higher 
affinity for the rs1173743-G probe than for the rs1173743-T probe, and band for this 
complex was abolished by 50 fold excess specific unlabelled rs1173743-G oligo (Fig 
3.6 A, lane 7) but not by an unspecific competitor (Figure 3.6 A, lane 6). Protein 
interaction was also detected for another intronic SNP, rs1173747, and the complex 
for the rs1173747-C allele was almost fully competed out by 50 fold excess unlabelled 
rs1173747-C oligo (lane 7 in Figure 3.6 B), whereas the complex for the rs1173747-
A allele was not (lane 7 in Figure 3.6 B), suggesting a difference between two alleles 
in their affinity with nuclear protein. . As shown in Figure 3.7, protein interaction was 
also detected for rs1173771 and rs1173756, and assays with competitors suggest an 
allelic effect on protein interaction by rs1173756 (Figure 3.7, lanes 9 and 12) but not 
rs1173771 (Figure 3.7, lanes 3 and 6).  
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Figure 3.5 Interaction of NPR3-intronic SNPs rs1173743 and rs1173747with 
HUASMC nuclear proteins in vitro.  
The Biotin-labelled oligonucleotide probes were incubated with HUASMC nuclear 
extracts, and also with or without-50 fold molar excess of unlabelled oligos as 
competitors. As shown in image A are assays of rs1173743-G and rs1173743-T 
probes and image B are assays of rs1173747-A and rs117374-C probes. 
 
 
 
 
 
131 
 
 
 
 
Figure 3.6 Interaction of NPR3 SNPs rs1173771 (intergenic) and rs1173756 
(located in 3’-UTR) with HUASMC nuclear proteins in vitro.  
Biotin-labelled oligonucleotide were incubated with HUASMC nuclear extracts, and 
also with or without 50 fold molar excess of unlabelled oligos as competitors. 
 
 
 
 
3.2.4 BP-associated variants reside in open chromatins in HUASMCs  
 
Open chromatin (euchromatin) is widely regarded as permissible structures for 
transcription through binding of regulatory elements (Clapier & Cairns, 2009). FAIRE 
was conducted here to explore whether blood-pressure associated variants reside in 
the open chromatin region, to further investigate the potential molecular mechanism 
of genetic regulation of NPR3 in HUASMCs. 
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3.2.4.1 BP-elevating allele of rs1173747 is less represented in open chromatin 
in HUASMCs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
To assess the potential allelic imbalance of open chromatin status, FAIRE and input 
DNA samples were subjected to Sanger sequencing. The sequencing signals of the 
rs1173747-BP-elevating allele (A) were less enriched in FAIRE DNA relative to input 
DNA of HUASMCs (Figure 3.8 A+B). Allelic-specific qPCR was also performed to 
determine the relative levels of BP-elevating allele (A) and BP-lowering allele (C) in 
the FAIRE DNA and corresponding input DNA, and also showed a much lower level 
of BP-elevating allele in FAIRE DNA (Figure 3.8 -C). These results indicate that the 
intronic SNP rs1173747 is located in the open chromatin in HUASMCs with an allelic 
imbalance pattern.   
 
 
Figure 3.7 Allele-specific difference of rs1173747 in open chromatin in 
HUASMCs.  
Sanger sequencing chromatograms of FAIRE and input DNA from the region around 
rs1173747 revealed that the minor allele (C) is enriched in open chromatin in 
HUASMCs (N=6) (A), and allelic-specific qPCR confirmed this finding (N=8) (B). 
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3.2.4.2 BP-elevating allele of rs1173756 is less represented in open chromatin 
in HUASMCs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
A similar assay was performed for rs1173756 and showed that the rs1173756-BP-
elevating allele (C) was less enriched in FAIRE DNA relative to input DNA in 
HUASMCs (Figure 3.9-A+B).This finding suggests the 3’-UTR SNP rs1173756 is 
located in the open chromatin in HUASMCs with an allelic imbalance pattern, which 
direction is also in line with the rs1173747 data. 
 
 
 
Figure 3.8 Allele-specific difference of rs1173756 in open chromatin in 
HUASMCs.  
Sanger sequencing chromatograms of FAIRE and Input DNA from the region flanking 
rs1173756 revealed that the minor allele (C) is enriched in open chromatin fragments 
in HUASMCs (N=5). 
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3.2.5 BP-elevating allele of variants in the rs1173771 LD block increases 
HUASMC proliferation 
 
Proliferation of VSMCs contributes to the development of hypertension. NPR-C, as a 
Gi protein coupled receptor, has been shown to regulate cell proliferation via NPR-C 
related signalling pathway 133, therefore, the primary HUASMCs proliferation was 
determined by cell counting assay (as described in section 2.10) to see whether there 
is an effect of BP-associated SNPs on cell proliferation. Cells were also incubated 
with or without 100nM CNP or C-ANF4-23 (a specific NPR-C agonist) for 24 hours to 
investigate the effect of this receptor related signalling on cell proliferation.   
 
rs1173771 genotype pattern in these HUASMCs studied is concordant with other 
three SNPs (rs1173743/rs1173747, rs1173756), thus the genotypes will be referred 
to as BP-elevating allele homozygotes, heterozygotes and BP-lowering allele 
homozygotes.   
 
The study revealed that there is a significant difference between genotypes of NPR3 
BP-associated SNPs in HUASMC proliferation, with a markedly increased 
proliferating rate in BP-elevating allele carriers in contrast to BP-lowering allele 
homozygous samples (Figure 3.10). Furthermore, treatment of CNP or C-ANF4-23 
significantly diminished proliferation in HUASMCs, with a trend of genetic difference 
of drugs inhibitory effect with less inhibition in HUASMCs carrying the BP-elevating 
allele compared with those of BP-lowering allele homozygotes (Figure 3.11), which is 
in line with the findings of their effects on NPR3 gene expression. 
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Figure 3.9 Effect of BP-associated variants in the rs1173771 LD block in NPR3 
on HUASMCs proliferation. 
A, Representative images showing differences between genotypes in cell density at 
baseline and in 24h. B, Cell proliferation was measured at 24h by cell counting assay 
(CCK-8). A significantly increased cell growth rate was observed in HUASMCs 
carrying the BP-elevating allele compared with cells of BP-lowering allele 
homozygotes (CC).  N≥6 for each genotype in at least duplicate. Values are presented 
as mean ± SEM, *P<0.05, **P<0.01 by one-way ANOVA with Bonferroni correction 
for a number of tests for different genotypes. 
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Figure 3.10 Inhibitory effect of CNP/ C-ANF4-23 on HUASMC proliferation.  
A, C-type natriuretic peptide (CNP) and the NPR-C specific agonist C-atrial natriuretic 
peptide (C-ANF4-23) attenuated HUASMC proliferation. N≥19 for each group in at least 
duplicate. Values are presented as mean ± SEM, **P<0.01, ***P<0.001 when 
comparing CNP or C-ANF4-23 vs control by Wilcoxon signed-rank test. B, when treated 
with CNP or CANF4-23, the inhibitory effect of drugs in BP-elevating allele homozygotes 
is less than BP-lowering allele homozygous samples. N≥6 for each genotype running 
at least duplicate. Values are presented as mean ± SEM, *P<0.05, when comparing 
BP-elevating allele homozygotes vs BP-lowering allele homozygotes by unpaired t 
test. 
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3.2.6 BP-associated variants at the NPR3 locus have no effect on HUASMC 
migration  
 
In addition to cell proliferation, I also sought to investigate whether BP-associated 
variants at the NPR3 gene locus have an impact on cell migration. Scratch assay, as 
described in section 2.11, was used here to explore the possible genetic effect of 
NPR3 variants in primary HUASMCs from different individuals. 
 
The study showed no significant association between SNPs in rs1173771 LD block 
studied and HUASMCs migration, although treatment of 100nM CNP or C-ANF4-23 
could inhibit the migration ability of HUASMCs (N≥5 for each genotype). (Figure 3.12), 
indicating association between these SNPs and BP control is not through regulating 
cell migration.  
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Figure 3.11 No significant effect of blood pressure (BP)-associated variants in 
rs1173771 LD block at the NPR3 locus on cell migration in HUASMCs. 
 A, CNP or C-ANF4-23 inhibited the migration rate of HUASMCs in in vitro scratch 
assay. N=19 for each group. B, No association was observed between BP-associated 
variants and cell migration in HUASMCs with or without CNP/C-ANF4-23. C, No genetic 
difference of inhibitory effect of CNP/C-ANF4-23 was observed in HUASMCs cell 
migration. N≥5 for each genotype running at least duplicate. Values are presented as 
mean ± SEM, Genetic difference among genotypes was analysed by one-way 
ANOVA with Bonferroni correction for the number of tests for genotypes. *P<0.05, 
**P<0.01 when CNP/CANF4-23 vs control by Wilcoxon signed rank test.  
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3.2.7 BP-elevating allele of variants in the rs1173771 LD block increases 
intracellular calcium flux in response to Ang II in HUASMCs. 
Calcium flux was carried out by FLIPR with previously optimized fluorescent loading 
dye, Calcium 6 (see section 2.12.1) in HUAMCs. The aim was to study the impact of 
BP-associated variants on intracellular calcium changes under stimulation of Ang II 
and Carbachol (positive control). A preliminary experiment indicated the concentration 
of EC50 of Ang II required to activate calcium flux is approximately 10nM in HUASMCs 
(see section 2.12.1). Cells were stimulated with 10nM Ang II (EC50), 100nM Ang II 
(EC80/90), or 10mM carbachol.  To explore the possible related signalling pathway, 
cells were also pre-treated with CNP/C-ANF4-23 before stimulation.  
 
Cells were plated at a similar density among genotypes and incubated with loading 
dye calcium 6 (Figure 3.13). No genetic association of intracellular calcium changes 
was observed in response to carbachol. However, HUASMCs that are either 
homozygotes for the BP-elevating allele or heterozygotes exhibited an augmented 
intracellular calcium level in response to Ang II in contrast to BP-lowering allele 
homozygotes (Figure 3.14). These results imply NPR3 gene with the risk variant is 
involved in the intracellular calcium response to Ang II.  
 
We next examined the effect of CNP and the NPR-C specific agonist, C-ANF4-23, on 
the calcium flux with losartan (1µmol/L) as antagonist control. In the presence of CNP 
or CANF4-23 (1μmol/L), HUASMCs continued to exhibit the same genetic difference in 
both doses of Ang II-stimulation (Figure 3.15A). CNP or CANF
4-23 
significantly 
counteracted the augment of intracellular calcium in response to the lower dose of 
Ang II (10nM), and even under a higher dose of Ang II (100nM), CANF
4-23 
was still 
effective. However, no significant difference of inhibitory effect of CNP or CANF4-23 on 
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genotype was detected, with a slightly lower effect on BP-elevating allele samples, 
which is in accordance with its NPR3 expression level (Figure 3.15). 
 
 
 
Figure 3.12 Representative figures to show cell density of human umbilical 
arterial smooth muscle cells in each genotype after incubated with fluorescent 
loading dye calcium 6.  
A, B, C, HUASMCs were plated into cell plate at a similar cell density and images 
were taken after 2 hours incubation with loading dye calcium 6. 
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Figure 3.13 Effect of NPR3 BP-associated variants in the rs1173771 LD block on 
the intracellular calcium changes induced by angiotensin II (Ang II) in 
HUASMCs.  
Representative traces showing the calcium flux in response to carbachol (1mM) 
(positive control) (A) and angiotensin II (Ang II) (100nM) (B) among genotypes using 
fluorescent imaging plate reader (FLIPR) assay. C, A higher Ang II-stimulated 
intracellular calcium level was observed in BP-elevating allele samples in both lower 
dose (10nM) and higher dose (100nM) groups, however, no genetic difference was 
observed in carbachol induced HUASMCs calcium flux. N≥5 for each genotype 
running at least duplicate. Values are presented as mean ± SEM, *P<0.05, analysed 
by one-way ANOVA with Bonferroni correction for the number of tests for different 
genotypes. 
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Figure 3.14 Effect of C-type natriuretic peptide and natriuretic peptide receptor 
C-specific agonist CANF4-23 on angiotensin II induced intracellular calcium 
changes in HUASMCs.  
Cells were treated with C-type natriuretic peptide (CNP, 1µM) or the natriuretic 
peptide receptor C-specific agonist C-ANF4-23 (1μM). The analysis showed a 
difference among genotypes with a higher intracellular calcium level in BP-elevating 
allele (major allele) carrier samples. N≥5 for each genotype running at least duplicate. 
*P<0.05 by one-way ANOVA with Bonferroni correction for the number of tests for 
different genotypes. 
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Figure 3.15 Effect of C-type natriuretic peptide and natriuretic peptide receptor 
C-specific agonist C-ANF4-23 on angiotensin II induced intracellular calcium 
changes in HUASMCs.  
Cells were treated with C-type natriuretic peptide (CNP, 1µM), the natriuretic peptide 
receptor C-specific agonist C-ANF4-23 (1μM) and angiotensin II (Ang II) receptor 
blocker losartan (1μM) as antagonist control. A, CNP or CANF4-23 could counteract 
the augment of intracellular calcium in response to the lower dose of Ang II (10nM), 
even under a higher dose of Ang II (100nM), CANF4-23 still could significantly diminish 
Ang II-stimulated calcium response. N≥20 for each group running at least duplicate. 
Values are presented as mean ± SEM, **P<0.01, ***P<0.001 when CNP/C-ANF4-23 
vs control by Wilcoxon signed rank test. B, No significant difference of compound 
(CNP/CANF4-23) inhibitory effect among genotypes in both Ang II groups. N≥5 for each 
genotype running at least duplicate. Values are presented as mean ± SEM, *P<0.05, 
analysed by one-way ANOVA with Bonferroni correction for the number of tests for 
different genotypes.  
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3.3 Functional study of variants in the rs1421811 LD block in HUASMCs 
3.3.1 Effect of BP-associated SNPs on NPR3 mRNA level in HUASMCs  
To see whether there is an impact of BP-associated variants in the rs1421811 LD 
block in NPR3 mRNA level of HUASMCs, qRT-PCR data was also analysed based 
on rs1421811 genotypes. NPR3 mRNA level was slightly decreased in BP-elevating 
allele carriers of intronic SNPs rs3762988 and SNP rs7729447 (Figure 3.17 B and C) 
respectively, but the difference was not statistically significant. However, there was a 
trend towards lower NPR3 mRNA level in BP-elevating allele (major allele) carrier 
samples compared with BP-lowering allele of intronic SNPs rs1421811/rs3828591 
(r2=1.0) (Figure 3.17 D), suggesting a possible impact of these two intronic SNPs on 
NPR3 gene expression.  
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Figure 3.16 Quantitative analysis of mRNA levels of NPR3 among BP-
associated SNPs in rs1421811 LD block in HUASMCs.  
A, Genetic positions of BP-associated variants of rs1421811 LD block in NPR3 gene 
locus. B,C,D, BP-associated variants drove a genotype- dependent effect on NPR3 
gene regulation in HUASMCs with reduced mRNA level of NPR3 in BP-elevating 
allele homozygous samples, such determined by quantitative reverse-transcription 
polymerase chain reaction (qRT-PCR) for intronic variants rs7729447(B), 
rs3762988(C), rs1421811 and rs3828591 (r
2
=1.0) (D). Values are presented as mean 
± SEM, *P<0.05, analysed by one-way ANOVA with post-test of Bonferroni's multiple 
comparison test.  
 
 
3.3.2 No significant effect of variants in the rs1421811 LD block on NPR-C 
expression level  
 
In the rs1421811 LD block, the BP-lowering allele homozygous samples are very rare, 
therefore the data was analysed by combining heterozygous and BP-lowering allele 
homozygous samples together versus BP-elevating allele homozygotes. There were 
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slightly lower expression levels of NPR-C in BP-elevating allele homozygous 
HUASMCs compared with the other two genotypes, however, there was no 
statistically significant association between NPR-C protein level and genotype for any 
of these SNPs (Figure 3.18).  
 
 
Figure 3.17 Effect of Blood pressure-associated variant in rs1421811 LD block 
on natriuretic peptide receptor C (NPR-C) protein level in human umbilical 
arterial smooth muscle cells (HUASMCs).  
 Western blotting shows NPR-C protein level is slightly lower in HUASMCs with 
genotype of BP-elevating allele homozygotes compared with other two genotypes, 
but no significance (N≥9 in each genotype). 
 
 
3.3.3 No significant association between variants in the rs1421811 LD block at 
NPR3 gene locus and HUASMC proliferation 
The possible genetic difference of variants in rs1421811 LD block in HUASMCs 
proliferation was also investigated here. The minor allele frequency (MAF) of these 
variants are low and there is only a few samples (N≤ 3) for BP-lowering allele (minor) 
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homozygotes harvested in our current collection, hence, the data was analysed by 
combination with heterozygous and minor allele homozygous.  As shown in Figure 
3.19, No significant genetic difference among genotypes of all investigated variants 
in rs1421811 LD block was detected in HUASMCs proliferation, and no genetic 
difference of compounds inhibitory effect as well.  
 
 
Figure 3.18 No significant effect of BP-associated variant in rs1421811 LD block 
in NPR3 on HUASMC proliferation. 
A, Cell proliferation was measured at 24h by cell counting assay (CCK-8). No genetic 
difference was detected among genotypes in HUASMCs proliferation and compounds 
inhibitory effect. N≥6 in each genotype running at least duplicate. Values are 
presented as mean ± SEM, data was analysed by unpaired t test between BP-
elevating allele homozygous and other two genotypes. 
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3.3.4 No significant association between variants in the rs1421811 LD block at 
the NPR3 gene locus and HUASMC migration 
When analysing data for rs1421811 LD block, the BP-lowering allele homozygous 
samples here is less than 3, thus this genotype was combined with heterozygous. 
However, no difference was observed between BP-elevating allele homozygous and 
other two genotypes in migration rate in HUASMCs and in compounds inhibitory effect 
either (Figure 3.20).  
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Figure 3.19 No effect of blood pressure (BP)-associated variants in the 
rs1421811 LD block at the NPR3 locus on HUASMC migration.  
A, No association was observed between BP-associated variants and HUASMCs cell 
migration. N≥5 in each genotype running at least duplicate. B, No genetic difference 
of compounds (CNP/C-ANF4-23) inhibitory effect was detected in HUASMCs migration. 
Values are presented as mean ± SEM, Genetic difference among genotypes was 
analysed by unpaired t test. 
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3.3.5 Impact of variants in the rs1421811 LD block in HUASMC calcium flux. 
 
No significant genetic association of intracellular calcium changes in response to 
lower dose of Ang II (10nM) was observed in HUASMCs, although with a slightly 
higher level in elevating allele homozygotes (N≥5 in each group). However, when 
induced with 100nM Ang II, it was exhibited a significantly augmented intracellular 
calcium level in BP-elevating homozygous samples in contrast to other two genotypes 
(N≥10 in each group) (Figure 3.21).  
As indicated in section 3.9.1, CNP or C-ANF
4-23 
significantly counteracted the 
augment of intracellular calcium in response to the lower dose of Ang II (10nM), and 
even under a higher dose of Ang II (100nM), C-ANF
4-23 
is still active. However, no 
significant genetic difference of inhibitory effect of CNP or C-ANF4-23 was detected 
either in HUASMCs for rs1421811 LD block (Figure 3.22). 
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Figure 3.20 Effect of variants in the rs142181 LD block on angiotensin II induced 
intracellular calcium changes in human umbilical arterial smooth muscle cells.   
A, no significant genetic difference of impact of variants in rs1421811 LD block in 
intracellular calcium changes in response to Ang II (10nM) was obtained. N≥5 in each 
genotype running at least duplicate, and difference between genotypes was analysed 
by unpaired t test.  B, Significantly genetic influence of variants in rs1421811 LD block 
in intracellular calcium changes in response to Ang II (100nM) was observed. N≥10 
in each genotype running at least duplicate, and *P<0.05 by unpaired t test when 
compared between genotypes.  
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Figure 3.21 No effect of C-type natriuretic peptide and natriuretic peptide 
receptor C-specific agonist CANF4-23 on angiotensin II induced intracellular 
calcium changes in human umbilical arterial smooth muscle cells.   
A, B, No significant genetic difference of compounds (CNP/CANF4-23) inhibitory effect 
among genotypes of SNPs in rs1421811 LD block in Ang II groups. N≥5 in each 
genotype running at least duplicate.  Values are presented as mean ± SEM, difference 
was analysed unpaired t test. 
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4. Result of Functional study of BP-
associated variants at the NPR3 
gene locus in HUVECs 
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4.1 Genotyping result of BP-associated SNPs at the NPR3 locus in HUVECs 
Genomic DNA of isolated HUVECs from different individuals was genotyped using the 
KASPar technique described in section 2.3. All of the BP-associated SNP genotyping 
results in HUVECs were in accordant with Hardy-Weinberg equilibrium as shown in 
Table 4.1.  
 
Table 4.1 BP-associated SNPs genotyping results in HUVECs and HWE 
calculation. 
Samples in genotype (No)  
variants in block 1 
rs1173743/ 
rs1173747(r2=1) rs1173756 rs1173771 
Major allele homozygotes  63 64 76 
Heterozygotes 93 94 89 
Minor allele homozygotes  34 35 26 
HWE calculation    
 P-value by Chi-Square Test  0.9623 0.9747 0.9816 
 
 variants in block 2 
Samples in genotype (No)  rs7729447 rs3762988 
rs1421811/ 
rs3828591(r2=1) 
Major allele homozygotes  121 89 99 
Heterozygotes 59 71 73 
Minor allele homozygotes  5 12 11 
HWE calculation    
 P-value by Chi-Square Test  0.9338 0.9757 0.9433 
 
HWE= Hardy-Weinberg equilibrium; Major allele is BP-elevating allele; Minor allele 
is BP-lowering allele. 
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4.2 Functional study of variants in the rs1173771 LD block in HUVECs  
4.2.1 Effect of BP-associated SNPs in the rs173771 LD block on NPR3 mRNA 
level in HUVECs 
4.2.1.1 No significant difference between genotypes in NPR3 mRNA in HUVECs.  
 
To investigate whether the BP-associated SNPs is associated with NPR3 gene 
regulation, qRT-PCR was also conducted on HUVEC mRNA by SYBR-Green qPCR 
technique (see section 2.5.1).  
In the HUVEC samples, there was a hint of lower relative NPR3 mRNA level in BP-
elevating allele (major allele) carrier samples compared with BP-lowering allele of all 
the detected SNPs (Figure 4.1). However, the difference was not statistically 
significant.  
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Figure 4.1 Quantitative analysis of mRNA levels of NPR3 among BP-associated 
SNPs in the rs1173771 LD block in HUVECs.  
A, Genetic positions of BP-associated variants of rs1173771 LD block at NPR3 gene 
locus. B,C,D, BP-associated variants drove a genotype- dependent effect on NPR3 
gene regulation in HUASMCs with a slightly lower NPR3 mRNA level in BP-elevating 
allele carriers, such determined by quantitative reverse-transcription polymerase 
chain reaction (qRT-PCR) for intronic variants rs1173743 and rs1173747 (r
2
=1.0) 
(B),3’UTR variant rs1173756 (C), and 3’ flanking region variant rs1173771 (D) 
respectively. Values are presented as mean ± SEM, data were analysed by one-way 
ANOVA with post-test of Bonferroni's multiple comparison test.  
 
 
4.2.1.2 Allelic expression imbalance of 3’-UTR SNP rs1173756 
In addition of real-time PCR, allelic expression imbalance was performed to 
investigate the possible genetic influence on NPR3 mRNA level. This assay was 
conducted in HUVEC heterozygotes for the 3-UTR SNP rs1173756 (C/T), and the 
ratio of the two alleles in genomic DNA and cDNA was detected by sequencing and 
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compared. As shown in Figure 4.2, the expression level of BP-elevating allele (major 
allele C) was significantly lower in HUVECs.  
 
 
 
 
Figure 4.2 Allelic expression imbalance of 3-UTR SNP- rs1173756 in NPR3 gene 
in HUVECs.   
Sequencing assay for the detection of rs1173756 (C/T) was applied in genomic DNA 
and corresponding cDNA samples from HUASMC. The peak value of each allele was 
determined by Peak Picker. Allelic expression imbalance (AEI) between genomic DNA 
and complementary DNA (cDNA) at the 3’ UTR SNP rs1173756 in HUVECs (N=7 
pairs), with a lower BP-elevating allele (C) signal in cDNA compared to genomic DNA. 
*P=0.015 by Wilcoxon signed-rank test.  
 
 
4.2.2 No effect of BP-associated SNPs on the NPR-C protein level in HUVECs  
Western blottoing analysis was conducted to investigate whether BP-associated 
SNPs influence NPR-C expression in HUVECs samples from different individuals, and 
the rs1173747 genotype pattern in those samples is concordant with other three BP-
associated SNPs (rs1173743, rs1173756 and rs1173771). The analsysis showed 
slightly lower NPR-C levels in BP-elevating allele homozygotes in contrast to BP-
lowering allele homozygotes, but no statistical siginifance (Figure 4.3).     
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Figure 4.3 No effect of BP-associated variant on NPR3 protein level in HUVECs.   
A,B, Western blotting shows NPR-C protein level is lower in HUVECs with genotype 
of BP-elevating allele homozygotes compared with BP-lowering allele homozygotes, 
difference was analysed by unpaired t test (N≥4 in each genotype). 
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4.2.3 Interaction of BP-associated SNP rs1173756 with nuclear proteins from 
HUVECs 
 
Electrophoretic mobility shift assays (EMSA) were conducted to investigate whether 
BP-associated SNPs interact with potential nuclear proteins in HUVECs in vitro. 
Biotin-labelled oligos representing DNA fragments flanking the BP-associated SNPs 
were incubated with HUVEC nuclear extracts.  
 
As shown in Figure 4.4, there was a DNA-protein complex visible for the 3’-UTR SNP 
rs1173756 probes when incubated with HUVEC nuclear extracts. The intensity of the 
complex of the rs173756-BP-elevating allele (C) was much lower than the BP-
lowering allele (T), indicating a potential allelic difference in nuclear protein binding 
with this DNA region. This possibility is in accordant with genetic difference of the 
allelic expression imbalance data with a lower level of BP-elevating allele in mRNA，
and may suggest some active transcription factors interacting with the BP-lowering 
allele. However, this still needs to be verified by following detection with specific or 
unspecific competitors and molecular mechanism study. Otherwise, complex was not 
shown in the lanes for intronic SNPs rs173743, rs173747 and intergenic SNP 
rs173771.   
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Figure 4.4 Detection of relative binding affinities of DNA sequences flanking BP-
associated SNPs to HUVEC nuclear extract in vitro.  
The biotin-labelled oligos were incubated with HUVEC nuclear extract. Complexes 
were visible in the lanes of rs1173756-centered flanking oligos with nuclear protein 
and indicated a potential allelic difference of affinity.  
 
 
4.2.4 Effect of BP-associated SNPs in HUVECs cell proliferation 
It has been shown that binding of NPR-C (as a Gi protein coupled receptor) with CNP 
could up-regulate HUVEC cell proliferation 133. Therefore, the primary HUVECs 
incubated with or without 1nM CNP or C-ANF4-23 were analysed by cell counting assay 
(as described in section 2.10) to explore the possible genetic impact of BP-associated 
SNPs on HUVECs proliferation. 
 
Again, rs1173771 genotype pattern in these HUVECs studied is concordant with other 
three SNPs (rs1173743/rs1173747, rs1173756), thus the data were analysed by 
comparing BP-elevating allele homozygous, heterozygous and BP-lowering allele 
homozygous groups.   
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There was no significant difference among genotypes of the NPR3 BP-associated 
SNPs in HUVEC proliferation, although there was a slightly higher proliferating rate in 
BP-lowering allele homozygous samples (Figure 4.5). When incubated with CNP or 
C-ANF4-23, a slightly higher proliferation rate was observed in CNP and/or C-ANF 
groups, but with no statistical significance. The genetic difference was not detectable 
in HUVECs under CNP or C-ANF4-23 as well (Figure 4.6). 
 
 
Figure 4.5 No effect of BP-associated variants in the rs1173771 LD block at 
NPR3 locus on human umbilical vein endothelial cells proliferation. 
Cell proliferation was measured at 24h by cell counting assay (CCK-8). No significant 
genetic impact was detected in HUVECs, N≥5 for each genotype. Values are 
presented as mean ± SEM, and difference was analysed by one-way ANOVA with 
Bonferroni correction of the number of tests for different genotypes. 
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Figure 4.6 No effect of CNP/ CANF4-23 on human umbilical vein endothelial cells 
proliferation. 
 A, C-type natriuretic peptide (CNP) and NPR-C specific agonist C-atrial natriuretic 
peptide (C-ANF4-23) slightly increased the HUVECs proliferation, but without 
significance. N≥8 in each genotype. Values are presented as mean ± SEM, difference 
between CNP or C-ANF4-23 and control was compared by Wilcoxon signed-rank test. 
B, C, no significant genetic difference was observed in HUVECs with treatment of 
CNP or C-ANF4-23. N≥5 for each genotype. Values are presented as mean ± SEM, 
difference was analysed by one-way ANOVA with Bonferroni correction for the number 
of tests for different genotypes. 
 
 
 
163 
 
4.3 Functional study of variants in the rs1421811 LD block in HUVECs 
4.3.1 No effect of BP-associated SNPs on the NPR3 mRNA level in HUVECs  
In the rs421811 LD block, NPR3 mRNA data also indicated a hint of lower relative 
expression level in BP-elevating allele (major allele) homozygous samples compared 
with BP-lowering allele homozygotes, but no significant difference among genotypes 
(Figure 4.7). For rs7729447, the number of BP-lowering allele homozygotes is only 
three in current mRNA collection, therefore data was analysed here by combining BP-
lowering allele homozygotes and heterozygotes (Figure 4.7 B).   
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Figure 4.7 Quantitative analysis of mRNA levels of NPR3 among BP-associated 
SNPs in the rs1421811 LD block in HUVECs.  
A, Genetic positions of BP-associated variants in rs1421811 LD block at NPR3 gene 
locus. B,C,D, BP-associated variants drove a genotype- dependent effect on NPR3 
gene regulation in HUASMCs with a slightly lower NPR3 mRNA level in BP-elevating 
allele carriers, such determined by quantitative reverse-transcription polymerase 
chain reaction (qRT-PCR) for  rs7729447 (B), rs3762988 (C), and 
rs1421811/rs3828591(r2=1.0) (D) respectively. Values are presented as mean ± SEM, 
data were analysed by one-way ANOVA with post-test of Bonferroni correction.  
 
 
4.3.2 Effect of BP-associated SNPs on HUVEC proliferation  
HUVECs were incubated with or without 1nM CNP, or C-ANF4-23 for 24 hours and 
proliferation was investigated by cell counting assay. The effect of CNP, or C-ANF4-23 
on cell proliferation see the section 4.2.4. When without treatment, a relatively 
increased level of proliferation was observed in heterozygotes of SNPs in contrast to 
their BP-elevating allele homozygotes, but without significance (Figure 4.8).   
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Figure 4.8 No effect of BP-associated variants in the rs1421811 LD block in 
NPR3 on human umbilical vein endothelial cells proliferation. 
Cell proliferation was measured at 24h by cell counting assay (CCK-8). No significant 
of genetic impact was implicated in HUVECs, but with a slightly higher proliferating 
level in heterozygous samples of all detected SNPs. N≥8 in each genotype. Values 
are presented as mean ± SEM, and difference was analysed by unpaired t test. 
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5. Discussion and Future work 
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An increasing number of DNA sequence variations in or near the NPR3 gene have 
been reported to be associated with cardiovascular diseases susceptibility, especially 
phenotypes related to blood pressure regulation.  
 
As described in section 1.5, lead SNPs rs1173771, rs173766 and rs1421811 have 
been identified as association with blood pressure by GWAS. Moreover, another 
combined admixture mapping and association analysis of 6303 un-associated 
African-American participants by the Candidate Gene Association Resource (CARe) 
consortium has shown variation (rs7726475, A/G) in the 5′-flanking region of the 
NPR3 gene has also been significantly associated with inter-individual variation in 
both systolic (β=2.00; P=8.85×10−7) and diastolic (β=1.04; P=3.64×10−6) blood 
pressure.109 
 
In addition to in the association with blood pressure, other association linking NPR3 
variants to blood pressure have also been demonstrated in related complications. For 
instance, three SNPs (rs6889608, rs1173773, and rs2270915) in NPR3 were 
significantly associated with systolic BP (SBP) in diabetes.142  rs2270915 (G/A) is a 
nonsynonymous SNP located in exon 8 of NPR3 and its association was replicated 
in the second step population of 2,452 French: AA homozygotes had a lower SBP 
than G carriers (137.4 ± 19.1 vs. 140.0 ± 20.2 mmHg, P = 0.004). It was also replicated 
with resequencing study in three ethnic groups (European American, African 
American, and Han Chinese American) and identified association with difference in 
SBP.  
 
These studies have demonstrated the association of SNPs at NPR3 locus with blood 
pressure regulation and highlighted the potential of NPR3 in blood pressure control 
and in the development of hypertension. However, the precise role of those blood-
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pressure associated SNPs and NPR3 in the development of hypertension remains to 
be elucidated.  
 
NPR3 encodes for the natriuretic peptide receptor C (NPR-C), previously regarded to 
predominantly function as a systemic clearance receptor that removes natriuretic 
peptides (NP) from the circulation.73,75,102  Recently, there is accumulating evidence 
suggesting a physiological role of NPR-C coupled to adenylyl cyclase / cyclic 
adenosine monophosphate (cAMP) signal transduction system through inhibitory 
guanine nucleotide regulatory protein (Gi).80–82  Upon binding with NPR-C, Gi is able 
to inhibit adenylyl cyclase, with the subsequently lower intracellular formation of cAMP 
via Gi-α subunit, and activates phosphoinositide phospholipase C (PLC) and 
phosphatidyl inositol (PI) by Gi-β/γ subunit.72,143  Studies have implicated NPR-C in 
mediating some of the cardio-protective actions of natriuretic peptides and its direct 
involvement in the pathogenesis of hypertension. 
 
 
NPR-C homozygous knockout mice have showed an average decrease of 8 mmHg 
(SBP) than the control which is also associated with an increased half-life of ANP, 
increased diuresis and reduced ability to concentrate urine. However, a whole body 
of NPR-C knock out mouse displayed profound skeletal abnormalities, and about 50% 
of the homozygous knockouts died before weaning.121 Thus, it is not very practical or 
proper to use NPR-C knockout mice as model to study blood pressure until possible 
tissue-specific knockout model is generated. 
 
Herein, we used the “human laboratory” by studying VSMCs and ECs isolated from 
human umbilical cords of different individuals partitioned by genotype as both 
represent tissues with high expression levels of NPR-C identified by a previous study 
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(Khambata, et al. 2011) which was confirmed by our data. These cell types are 
particularly relevant in the study of blood pressure. Vascular smooth muscle cells 
(VSMCs) are critically involved in maintaining vascular integrity. Numerous 
pathophysiological processes with VSMCs hyperplasia, hypertrophy, apoptosis, cell 
elongation, migration, inflammation and its altered extracellular matrix proteins could 
contribute to arterial remodelling, finally to the development of hypertension.144  
Endothelial cells (ECs) can release both relaxing and contracting factors that 
modulate vascular smooth muscle tone and also participate in the pathophysiology of 
essential hypertension.145  
 
With an aim to understand the functional effects of the blood pressure-associated 
SNPs at the NPR3 locus, I sought to investigate whether these SNPs have an effect 
on NPR3 expression, together with human vascular SMC and endothelial BP-related 
cell phenotypes in vitro.  
 
 
5.1 BP-associated SNPs in rs1173771 LD block influence NPR3 gene expression 
in HUASMCs.    
 
Gene expression studies were conducted on mRNA and protein levels of NPR-C and 
analysed by genotype. My data showed that a decreased expression level of NPR-C 
in BP-elevating allele carrier genotypes in human vascular SMCs (see section 3.2.1-
3.2.2). Reduced NPR-C mRNA levels were observed in HUASMCs homozygous and 
heterozygous for BP-elevating (major) allele, as compared with BP-lowering (minor) 
allele homozygous HUASMCs, by qRT-PCR. This finding was confirmed with the 
complementary method of allelic expression imbalance analysis using genomic DNA 
and mRNA from HUASMCs that were heterozygous for 3’-UTR SNP rs1173756. 
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Consistent with the qRT-PCR results, the BP-elevating allele (C) had lower 
expression as compared to the BP-lowering allele (T). Protein detection by western 
blotting subsequently validated a compatibly diminished NPR-C level in BP-elevating 
allele homozygous group in HUASMCs. In concert, these observations provide strong 
support for a genetic influence of NPR3 SNPs on NPR-C expression at a 
transcriptional level. In the blood pressure GWAS, the major allele C of rs1173771 is 
indicated association with elevated blood pressure (0.504mmHg for SBP and 0.261 
mmHg for DBP).146 The results presented above also implies the higher blood 
pressure-associated risk allele C may exert its effect through lower NPR3 expression 
and subsequent NPR-C related signalling.  
 
A recent study revealed eight nonsynonymous SNPs in NPR3 gene have a functional 
significance by demonstrating their effect on protein expression, which is 
characterized autophagy-dependent degradation by the incompatible Arg146 variant 
allozyme with protein conformation. This finding implicated a mechanism of SNPs in 
altering NPR3 expression through the protein activity of miss-folding or instability.147  
However, all the BP-associated SNPs in rs1173771 LD block are not located in protein 
coding region of NPR3, they reside in intron, 3 untranslated region and downstream 
of gene. Therefore, it is hypothesised these BP-associated SNPs may affect the 
transcription/co-transcription process, and some detection for possible interaction of 
SNPs with regulatory factors were also conducted in this study. 
 
Chromatin compactness is regarded to reflect its accessibility for the transcription 
machinery. Euchromatin (loose or open chromatin) is widely regarded as permissible 
structure for transcription through binding some regulatory elements, whereas 
heterochromatin (tight or closed chromatin) is more compact and refractory to factors 
that need to gain access to the DNA .148  FAIRE was conducted to explore whether 
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blood-pressure associated variants reside in the open chromatin fragments, to further 
investigate their potential molecular mechanism on genetic regulation of NPR3. 
FAIRE results indicated the sequencing signals at BP-elevating allele of rs1173756 
(C) or rs1173747 (A) were less enriched in FAIRE DNA compared with reference DNA 
in HUASMCs, which suggests both SNPs may reside in the regulatory elements in 
open chromatin and has differential function in an allelic-specific manner (see section 
3.2.4). Considering the regulation pattern, the BP-lowering alleles may preferentially 
bind active transcription factors such as enhancers to upregulate the gene expression.   
 
EMSA was also carried out to detect the possible interaction of HUASMC nuclear 
protein extracts with SNPs flanking DNA fragment in vitro. It shows an allelic binding 
specificity of NPR3-rs1173747 with HUASMC nuclear extract, indicating 
transcriptional or co-transcriptional factor may bind the DNA segment surrounding the 
BP-lowering allele of rs1173747 DNA fragment in vitro. Combined with qRT-PCR 
results showing a lower NPR3 gene expression in BP-elevating allele of rs1173747, 
a possible explanation for this EMSA finding is rs173747 BP-lowering allele may 
overlap with some active transcriptional factors recognition sites hence upregulating 
the NPR3 gene expression. This is also in line with FAIRE data with a preferable 
enrichment of rs1173747-lowering allele in open chromatin. This is supported by 
bioinformatics analyses showing rs1173747 being predicted to interact with some 
histone-modifications or transcription factors such as H3K27AC that upregulate gene 
expression.  
 
Moreover, AEI, which was only technically possible to be conducted for 3-UTR SNP 
rs1173756 in this study also indicated a lower mRNA level of BP-elevating allele (C) 
comparing to BP-lowering allele (T) (see section 3.2.1.2). This finding is accordant 
with qRT-PCR result of lower NPR3 mRNA expression in BP-elevating allele 
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homozygotes and FAIRE data with less enriched sequencing signals at BP-elevating 
allele of rs1173756 (C) in open chromatin.  This also suggests rs1173756 may be a 
regulatory polymorphisms (rSNPs) or a structural RNA SNPs (srSNPs) interacting 
with some transcriptional factors, micRNA or other elements which could affect mRNA 
processing and turnover.  
 
Altogether, the results provide a mechanistic explanation for the association of risk 
allele in rs1173771 LD block with elevation of blood pressure that may be through a 
lower NPR3 expression. Findings from FAIRE, EMSA and AEI also imply the intronic 
SNP rs1173747 and/or 3-UTR SNP rs1173756 might be the functional SNPs. 
However, there are limitations of FARIE and EMSA conducted in this subject with 
absence of transcription factor foot printing, and some other technical limitations such 
as a relatively lower signal-to-noise ratio in FAIRE compared with ChIP-seq or DNase-
seq experiments, leading to a reduced confidence in the sites identified 140. Thus, it is 
not very clear of the molecular mechanism behind the genetic regulation at this stage. 
 
 
5.2 BP-associated SNPs in rs1173771 LD block influence HUASMC proliferation 
via NPR-C signalling pathway.  
 
The increase in vessel wall thickness/lumen (w/l) ratio resulting from vascular 
remodelling leads to greater vascular reactivity and elevated blood pressure,149  while 
human vascular smooth muscle cell proliferation and migration contribute to vascular 
remodelling in hypertension and atherosclerosis.150,151  Thus, SMC cell proliferation 
and migration ability are very relevant phenotypes to blood pressure control.  
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As a Gi-coupled receptor, NPR-C has been identified as a regulator of vascular SMC 
proliferation through mitogen-activated protein kinase (MAPK) and PI3-kinase.152,153  
Hobbs et al further investigated the vasoprotective profile of NPR-C, and revealed its 
binding of CNP could inhibit aortic smooth muscle cells (AoSMC) proliferation 
mediated by extracellular signal-regulated kinase (ERK) 1/2 phosphorylation.133  
 
Here, the cell counting assay was conducted to investigate the cell viability with or 
without treatment of 100nM CNP or 100nM C-ANF4-23. It is shown that treatment of 
CNP or C-ANF4-23 after 24 hours could diminish human VSMCs proliferation in 
contrast to control group, and this inhibitory effect also revealed a trend of genetic 
difference with a relatively higher inhibitory influence on BP-lowering allele 
homozygotes. This is in agreement with their NPR-C expression level among 
genotypes and all support that stimulation of NPR-C could have an impact on cell 
proliferation in vitro (Figure 3.10). 
 
Independent of CNP or C-ANF4-23 exposure, HUASMCs proliferation over 24 hours 
also showed a remarkable difference between genotypes (Figure 3.9) offering a 
mechanistic link from the BP-elevating allele, to lower NPR3 expression and 
subsequently higher VSMCs proliferation. The mechanism behind this kind of intrinsic 
genetic difference in cell proliferation is currently unclear. The possible explanation 
may be the presence some autocrine secretion of natriuretic peptides, such as ANP, 
BNP and CNP, that could activate NPR-C and influence cell proliferation. Some 
literature have implicated ANP and BNP modulation of vascular cells proliferation. 
BNP has been shown to exert an anti-proliferative action on human fibroblasts.154  
ANP inhibited the growth of VSMCs in vitro and recombinant adenovirus (Ad-RSV)-
ANP showed the respect to inhibiting rat VSMC proliferation and migration following 
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endothelial injury.155  However, the precise role of NPR-C on vascular cell proliferation 
is so far unknown. 
 
Furthermore, the possible genetic difference on HUASMCs migration was also 
detected here. It is shown CNP or C-ANF4-23 could slightly inhibit the cell migration, 
and this is in line with previous finding that CNP or C-ANF4–23 directly inhibited rat 
aortic smooth muscle migration in vitro.111  Whereas, no significant genetic difference 
was observed among genotypes, although with a slightly higher migration in BP-
elevating allele carriers (Figure 3.12), suggesting association between NPR3 risk 
variants and BP control might not through regulating cell migration. Moreover, Hobbs 
et al. found CNP inhibitory effect on migration may be related with NPR-B in their 
current study (unpublished), providing a support for the concept. However, the limited 
size (N≥5 in each genotype) of HUASMC samples were utilised in scratch assay, thus 
future work with more samples might be explored.  
 
Together, it is revealed HUASMCs carrying BP-elevating allele had a higher 
proliferation than BP-lowering allele homozygotes, with persists even after exposure 
to CNP or C-ANF4-23. The finding of genetic differences in HUASMCs proliferation 
implies that the risk allele was associated with blood pressure elevation in individuals 
might partially result from the increased VSMCs proliferation via NPR-C signalling 
pathway. 
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5.3 BP-associated SNPs in rs1173771 LD block affect HUASMC calcium flux in 
response to Ang II  
 
It is widely recognised that augmented intracellular calcium levels have an important 
role in compacting the vascular tone and precipitating blood pressure elevation.156  By 
contraction and relaxation of smooth muscle cells, the luminal diameter of the 
vasculature was altered, which enables blood vessels to maintain an appropriate 
blood pressure.157  Herein, carbachol and Ang II were both utilised to stimulate 
HUASMCs calcium flux. Optimization work of Ang II concertation in HUASMCs 
indicated an EC50 of approximately 10nM, an EC90 of 100nM. Both concertation of 
Ang II were used here to investigate the possible genetic difference among genotypes 
and inhibitory effect of CNP or C-ANF4-23 on Ang II- stimulated intracellular calcium 
increase with carbachol as agonist control. 
 
Carbachol, a muscarinic and nicotinic receptor agonist, can increase human SMC 
intracellular free calcium concentrations.158 Carbachol-induced contraction is 
predominantly initiated by M3 muscarinic receptor-mediated activation of the Gq/11-
phospholipase C β-protein kinase C (PKC) and the G12/13-RhoGEF-Rho kinase 
(ROCK) pathways. However, these pathways and their downstream effectors are not 
well understood.159,160  Herein, carbachol was utilised as a control agonist to explore 
the calcium flux. It is observed there is no genetic difference in carbachol-induced 
intracellular calcium increase in HUASMCs (Figure 3.13). This confirmed that the 
samples were able to mount an appropriate Ca2+-response that was independent of 
genotype. With this, the observed genotype-associated differences in response to 
Ang II is more likely to be due to the genetic differences itself, rather than confounding 
factors such as differences in cell viability. 
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Ang II is an octapeptide hormone exerting vasoconstriction mediated by Gq protein-
dependent signalling pathway, which activates PLC and increases cytosolic calcium 
concentrations.161  Similarly, NPR-C has been recognized as a Gi protein coupled 
receptor which may influence PLC via the Gi-β/γ subunit,85  suggesting a potential 
crosstalk between Ang II and NPR-C on intracellular calcium regulation. Thus Ang II 
was used here to investigate the possible genetic impact of NPR3 BP-associated 
variants on calcium flux which may link to NPR-C signalling pathway.  
 
It is observed there was a genetic impact of BP-associated variants on intracellular 
calcium flux in human VSMCs with an augmented level in BP-elevating allele carriers 
when stimulated by 10nM or 100nM Ang II (Figure 3.13). This genetic pattern is 
compatible with their NPR3 gene expression, indicating risk allele effect on blood 
pressure occurs by a mechanism of regulating VSMCs calcium flux in response to 
Ang II.  
 
Here, we showed for the first time that human VSMCs presenting high NPR-C level 
could blunt the intracellular calcium reaction to Ang II, supporting the potential role of 
NPR-C in regulating VSMCs calcium current and blood pressure homeostasis. 
Several studies demonstrated NPR-C could reduce L-type calcium current (ICa,L) via 
binding with CNP in mouse vascular and sinoatrial node myocytes,88 and (100nM) 
Ang II-stimulated mesenteric artery smooth muscle cells calcium flux.134  Therefore, 
the effect of NPR3 variations on the intracellular calcium changes may be through a 
CNP-related signalling pathway. Indeed, CNP inhibited the observed intracellular 
calcium response to 10nM Ang II in human umbilical arterial SMCs when pre-treated 
with CNP in vitro, which indicates NPR-C effect on human arterial VSMCs calcium 
flux might be involve CNP signalling pathway. 
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However, in my study, CNP did not inhibit the higher Ang II (100nM) stimulated 
intracellular calcium increase. This is might be explained by pharmacological 
antagonism. Moyes et al. showed CNP efficiently counteracted to 100nM Ang II-
stimulated mesenteric artery smooth muscle cells calcium flux,134  and implied CNP 
may have a tissue specificity. However, stimulation of NPR-C by C-ANF4-23, mimicking 
the effect of natriuretic peptides, still displayed inhibitory effect of calcium flux in 
response to higher Ang II, indicating a possibility of NPR-C effect on HUAMSCs 
calcium signalling might be via more than CNP.   
 
This thesis is consistent with other studies on NPR-C with other NPs (ANP or BNP) 
in hypertensive phenotype research. It has been demonstrated that ANP-induced 
vasodilation was significantly reduced by inhibition of the large-conductance calcium 
channel,162  suggesting a link between ANP and calcium flux.  BNP attenuated the L-
type calcium current in ventricular myocytes.163  Some future work targeting the 
interaction between NPR-C with ANP or BNP on human vasculature might be further 
explored.  
 
 
5.4 No significant correlation of genetic impact on cell proliferation and calcium 
flux in response to Ang II 
 
The same pattern was observed in both HUASMCs proliferation and calcium flux in 
response to Ang II, which was both higher in BP-elevating allele carriers, implicating 
a possibility of  a correlation between these two phenotypes based on genotype.   
 
The current literature indicates an influence of calcium signalling on cell proliferation. 
It has been revealed that increases in the basal cytosolic calcium concentration could 
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activate the immediate early genes responsible for inducing resting cells (G0) to re-
enter the cell cycle and promote the initiation of DNA synthesis at the G1/S 
transition.164,165  However, when exceeding its normal spatial and temporal boundaries, 
calcium can result in cell death through both necrosis and apoptosis.166 
 
In my study, carbachol was also utilised to induce the HUASMC calcium flux, but no 
genetic difference was observed, suggesting the intracellular calcium flux was not 
related to cell proliferation status. Moreover, the correlation analysis between cell 
proliferation/viability in 24 hours and calcium flux in response to Ang II did not show a 
significant association as displayed in Figure 5.1. Thus, the genetic impact on Ang II-
induced calcium flux was correlated with NPR-C expression level and might be 
independent from the proliferation via different signalling pathways.  
 
 
 
Figure 5.1 No correlation between cell viability in 24 hours and calcium flux in 
response to Ang II. 
HUASMCs (N=20) conducted in both cell viability assay and calcium flux assay 
were subjected to linear regression analysis, and no significant linear relationship 
(p=0.14) was found between cell viability in 24 hours and calcium flux in response to 
Ang II. 
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5.5 Effect of BP-associated variants in rs173771 LD block on HUVECs  
 
In addition to human VSMC studies, investigation of potential genetic impact of BP-
associated variants on HUVECs were also conducted. Gene expression studies were 
firstly carried out on mRNA and protein levels of NPR-C to explore the possible 
genetic regulation on NPR3 gene expression in HUVECs.  A significant genetic 
difference was not detected in HUVEC NPR3 mRNA expression, although with a 
slightly lower NPR3 mRNA level in BP-elevating allele carrier genotypes (see section 
4.2.1-4.2.2). Complementary method of allelic expression imbalance analysis using 
genomic DNA and mRNA from HUVECs that were heterozygous for 3’-UTR SNP 
rs1173756 was conducted and indicated an obvious imbalance of allele’s level with a 
lower expression of the BP-elevating allele (C) in mRNA comparing to the BP-lowering 
allele (T). Subsequent protein detection by western blotting did not validate a 
difference of NPR-among genotypes in HUVECs. These gene expression data 
presented above suggests a weak correlation of BP-associated SNPs with NPR3 
gene expression. However, the positive genetic difference observed in allelic 
expression imbalance study still could reflect the potential impact on the population 
individual difference indicated by GWAS study.  
  
Moreover, no significant genetic impact was detected on HUVECs proliferation 
(section 4.2.4). Together with VSMCs data, it is implied a cell-type dependent 
specificity of such association mainly on VSMCs rather than ECs. As indicated in 
Figure 5.2, the expression level of NPR3 mRNA in HUASMCs was remarkably higher 
compared with HUVECs, this might explain the cell-type dependent specificity which 
may link to the different NPR3 expression levels in these cells. In addition, considering 
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the dual–capacity of NPR-C in both clearance and signalling pathway, there is a 
possible concept that NPR-C in VSMC mainly exert the signalling, otherwise, NPR-C 
in ECs may play a role of the clearance receptor based on their physiological locations 
in vasculature. However, more study still needs to be conducted to further study the 
mechanism.  
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Figure 5.2 A much higher relative expression level of NPR3 mRNA was detected 
in HUASMCs compared with HUVECs.  
NPR3 mRNA level in HUASMCs and HUVECs were determined by quantitative 
reverse-transcription polymerase chain reaction (qRT-PCR), N ≥ 110 in each group, 
values are presented as mean ± SEM, ***P<0.001 analysed by unpaired t-test when 
HUASMC vs HUVEC.   
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5.6 Effect of other LD block at NPR3 gene locus in HUASMCs and HUVECs 
 
A recent hypertension susceptibility study by bespoke gene–centric assay found 
another BP-associated LD block with lead SNP rs1421811,70  Although SNP rs421811 
is in low LD (r2=0.13) with rs1173771 LD block indicated by SNAP, its minor allele (G) 
is indicated as a BP-lowering allele, which is in line with genetic pattern on BP control 
for variants located in rs173771 LD block with BP-lowering allele being minor allele. 
 
There are 20 SNPs in high LD (r2≥0.8) with rs421811 in this LD block in CEU 
population, which are either intronic or intergenic variants. Predicted by bioinformatics 
programs such as ENCODE, a few SNPs (rs421811, rs3828591, rs3762988, 
rs7729447) with relatively higher score in location of regulatory factors binding sites 
were chosen as candidates to conduct the functional study in HUASMCs and 
HUVECs in vitro.  
 
Firstly, gene expression data in HUASMCs (see section 3.3.1-3.3.2) revealed a trend 
of genetic regulation of rs1421811 or rs3828591 (r2=1.0) on NPR3 mRNA level with a 
lower level in BP-elevating allele homozygotes. But this pattern was not validated at 
the protein level, although with a slightly lower NPR-C protein level in BP-elevating 
allele homozygote. Cell phenotypes detection for proliferation and migration did not 
show any genetic difference among genotypes. However, a much higher intracellular 
calcium flux in response to 100nmol/L Ang II was observed in BP-elevating allele 
homozygotes compared with other two genotypes (Figure 3.19-B).  
 
Secondly, functional study based on HUVECs presented no significant genetic 
association with NPR3 gene expression and cell proliferation, but with a relatively 
lower levels in BP-elevating allele homozygote (see section 4.3).  
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In total, current data in HUASMCs show a hint of genetic influence on NPR3 mRNA 
expression level and intracellular calcium flux in response to Ang II with a very limited 
size of BP-lowering allele (minor allele) homozygotes (see section 3.1), in which the 
direction of genetic impact was not clear or consistent. Therefore, it is not safe to get 
a solid conclusion based on current data.  
 
 
5.7 Conclusion  
 
This study demonstrated that the hypertension-associated variants in the rs1173771 
LD block exhibited lower NPR-C expression in individuals carrying BP-elevating allele. 
Human VSMC samples carrying the BP-elevating allele had augmented cell 
proliferation and Ang II-stimulated intracellular calcium response. However, we did not 
observe such a genetic association in HUVECs, suggesting a tissue specific impact 
on vascular smooth muscle. Altogether, the results has provided a mechanistic insight 
for the association of NPR3 risk variants with elevation of blood pressure that may be 
through a lower NPR-C expression and subsequent modification of VSMCs 
phenotype via NPR-C related pathways. 
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Figure 5.3 A proposed model to show the systemic mechanism between risk 
variants in natriuretic peptide receptor C (NPR3) gene and hypertension risk. 
The risk variants major allele (BP-elevating allele) presented a lower NPR3 
expression and upregulated the human vascular smooth muscle cells proliferation 
and intracellular calcium changes in response to angiotensin II (AngII) NPR-C 
signalling pathway, which could lead to high risk for the development of hypertension. 
 
 
Observations in human VSMCs proliferation and calcium flux studies provide a 
support for the concept that NPR-C has a physiological impact on blood pressure 
control. Indeed, C-atrial natriuretic peptide (C-ANF4-23), a ring-deleted analog of ANP, 
is able to specifically interact with NPR-C. It has been demonstrated to attenuate the 
elevated BP of SHRs via decreasing the enhanced oxidative stress.167  Additionally, 
C-ANP compound 118, an NPR-C agonist, caused relaxation of isolated mesenteric 
resistance arteries, an effect blocked by NPR-C antagonism. It also promoted a 
reduction of blood pressure in wild-type mice, which could be blunted in NPR-C KO 
mice.134  
 
So far, researchers have identified more than 60 genes that harbour variations 
underlying the risks of hypertension.45 These newly discovered candidate genes, 
proteins and their related pathways can represent powerful new drug targets. Here, 
we conducted a functional study base on the NPR3 locus and provided an evidence 
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that NPR3 is strongly involved in the development of hypertension, indicating NPR3 
can be regarded as a therapeutic target for hypertension. 
 
Moreover, It has been evident that single nucleotide polymorphisms (SNPs) in protein-
coding region comprise merely 7% of complex disease-associated variants, while a 
striking majority of associated SNPs are either intronic or intergenic.168,169  However, 
only a small fraction of molecular mechanisms in the development of disease may 
have been unravelled. Our functional experiments assessing the effect of these 
intronic and intergenic BP-associated variants on associated-gene regulation and 
cellular phenotypes have provided one example for this kind of study.   
 
 
5.8 Future work  
5.8.1 Original hypothesis 
 
A number of studies have shown the SNPs within the NPR3 locus are association 
with blood pressure in different populations. Additionally, previous work has also 
revealed the potential role of NPR-C in hypertension. However, the precise role of 
those blood-pressure associated SNPs and NPR3 in the development of hypertension 
has not elucidated. So the major points are to be explored as follows: 
 
1. The possible molecular mechanism associated to BP-associated SNPs at NPR3 
locus: whether these SNPs affect NPR3 gene expression or structural modelling 
/activity,  
2. The role of NPR-C with its associated signalling pathway on cell phenotypes and 
in the development of hypertension.  
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5.8.2 Future work 
 
This study have provided a mechanistic explanation for the recently reported 
association between NPR3 variants and hypertension susceptibility. However, much 
more work needs to be done to further investigate the molecular mechanism behind 
and the role of NPR-C in the development of hypertension.  
Some of the future work as discussed as below. 
 
1. The study described in chapter 3.2.1-3.2.4 has shown the genetic regulation of 
BP-associated SNPs on NPR3 expression. EMSA and FAIRE data provided a clue 
that rs1173747 and/or rs1173756 can be functional SNPs as residing in the 
regulatory elements region, but the precise molecular mechanism still needs to be 
explored with further experiments. The strategy would be that utilise antibodies 
targeting candidate transcription factors chosen by bioinformatics prediction to 
conduct ChIP assay or EMSA to determine whether there is interaction of SNPs 
flanking region with these transcription factors. 
 
2. The findings indicated in chapter 3.2.5 and 3.2.7 presented a genetic impact of 
NPR3 risk variants on HUASMCs proliferation and calcium flux in response to Ang 
II, even without treatment of CNP or C-ANF4-23. A hypothesis would be there is 
CNP (maybe even ANP or BNP) present in the growth medium to activate the 
signalling pathway leading to the genetic difference in proliferation and calcium 
flux. To validate the hypothesis to elucidate the NPR-C signalling pathway behind, 
protein detection for CNP/ANP/BNP in growth medium would be done by western 
blotting, and more work with ANP/BNP on cell proliferation and calcium flux would 
be possibly conducted as well.  
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3. Data as described in chapter 3.3 revealed a hint of a genetic influence of BP-
associated variants in rs1421811 LD block on NPR3 mRNA expression level and 
intracellular calcium flux in response to Ang II. More samples, especially with the 
minor allele homozygotes would be needed to fully explore effect of the BP-
associated SNPs on cell phenotypes, such as, cell proliferation, migration and 
calcium flux.  
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7. Appendix  
Reagents, buffers and solution 
1L 10X phosphate buffered saline (PBS) – 1X is to be autoclaved   
 80g    NaCl 
 2.0g    KCl 
 14.4g   Na2HPO4 
 2.4g     KH2PO4  
 Up to volume with ddH2O 
 
500ml 0.2% w/v gelatin – to be autoclaved  
 1.0g  Gelatin 
 Up to volume with ddH2O  
 
500ml 0.04% w/v gelatin – to be autoclaved  
 0.2g   Gelatin  
 Up to volume with ddH2O  
 
50ml 1x lysis buffer for DNA extraction 
 500µl     1M Tris pH 8.0 
 1ml        0.5 M EDTA, pH 8.0   
 100µl     5M NaCI,  
  2.5ml     10 % SDS 
 Up to volume with ddH2O 
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100ml RIPA lysis buffer  
 3ml 5 M NaCl 
 1ml 0.5 M EDTA, pH 8.0  
 5ml     1 M Tris, pH 8.0  
 1ml     Triton-X-100  
 5ml     10% sodium deoxycholate  
 1ml      10% SDS  
 84ml   ddH2O  
 
2L 10x running buffer  
 60.4 g     Tris base 
 288 g      Glycine 
 20 g        SDS 
 Up to volume with ddH2O 
 
1L 1.5 M Tris, pH 8.8  
• 181.65 g      Tris base  
• Adjust the pH to 8.8 with concentrated HCl 
• Up the volume to 1 L with ddH2O 
 
1L 1.5 M Tris, pH 6.8 (stock buffer for stacking gels) 
• Dissolve 181.65 g    Tris base 
• Adjust the pH to 6.8 with concentrated HCl 
• Up the volume to 1 L with ddH2O 
 
 
4L 10x Transfer buffer: 
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• 121.1 g   Tris base 
• 576 g      Glycine 
• Up the volume to 4 L with ddH2O 
 
1L 1x Transfer buffer: 
• 700 mL      cold ddH2O 
• 100 mL     10x Transfer buffer 
• 200 mL      Methanol 
 
4L 10x TBS: 
• 96.3 g    Tris base 
• 320 g     NaCl 
• Adjust the pH to 7.6 with concentrated HCl 
• Bring up the volume to 4 L with ddH2O 
 
1L 1x TBST: 
 100ml 10xTBS 
 Add 1 mL Tween-20  
 up the volume to 1 L with ddH2O 
 
200ml 5% blocking solution  
 10g    non-fat milk  
 Up the volume to 200ml with 1x TBST  
 
50ml 1x Annealing buffer  
 500µL   1M Tris, pH8.0,  
 2.5ml    5M NaCI,  
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 100µl    0.5M EDTA, pH8.0 
 up the volume with ddH2O 
 
50ml 1x buffer A for nuclear protein extraction  
 500µL  1MHEPES, PH 7.9  
 500µL   1M KCI  
 100µl    0.5M EDTA, pH8.0 
 20 µl     NP-40 
 up the volume to 50ml with ddH2O 
Add 40 µl 25XPI in 960μl when used  
 
10ml 1x buffer B for nuclear protein extraction  
 100µL  1MHEPES, PH 7.9  
 800µL    5M NaCI  
 20µl     0.5M EDTA,pH8.0 
 1ml      Glycerol 
 Up the volume to 10ml with ddH2O 
Add 40 µl 25XPI in 960μl when used  
 
